S3 - European Dermatology Forum Guideline
for the Treatment of Androgenetic Alopecia in Women and in Men

Developed by the Guideline Subcommittee “Androgenetic Alopecia” of the
European Dermatology Forum

Subcommittee Members:
Dr. Varvara Kanti, Berlin (Germany)
Prof. Dr. Andrew Messenger, Sheffield (UK)
Dr. Gabor Dobos, Berlin (Germany)
Prof. Dr. Pascal Reygagne, Paris (France)
Dr. Andreas Finner, Leipzig (Germany)
Dr. Anja Blumeyer, Neuenhagen (Germany)

Prof. Dr. Myrto Trakatelli, Thessaloniki (Greece)
Prof. Dr. Antonella Tosti, Miami (USA)/Bologna (Italy)
Prof. Dr. Veronique de Marmol, Brussels (Belgium)
Prof. Dr. Bianca Maria Priaccini, Bologna (Italy)
Prof. Dr. Alexander Nast, Berlin (Germany)
Prof. Dr. Ulrike Blume-Peytavi, Berlin (Germany)

Members of EDF Guideline Committee:
Prof. Dr. Werner Aberer, Graz (Austria)
Prof. Dr. Martine Bagot, Paris (France)
Prof. Dr. Dr. Lasse Braathen, Bern (Switzerland)
Prof. Dr. Sergio Chimenti, Rome (Italy)
Prof. Dr. Alexander Enk, Heidelberg (Germany)
Prof. Dr. Claudio Feliciani, Parma (Italy)
Prof. Dr. Claus Garbe, Tübingen (Germany)
Prof. Dr. Harald Gollnick, Magdeburg (Germany)
Prof. Dr. Gerd Gross, Rostock (Germany)
Prof. Dr. Michael Hertl, Marburg (Germany)
Prof. Dr. Dimitrios Ioannides, Thessaloniki (Greece)
Prof. Dr. Gregor Jemec, Roskilde (Denmark)
Prof. Dr. Lajos Kemény, Szeged (Hungary)
Dr. Gudula Kirtschig, Tübingen (Germany)
Prof. Dr. Robert Knobler, Vienna (Austria)
Prof. Dr. Annegrêt Kuhn, Muenster (Germany)
Prof. Dr. Marcus Maurer, Berlin (Germany)
Prof. Dr. Dieter Metze, Muenster (Germany)
Prof. Dr. Kai Munte, Rotterdam (Netherlands)

Prof. Dr. Gillian Murphy, Dublin (Ireland)
Prof. Dr. Alexander Nast, Berlin (Germany)
Prof. Dr. Dr. Martino Neumann, Rotterdam (Netherlands)
Prof. Dr. Tony Ormerod, Aberdeen (United Kingdom)
Prof. Dr. Mauro Picardo, Rome (Italy)
Prof. Dr. Annamari Ranki, Helsinki (Finland)
Prof. Dr. Johannes Ring, Munich (Germany)
Prof. Dr. Berthold Rzany, Berlin (Germany)
Prof. Dr. Rudolf Stadler, Minden (Germany)
Prof. Dr. Sonja Ständer, Münster (Germany)
Prof. Dr. Wolfram Sterry, Berlin (Germany)
Prof. Dr. Eggert Stockfleth, Bochum (Germany)
Prof. Dr. Dr. Alain Taieb, Bordeaux (France)
Prof. Dr. George-Sorin Tiplica, Bucharest (Romania)
Prof. Dr. Elke Weisshaar, Heidelberg (Germany)
Prof. Dr. Sean Whittaker, London (United Kingdom)
Prof. Dr. Fenella Wojnarowska, Oxford (United Kingdom)
Prof. Dr. Andreas Wollenberg, Munich (Germany)
Prof. Dr. Christos Zouboulis, Dessau (Germany)
Prof. Dr. Dr. Torsten Zuberbier, Berlin (Germany)

Chairman of EDF Guideline Committee:
Professor Dr. Alexander Nast, Berlin (Germany)

Expiry date: 06/2020

EDF Guidelines Secretariat to Professor Dr. Nast:
Bettina Schulze, Klinik für Dermatologie, Venerologie und Allergologie, Campus Charité Mitte, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
phone: ++49 30 450 518 062, fax: ++49 30 450 518 911, e-mail: bettina.schulze@charite.de
EVIDENCE BASED (S3) GUIDELINES FOR THE TREATMENT OF ANDROGENETIC ALOPECIA IN WOMEN AND IN MEN

Varvara Kanti1, Andrew Messenger2, Gabor Dobos3, Pascal Reygagne3, Andreas Finner4, Anja Blumeyer5, Myrto Trakatelli6, Antonella Tosti7, Veronique del Marmol8, Bianca Maria Piraccini9, Alexander Nast10, Ulrike Blume-Peytavi1

1 Department of Dermatology and Allergy, Clinical Research Center for Hair and Skin Science, Charité – Universitätsmedizin, Berlin, Germany
2 Department of Dermatology, University of Sheffield, UK
3 Centre Sabouraud, Hôpital St. Louis, Paris, France
4 Private Practices, Berlin, Leipzig, Germany
5 Private Practice, Neuenhagen, Germany
6 Department of Dermatology and Venerology, Papageorgiou Hospital, Aristotle University, Thessaloniki, Greece
7 Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA, Private Practice, Bologna, Italy
8 Private Practice, Berlin, Brussels, Belgium
9 Department of Dermatology, University of Bologna, Italy
10 Department of Dermatology and Allergy, Division of Evidence based Medicine, Charité – Universitätsmedizin, Berlin, Germany

ABSTRACT
Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80% Caucasian men and 42% of women. Patients afflicted with androgenetic alopecia may undergo significant impairment of quality of life. Hair is an important feature of image. Hair loss affects self-esteem, personal attractiveness and may lead to depression and

1 INTRODUCTION TO THE GUIDELINE

1.1 Needs/problems and issues in patient care
Androgenetic alopecia is a common form of scalp hair loss that affects both men and women. It is characterized by progressive hair loss, usually in a pattern distribution. The onset may be at any age following puberty and the frequency increases with age. By the age of 70 or beyond 80% of Caucasian men and up to 40% of women have signs of androgenetic alopecia.

Age- and gender-independent, androgenetic alopecia may be associated with significant impairment in quality of life. Hair is an important feature of image. Hair loss affects self-esteem, personal attractiveness and may lead to depression and
other negative effects of life (1). Androgenetic alopecia can be a burden for both sexes, but it is substantially more distressing for women (2).

**Therapeutic experiences.** Alfonso et al reported that three out of four men with androgenetic alopecia had never pursued therapy for hair loss although over half experienced a significant adverse effect on quality of life (1). On the other hand, some have tried different therapies in vain and are dissatisfied with current therapeutic approaches, before they come to see the specialist. Consequently their compliance is poor. Men who treated their hair loss successfully reported psychosocial benefits with improvements for self-esteem and personal attractiveness (1).

**Patient compliance.** There are discrepancies between the wish for hair regrowth and consequent willingness to undertake a therapeutic regimen. Limited efficacy, poor tolerance, fear and lack of information on treatment duration and possible adverse events may lead to disappointment.

1.2 Purpose of the guideline

The purpose of the guideline is to provide dermatologists with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia. The current guideline aims to prevent progressive hair loss and associated dermatological and psychosocial long-term complications by improving the individual therapeutic recommendations and strategy.

**Improved patient care.** The use of these evidence-based recommendations in clinical routine should improve patient care.

**Ensure optimal usage of the therapeutic regimen.** In addition to the efficacy assessment, the guideline provides details on administration and safety aspects of systemic, topical or surgical therapy.

**Improvement of patient knowledge and compliance.** Patient compliance is most important in the individual response to treatment. Good compliance is not only related to balance of benefits, costs and adverse effects, but also requires that the patients are well informed. By increasing the level of patient knowledge about the optimal use of each therapy and its possible complications compliance, response rates and satisfaction will increase.

1.3 Directions for use of the Guideline

The current guideline is meant for dermatologists, general practitioners in clinics as well as in private practice and other specialists who are involved in the treatment of androgenetic alopecia.

Each chapter summarizes the efficacy resulting from the evidence-based evaluation separately for men and women, and provides information on practical aspects important for the different therapeutic regimens. The users of the guideline should be aware that the listed aspects are not intended to be exhaustive. General obligations, which are part of every individual therapeutic decision, like known allergies, potential intolerance reactions or contraindications, are not conclusively individually listed. Consequently, the users of the guideline should also consider the manufacturer’s up-to-date product information and check the recommendations concerning dosages, safety, contraindications and drug-interactions.

Although the authors took care that the guidelines correspond to the current state of the art at the time of completion, authors and publishers cannot take responsibility for
dosages and therapeutic choices, as therapy of androgenetic alopecia may change between cycles of the guideline. Therefore the use of this guideline is at the physician’s responsibility and users are requested to keep informed about new knowledge published in parallel to the guidelines. The authors and publishers of the guideline would be grateful if readers could inform them of any inaccuracies.

1.4 Methodology

**Literature research.** This guideline was conducted as the update of the evidence-based (S3) Guideline for the treatment of androgenetic alopecia in women and men (3). A detailed description of methodology used in developing the guidelines can be found in the method report. The search strategy and methodology of this guideline and its update was orientated on the standards of the AGREE instrument and on the methodology of the European S3 guideline for the treatment of psoriasis vulgaris.

To assess the efficacy of the individual therapeutic processes, a systematic search of literature of the databases Medline, Medline in Process, Embase and Cochrane Library was conducted.

To enhance the sensitivity of the search reference lists of articles were screened and hand searches were conducted by the authors to identify articles which are not listed in the databases. The searches comprised the period since the search for the first version of the S3 guideline in 2008 to 15th October 2015. Identified articles were screened for eligibility by at least two independent authors and were retained if they met the predefined criteria (see Attachment 1, literature evaluation form). All discrepancies were solved by consensus or involvement of a third author.

**Results.** Overall 797 articles were found in the update search. After checking for duplicates and relevance 184 articles were evaluated in full text using the literature evaluation form (LEF) (see Attachment 1). Forty seven articles met the inclusion criteria of the guideline and built the basis of the guideline. Figure 1 summarizes the process of literature research.

**Data extraction.** Data extraction was also conducted by two independent reviewers, resolving discrepancies by discussion with a third author. Extracted data included source, target population, treatment areas, description of treatment and study design, study duration, used outcome assessments and results. Included articles were graded for their degree of evidence

The evidence-based evaluations of these guidelines are based on objective evaluations and standardized criteria using the evidence assessment and the level of evidence scale. All other issues, which are outlined in the guideline, e.g. instructions for use, adverse events, contraindications, are based on opinions and personal experiences of the members of the guideline group.

**Evidence assessment.** The methodological quality of each study, which was included in the evidence-based analysis, was defined by the GRADE OF EVIDENCE. We assessed the grade of evidence according to the following scheme:

- **A₁** Meta-analysis, which includes at least one randomized clinical trial of grade A₂ evidence with consistent results of the different studies.
- **A₂** Randomized, double-blind, comparative clinical studies of high-quality (e.g. sample size calculation, flow chart of patient inclusion, ITT-analysis, sufficient size).
B Randomized, clinical studies of lesser quality or other comparable studies (not- randomized, cohort- or case-control-studies).

C Non-comparable studies.

D Expert opinion.

The determination of grade of evidence was done within the LEF form by the particular expert group and the staff member. The scheme for grading the evidence was used for assessment of monotherapies as well as combination therapies.

**Level of evidence.** After determining the grades of evidence of the individual studies, the grades of all studies belonging to a particular therapeutic regimen were summarized in a level of evidence. The **LEVEL OF EVIDENCE** takes into account the methodological quality of the trials (grade of evidence) and the intertrial consistence of the results.

1 Studies grade A1 evidence or studies with mainly consistent results grade A2 evidence

2 Studies grade A2 evidence or studies with mainly consistent results grade B evidence

3 Studies grade B evidence or studies with mainly consistent results grade C evidence

4 Little to missing systematic evidence

**Therapeutic recommendation.** Grades and levels of evidence were considered in the formal consensus process. The guideline group defined particularly relevant sections requiring consensus. These passages were discussed and approved at the consensus conferences. The resulting evidence-based therapeutic recommendations aim to optimize the therapeutic process and to support the practitioner in the individual decision on a suitable therapy. Nevertheless, the decision process on a particular therapy remains complex and limited on the individual case. It is not possible to define a strict clinical algorithm.

**Strength of recommendation.** This guideline summarizes the characteristics of the available drugs and their evidence-based therapeutic efficacies. The consented therapeutic recommendations were additionally weighted by the **STRENGTH OF RECOMMENDATION.** The strength of recommendation considers efficacy, evidence level, safety and practicability and was agreed in a formal consensus process. The expert group agreed on a 6-point scale. This scale is illustrated by arrows:

↑↑ We recommend

↑ We suggest

→ Can be considered (may be considered if a higher-strength recommendation is not available or appropriate)

↓ We suggest not

↓↓ We do not recommend

O We cannot make a recommendation for or against treatment X at the present time
2 INTRODUCTION TO ANDROGENETIC ALOPECIA

Androgenetic alopecia is the most frequent form of alopecia in men and women. Today, in our societies, strong and dense hair is associated with youth, beauty, healthiness and success. Consequently, in patients presenting with androgenetic alopecia progressive thinning of hair often causes a psychological distress. Patients are looking for effective hair loss treatments in order to stop and prevent further thinning and optimally stimulate regrowth. Knowledge of the efficacy of the different therapeutic options is essential for those involved in treating AGA.

2.1 Epidemiology

The population frequency and severity of androgenetic alopecia in both sexes increase with age. Almost all Caucasian men develop some recession of the frontal hair line at the temples during their teens. Deep frontal recession and/or vertex balding may also start shortly after puberty although in most men the onset is later. About 50-60% of men are affected by the age of 50 increasing to about 80% by the age of 70 and beyond (4, 5). Hair loss progresses to a bald scalp (Norwood-Hamilton VI/VII) in 50-60% of men by the age of 70 (5). The prevalence of androgenetic alopecia is reportedly lower and its severity less among Asians, Native Americans and African-Americans compared to the European population (6, 7). Two studies in Chinese men found a prevalence rate of 10-20% in men aged 40-49, rising to 40-60% in men aged 70 and over (8, 9).

The frequency and severity of androgenetic alopecia is lower in women than in men but it still affects a sizeable proportion of the population. Two studies in Caucasian women in the UK and USA reported prevalence rates of 3-6% in women aged under 30, increasing to 29-42% in women aged 70 and over (10, 11). As in men, androgenetic alopecia is less common and appears to start later in life in Asian women although nearly 25% of Korean women over 70 years of age show evidence of hair loss (12). The prevalence appears lower in Chinese women with 12-15% of women aged 70 and over reported to show hair loss (8, 9).

2.2 Aetiology

Androgenetic alopecia in both men and women is characterized by progressive shortening of the anagen phase of the hair cycle, prolongation of the post-exogen phase of telogen (latent phase or kenogen) and miniaturization of the hair follicle in predisposed men and women. Its aetiology is multifactorial and polygenic (13).

Men Androgenetic alopecia in men is an androgen-dependent trait (14). Evidence from genetic disorders and from clinical trials of 5α-reductase inhibitors has shown that dihydrotestosterone (DHT) is the androgen chiefly responsible for the follicular pathology although the molecular and cellular events are only partially understood. DHT probably acts primarily on dermal papilla, the predominant site of androgen receptor and Type II 5α-reductase expression within the hair follicle. A number of signaling molecules have been implicated in the inhibition of hair growth in AGA including TGF-β1 and TGF-β2(14), dickkopf 1 (a member of the WNT-signaling family)(15) and IL-6(16). There is also evidence for involvement of prostaglandins in AGA. The enzyme PGD(2)-synthase and its product PGD(2) are elevated in balding scalp skin; PGD(2) has an inhibitory effect on hair growth in animal and in in vitro experiments (17).
Twin studies have shown that male AGA is largely determined by genetic factors (18, 19). There is also a strong paternal influence on the risk of balding (and non-balding) (5). Although once thought to be an autosomal dominant trait it is now clear that, like other common human attributes, AGA has a complex polygenic basis. To date, molecular studies have recognised twelve genetic regions that associate with AGA and identified some candidate genes. These include genes for the androgen receptor (AR), histone-deacetylases (HDAC) 4 and 9, and the WNT molecule WNT10A (20).

**Women** Less is known about the aetiology of androgenetic alopecia in women. There is an increased frequency of balding in first degree male relatives of women with androgenetic alopecia suggesting at least some genetic commonality between female and male AGA (21). On the other hand, the results of a twin study in women, while showing a significant genetic contribution to fronto-temporal recession, suggested that general hair thinning as a non-genetic aetiology (22). However, this study was conducted in older women and does not exclude a genetic component to early onset female AGA. Case control gene association studies have found a weak association between the AR/EDA2 locus and early onset female AGA but no association with the 11 autosomal loci that associate with male AGA (23-25). There is a weak association with the gene for estrogen receptor 2 (ESR2) suggesting involvement of estrogenic pathways in female AGA (26, 27). To date there have been no genome-wide studies in women.

The role of androgens in female AGA is also less certain than in men. Hair loss is undoubtedly a feature of severe hyperandrogenemia, such as occurs with androgen-secreting tumours. Some studies have shown an increased frequency of biochemical hyperandrogenism, mostly minor in degree (28), and of other clinical features of androgen excess such as polycystic ovaries (29). However, many women with AGA show no other clinical or biochemical features of androgen excess. Nevertheless, it is important to bear in mind that there is a subset of women with androgenetic alopecia and associated hormonal dysregulation. Detailed information on the steps in diagnostic procedure can be found in the S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents (13).

### 2.3 Clinical features

Androgenetic alopecia is characterized clinically by a drift from terminal to vellus hairs and progressive thinning, usually in a pattern distribution. The different patterns can occur in men as well as in women, though the frequencies are gender-specific. Moreover, it is not rare, that additionally to the pattern a diffuse thinning of the parietal and occipital areas can be observed (13).

**Male pattern, Hamilton-Norwood**

This is the most frequent clinical pattern in men with androgenetic alopecia, only occasionally observed in women. Recession of the frontal hair line, mainly in a triangular pattern is the characteristic finding, later followed by a vertex thinning (Figure 2).

**Female pattern, Ludwig**

The so called female pattern is characterized by a diffuse thinning of the centro-parietal region with maintenance of the frontal hair line (Figure 3). It is the most common type in women, occasionally also observed in men.

**Christmas tree pattern**
Similar to the Ludwig pattern the Christmas tree pattern shows diffuse centro-parietal thinning, but additionally, the frontal hair line is breached (Figure 4). The Christmas tree pattern is another common pattern in women.

2.4 Diagnosis

The diagnosis of androgenetic alopecia is usually made clinically by inspection of the hair and scalp showing a non-scarring alopecia in the typical pattern distribution (13). The clinical examination should also include a pull test as well as examination of facial and body hair and nails to exclude differential diagnoses; in particular diffuse telogen effluvium, alopecia areata and cicatrical alopecia (13).

Trichoscopy should be used in doubtful cases. The typical trichoscopy features of androgenetic alopecia include; hair shaft thickness heterogeneity of 20% or more, vellus hairs above 10%, increased percentage of follicular units with only one hair shaft, yellow dots, perifollicular discoloration (peripilar sign), empty follicles, circle hair and honey comb pigment pattern and higher prevalence of these abnormalities in the frontal area compared to the occipital area (30).

Due to the high prevalence of androgenetic alopecia its coincident appearance to other hair diseases should be taken into account. If a differential diagnosis cannot be excluded clinically, laboratory tests or histology can be helpful.

2.5 Hair growth assessment techniques

To document the extent of androgenetic alopecia in clinical practice the different classifications of the pattern distribution are subdivided (Hamilton-Norwood I-VII, Ludwig I-III, Christmas tree pattern I-III). However, a generally applicable definition for the extent of androgenetic alopecia does not exist. Moreover, the documentation of degree of the pattern distribution is often not suitable to reflect the course of androgenetic alopecia.

As it is a naturally progressive disease, therapy can have two required outcomes, namely stop of hair loss and induction of hair regrowth. In clinical practice the evaluation and follow-up of hair growth is generally restricted to individual assessment of patient and physician. In clinical studies, the subjective hair growth assessment by patient and investigator are substantiated by objective hair count/density methods and assessment of standardized global photographs.

The global photographic assessment is a semi-objective tool in evaluation of hair growth. Global photographs are assessed by experts blinded to treatment and time.

Automatic digitalized photographic systems are able to quantify hair density, hair thickness, anagen/telogen hair ratio, terminal/vellus hair ratio within an investigational area. To ensure reproducibility in studies a tattoo is generally used to guarantee analysis of the same area. The technique is limited by the size of the measured area. In clinical trials comparison to baseline and to placebo resp. another treatment is necessary for efficacy assessment of a therapeutic option.

Within the development of the S3 guideline the guideline group voted on a ranking of the different investigative methods and outcome parameters. The global photographic assessment was voted to be most effective in evaluation of hair growth, as the whole scalp hair is evaluated in a standardized way. Patient and investigator perceptions can be excluded. In the opinion of the guideline group global photographs should also be used in routine clinical practice for long term-follow-up.

2.6 Risk/benefit considerations
In routine clinical practice the individual decision for a particular treatment of androgenetic alopecia depends not only on the efficacy, but also on practicability, risks and costs. The assessment of cost effectiveness is important for counselling patients and may contribute to patients’ decisions.

As the patient usually has to bear the full costs of the treatment, consideration of patient-relevant benefit is essential. The benefit attained in the therapy of androgenetic alopecia is not only stabilization, prevention of progression and induction of hair growth, but may contribute to an improved quality of life.

The guideline offers evidence-based analyses of the existing therapeutic options that help to take suitable cost-benefit decisions in the assessment of the specific case.

3 THERAPEUTIC OPTIONS AND THERAPY ASSESSMENT

The following chapters summarize the evidence-based efficacy assessment of the different therapeutic options in the treatment of androgenetic alopecia in men and women. Efficacy was evaluated separately for men and women.

**Result tables.** All studies that fulfilled the inclusion criteria of the guideline are listed in result tables (*see attachment 2*). The evidence-based results of the trials are outlined in the particular chapter, but can be read in detail in the result tables, if required. Based on the result tables the expert group passed therapeutic recommendations for the different regimens by formal consensus process.

*Overview of common therapeutic options.* Table 1 shows a summary of evidence level, efficacy to prevent progression and/or improve androgenetic alopecia, safety aspects and practicability for the most common therapeutic interventions. Its intention is to provide a first rough orientation. Its exclusive use is not sufficient for individual therapeutic choices. Deeper observation of the individual factors of a given patient and its impact on the different therapeutic regimens are necessary.

3.1 MINOXIDIL

3.1.1 Introduction
Minoxidil was originally developed as an oral drug (trade name Loniten®) to treat high blood pressure. Its possible use in androgenetic alopecia was discovered by noticing, that it has a rather interesting side effect: to cause increased hair growth. Chemically, minoxidil is a pyrimidine derivat. It was the first product to be approved for the treatment of AGA in both men and women. The 2% topical solution was first approved by the FDA in 1988 for the treatment of androgenetic alopecia in men and in 1991 in women. The 5% solution was approved in 1997 for the treatment of androgenetic alopecia in men followed by approval of the 5% foam in 2006 also for the treatment of androgenetic alopecia in men and in 2014 for the androgenetic alopecia in women (31).

3.1.2 Mechanism of action
To exert its effect minoxidil needs to be transformed to its active metabolite, minoxidil sulphate by the enzyme sulphotranspherase, which is present in the outer root sheath of anagen follicles. The exact mechanism by which minoxidil promotes hair
growth is still unclear. Its active metabolite, minoxidil sulphate opens ATP-sensitive potassium channels in cell membranes, which conveys vasodilatory effect. Vasodilatation however does not appear to be responsible for minoxidil induced hair growth. Studies on skin blood flow after topical minoxidil application produced inconsistent results.

Other possible effects of minoxidil on the hair follicles include:

a) increased expression of vascular endothelial growth factor (VEGF) mRNA in the dermal papilla. This indicates that the drug induces angiogenesis in the dermal papilla.

b) activation of cytoprotective prostaglandin synthase-1, a cytoprotective enzyme that stimulates hair growth.

c) increased expression of hepatocyte growth factor (HGF) m-RNA; HGF is an hair growth promoter.

3.1.3 Efficacy – males

48 studies assessing the efficacy of minoxidil in male patients with androgenetic alopecia met the inclusion criteria for the guideline (6, 32-79). 1 out of them assessed the effect of oral minoxidil (76). 5 out of them treated male and female patients. 30 studies were placebo controlled. The majority of studies obtained grade A2 and B evidence (A2 = 22, B = 18, C = 8) resulting in EVIDENCE LEVEL 1. In general most of the trials assessed the efficacy of topical minoxidil solution or foam 5% and of minoxidil solution 3% or 2% applied twice daily. In most trials that examined the effect of topical minoxidil > 2%, regular topical application resulted in hair regrowth.

OUTCOMES

The mean change from baseline total hair count ranged between 5.4 hairs/cm² and 29.9 hairs/cm² (11.0 – 54.8%) at 4 to 6 months and between 15.5 hairs/cm² and 83.3 hairs/cm² (14.8-248.5%) at 12 months (6, 36, 39-43, 47-49, 51, 52, 56, 59-61, 64, 66).

At 4 to 6 months the mean total hair count changes in the majority of studies were statistically significant compared to placebo (p between 0.074 and < 0.0001). At 12 months most of the older trials switched the placebo group also to minoxidil treatment.

Comparable to the results in total hair count the mean changes in nonvellus hair counts were also significantly different to placebo (p between < 0.05 and 0.001). There was a mean change in nonvellus hair counts between 4.7 hairs/cm² to 37.3 hairs/cm² (17.2 – 59.4%) at 6 months, between 9.4 hairs/cm² to 41.8 hairs/cm² (8.8 – 443.8%) at 12 months (39-49, 51-54, 56, 57).

The increases from total and nonvellus hair counts at 6 and 12 months did significantly differ from baseline hair counts (p between 0.01 > p < 0.0001).

In a study by Hillmann et al. minoxidil 5% topical foam showed a difference from baseline non-vellus hair count of 27.7 hairs/cm² (14.4%) in the frontotemporal region and of 25.6 hairs/cm² (13.1%) in the vertex region after 16 weeks of application whereas placebo showed a difference from baseline non-vellus hair count of 4.5 hairs/cm² (2.7%) in the frontotemporal region and of 5.9 hairs/cm² (33%) in the vertex region. Comparing the groups a statistically significant increase was found for the minoxidil 5% group compared to placebo (p=0.0001). After 24 weeks of application,
however, minoxidil 5% foam showed a difference from baseline non-vellus hair count of 7.8 hairs/cm² (4.4%) in the frontotemporal region and of 8.7 hairs/cm² (4.9%) in the vertex region whereas placebo showed a difference from baseline non-vellus hair count of -1.5 hairs/cm² (-0.2%) in the frontotemporal region and of 0.4 hairs/cm² (0.9%) in the vertex region. This difference between the groups did not prove to be statistically significant (59).

In an open label 104-week clinical trial by Kanti et al. no significant differences in the growth profile of mean non-vellus hair count or cumulative hair width were found between the frontotemporal and vertex regions in men with androgenetic alopecia treated with minoxidil 5% topical foam (37).

It has to be mentioned, that the reported placebo rate in most of the minoxidil studies is very high. The mean increase from baseline total hair count of the placebo group ranged between 6.1 hairs/cm² and 22.4 hairs/cm² (9.3 and 48.8%) at 4 to 6 months. In the study by Sakr et al, a mean decrease from baseline total hair count of 57 hairs/cm² (-41%) was reported at 24 weeks in the placebo group (72). A study by Hillmann et al. reported a mean change of non-vellus hair count of -1.5 hairs/cm² (-0.2%) in the frontotemporal region in patients with androgenetic alopecia receiving placebo topical foam twice daily for 24 weeks (59).

**Minoxidil p.o.**

Lueangarun et al. investigated the efficacy of oral minoxidil 5 mg once daily per os in men (76). After 24 weeks of treatment, total hair count showed an increase of 35.1 hairs/cm² (19.3%, p = 0.007), which is only slightly higher compared to topical administration. Side effects included hypertrichosis (93%), pedal edema (10%) and ECG alteration (10%).

**Dosage**

**Concentration.** Minoxidil dosages below 2% showed significant reduced mean changes from baseline total hair count in comparison to minoxidil 2% at 6 months (43, 44). The mean changes from nonvellus hair counts were not significantly different for minoxidil 0.1%, 1%, 2% at 6 months.

Minoxidil 3% solution, applied twice daily was not significantly different from minoxidil 2%, twice daily (mean change from total hair count/nonvellus hair count at 4 respectively 12 months) (33, 35, 51, 52, 54-56, 60, 61). Only Katz et al. reported a significance of p = 0.0464 at 4 months in mean change of nonvellus hair counts (53). Tanglertsampan reported a statistically non-significant change from baseline in the mean hair count after 24 weeks of twice daily application of minoxidil 3% lotion (70). 2 studies comparing minoxidil 2% solution, twice daily and minoxidil 5% solution, twice daily were included in the evidence based analysis (45, 58). In both studies the outcome of the minoxidil 5% group was superior to minoxidil 2% (mean change from baseline nonvellus hair count 18.6 hairs/cm² (12.3%) vs. 12.7 hairs/cm² (8.8%) at 12 months, p = 0.025, mean % change from baseline total hair count 30% vs. 25% at 24 months, p = 0.455). Furthermore, in a study by Tsuboi in japanese males twice daily application of minoxidil solution 5% was found to be superior than 1% after 16 weeks (p=0.02). The mean change of nonvellus hair count from baseline was 26.4 hairs/cm² (20.4%) for the minoxidil 5% group and 21.2 hairs/cm² (16.2%) for the minoxidil 1% group (6).

Topical minoxidil 5% was reported to lead to a statistically significant increase of mean non-vellus hair count after 3, 4, 6, 12 and 18 months (p= 0.039, p≤0.0001,
p<0.001, 0.014 and 0.030 respectively) (37, 38, 59, 71, 79). After 24 months of treatment with minoxidil 5% topical foam in men with androgenetic alopecia, no significant differences in the growth profile of non-vellus hair count were found between the frontotemporal and vertex regions (37).

**Application frequency.** Olsen et al. showed, that minoxidil 3% applied twice daily was superior to application once daily (mean change from baseline total hair count 64.4 hairs/cm² vs. 44.1 hairs/cm² at 33 months, p = 0.015, mean change from baseline nonvellus hair count 4.4 hairs/cm² vs. -13.4 hairs/cm² at 36 months) (35).

**Formulation**

Minoxidil is available as a standard thermolabile formulation as a solution containing propylenglycol and as a thermolabile foam formulation. Olsen et al. studied the application of a foam formulation containing 5% minoxidil in the vertex area in male patients (38). The mean change from baseline nonvellus hair count was highly significant different from placebo at 16 weeks (20.9 hairs/cm² (13.4%) vs. 4.7 hairs/cm² (3.4%), p < 0.0001). Hillmann et. al studied the application of minoxidil 5% foam in both the frontotemporal and vertex areas (59). The mean change from baseline nonvellus hair count was highly significant different from placebo at 16 weeks (27.7 hairs/cm² (14.4%) in the frontotemporal region and 25.6 hairs/cm² (13.1%) in the vertex region vs 4.5 hairs/cm² (2.7%) in the frontotemporal region and 5.9 hairs/cm² (33%) in the vertex region, p=0.0001). After 24 weeks of application, no significant changes from baseline were found in either group. Kanti et al. reported stable mean non-vellus hair count between baseline and week 104 in the frontotemporal and vertex regions in men treated with minoxidil 5% topical foam twice daily (37).

Piekpork et al. examined minoxidil 2% in a gel formulation and as solution (50). Whereas placebo gel and solution reached comparable percentage improvement in subject’s assessment (33 vs. 36%), minoxidil 2% gel, twice daily had 26% improvement, minoxidil 2% solution, twice daily 48% improvement after 6 months in subject evaluation.

**Minoxidil vs. finasteride**

4 studies obtaining grade B evidence where identified comparing the use of oral finasteride 1mg and topical minoxidil, resulting in in **EVIDENCE LEVEL 2**.

Hu et al compared finasteride 1 mg daily per os to minoxidil 5% topical solution twice daily for 12 months in Chinese males with androgenetic alopecia, showing statistically significant increase of hair growth in both groups over time (P<0.01, improvement 80.5% and 59% respectively, based on investigator’s assessment) (73). A more pronounced improvement was found in the finasteride group (p<0.01). A study by Saraswat et al. reported superiority of finasteride 1 mg/d per os compared to minoxidil 2% topical solution, applied twice daily, (mean change from baseline total hair count 36.1 hairs/cm² (29.1%) vs. 19.6 (14.8%) at 12 months, p = 0.003) (64). Khandpur et al. reported improvement in 87% of the patients receiving finasteride 1mg daily and 42% in patients receiving minoxidil 2% solution twice daily, as rated by an investigator (67).
On the other hand, Arca et al. reported 80% improvement in global photographic assessment for minoxidil 5%, twice daily and 52% for finasteride 1mg daily at 12 months (63).

**Minoxidil vs. Topical 5a-Reductase Inhibitor**

In a study by Pumthong et al., males with androgenetic alopecia were randomized to receive a hair tonic including 5% hexane extract of Curcuma aeruginosa, a botanically derived 5a-reductase inhibitor, minoxidil 5% topical hair tonic, combination formulation (5% hexane extract of Curcuma aeruginosa + 5% minoxidil) or placebo. Hair tonic twice daily for 6 months (79). Mean changes from baseline non-vellus hair counts were 30.62 hairs/cm² (20.0%) for the Curcuma aeruginosa 5% extract, 31.32 hairs/cm² (18.1%) for minoxidil 5% topical hair tonic, 32.59 hairs/cm² (20.7%) for the combination topical treatment and 20.41 hairs/cm² (11.4%) in the placebo hair tonic group. However, when percent changes between baseline and month 6 of the four groups were compared, these differences did not reach statistically significant levels (p > 0.05).

This study obtained grade A2 evidence, resulting in an **EVIDENCE LEVEL 2**.

**Minoxidil vs. Adenosine**

Faghihi et al. failed to prove superiority of the application of adenosine 0.75% solution compared to minoxidil 5% topical solution twice daily during 6 months (78). According to the global expert panel assessment, after 3 months of treatment relative recovery was achieved in 1.9% and 2.4% of the patients in the two groups respectively, with no significant between-group difference (p=0.17). At the end of 6 months of treatment, complete and relative recovery did not reveal changes between the groups (p=0.99), except for the patient satisfaction score, which showed a significant preference for adenosine (p=0.003).

**Minoxidil vs. Rosemary Oil**

Panahi et al. did not find any significant differences in hair growth between therapy with minoxidil 2% topical solution and a formulation containing rosemary oil after 6 months (p>0.05) (68).

### 3.1.4 Efficacy – females

19 studies that investigated the efficacy of topical minoxidil in female patients suffering from androgenetic alopecia could be included in the evidence based evaluation (60, 61, 74, 75, 77, 80-93). 5 studies treated male and female patients. 7 studies obtained grade A2 evidence, 9 studies grade B evidence, 3 studies grade C evidence resulting in an **EVIDENCE LEVEL 1**.

**Outcomes**

Minoxidil 1% solution, applied twice daily led to mean changes from baseline total hair count at 6 months from 15.2 hairs/cm² (8.0%) (94). Minoxidil 2% solution showed mean changes from baseline nonvellus hair count at 6 months between 21.0 hairs/cm² and 50.1 hairs/cm² (12.4-31.3%) (60, 81-85, 87, 90, 91). Minoxidil 3% solution showed a mean change from baseline hair count of 11.9 hairs/cm² (12.4%) at 6 months (92).

Minoxidil 5% topical foam, applied once daily led to mean changes from baseline nonvellus hair count between 13.4 and 31.9 hairs/cm² (16.2%) after 6 months (89-91). A significantly different mean change was shown in comparison to placebo
Two studies by Blume-Peytavi et al. showed noninferiority of minoxidil 5% foam used once daily compared to minoxidil 2% solution used twice daily for 6 months and 1 year (90, 91). A further study by Sheng et al. showed comparable improvement ratio in female patients applying minoxidil 2% topical solution twice daily and minoxidil 5% topical solution once daily for 6 months (p=0.076) (88).

In the study by Lucky et al., topical minoxidil 5% solution twice daily, topical minoxidil 2% solution twice daily or placebo twice daily was applied for 48 weeks in women with androgenetic alopecia (83). No significant difference was found between the 5% and 2% topical minoxidil groups in the mean change from baseline in non-vellus hair count at week 48. In adverse event reporting, 46% of the patients in the 5% minoxidil group reported increased facial hair growth vs. 22% in the 2% minoxidil group and 16% in the placebo group.

Except the study by Whiting et al. all studies showed significant different mean changes from baseline hair counts in comparison to placebo (p between 0.02 and <0.00001 (81-84, 89-91, 94).

**DOSAGE**

*Concentration.* The mean changes in nonvellus hair counts between minoxidil 5% and 2% in female patients were not statistically significant (p = 0.129) (83). At 12 months the mean change from nonvellus hair count was 20.7 hairs/cm² (13.8%) for minoxidil 2%, twice daily, 24.5 hairs/cm² (17.3%) for minoxidil 5%, twice daily and 9.4 hairs/cm² (6.8%) for placebo, twice daily (p < 0.001 vs. placebo).

Two studies by Blume-Peytavi et al. showed noninferiority of minoxidil 5% foam once daily compared to minoxidil 2% solution twice daily for 6 months and 1 year (90, 91).

**MINOXIDIL VS. ALFATRA DIOL**

In comparison to topical Alfatradiol 0.025%, once daily, minoxidil 2% solution, twice daily led to increased hair counts after 6 months (80). The mean change from baseline total hair count was -7.8 hairs/cm² (-4.3%) for alfatradiol and 15.3 hairs/cm² (8.7%) for minoxidil 2% (p < 0.0005).

**3.1.5 Instructions for use / Practicability**

Treatment with minoxidil converts partially miniaturized (intermediate) to terminal hair and produces at least a partial normalization of the hair follicle morphology.

Minoxidil should be applied as 1 ml of solution with a pipette or half a cap of foam to dry hair and scalp once in the morning and again in the evening and left in place for at least four hours. In women the foam formulation is recommended only once daily. When using spray applicator it has to be spread evenly over the affected areas. After application the hands should be washed with warm water.

Treatment efficacy should be assessed at least 6 months after initiation of therapy and treatment should be maintained as long as the effect is to be desired by the patient in order to prevent hair loss.

Some patients may experience *increased hair shedding* during the first months of the treatment. This is transitory and only indicates that the drug is stimulating telogen follicles to re-enter anagen. It is important to inform the patient about a possible
telogen shedding, before the treatment is started. If shedding occurs, therapy should be maintained. Usually, increased hair loss and reduced hair density due to telogen shedding normalizes within a few weeks to months. Good patient-practitioner-relationship and detailed patient information are essential for good compliance. Interruption of topical minoxidil is followed by increased hair loss, which usually starts 3 months after stopping the treatment.

Main side effect of topical minoxidil is hypertrichosis, which is more common with the 5% concentration and is usually due to incorrect application and rarely to systemic absorption. To avoid contamination of the pillow with subsequent contact with face patients should be advised to apply the drug at least 2 hours before going to bed. Irritant and allergic contact dermatitis may also occur. Irritation is more common with the 5% solution due to its higher content in propylen glycole. Contact dermatitis should be confirmed by patch testing. If it is due to propylen glycole, an alternative vehicle can be used, whereas if irritation and contact dermatitis are due to minoxidil itself, drug interruption is unavoidable.

Some women report difficulties in topical foam application in daily use. Evaluation of hair density, practicability for the patient and thorough instructions are needed prior to first prescription.

Minoxidil is contraindicated in pregnancy and lactation.

3.1.6 Combination therapies – males

9 studies investigating the effect of minoxidil topical solution alone vs combination therapy could be included in the evidence based evaluation (67, 69-75, 79). 2 studies treated male and female patients. 3 studies obtained grade A2 evidence and 6 studies grade B evidence resulting in an EVIDENCE LEVEL 3.

Minoxidil and finasteride combination

In a study by Hu et al., Chinese males with androgenetic alopecia were randomized into three groups, treated with finasteride 1 mg per os once daily, topical minoxidil 5% twice daily and combination treatment with finasteride 1 mg per os once daily and topical minoxidil 5% twice daily for 12 months. According to the investigator’s assessment, the efficacy of the combined treatment was the best (p<0.01) with an increase of 94.1% in hair growth after 12 months (73).

Khandpur et al. reported improvement in 100% of the patients receiving combination therapy with finasteride 1mg per os daily and minoxidil 2% topical solution twice daily and 42% in patients receiving minoxidil 2% topical solution twice daily, as rated by an investigator (67).

Minoxidil and topical 5a-reductase inhibitor combination

A study by Tanglertsampan did not show any difference in the mean change in hair counts between two groups treated for 24 weeks with minoxidil 3% topical lotion vs combined minoxidil 3% and finasteride 0,1% topical lotion (p=0.503) (70). Another study by Pumthong et al failed to show superiority of a combination hair tonic formulation containing 5% hexane extract of Curcuma aeruginosa and 5% minoxidil compared to a hair tonic containing 5% hexane extract of Curcuma aeruginosa, 5% minoxidil hair tonic or placebo hair tonic (79).
**Minoxidil and Pyrithione Zinc Shampoo Combination**

A study by Berger et al. failed to show that combination of minoxidil 5% solution and pyrithione zinc shampoo is superior to minoxidil monotherapy (65). Minoxidil 5% solution, twice daily combined with pyrithione zinc shampoo 1x/d vs. minoxidil 5% solution twice daily and placebo shampoo showed mean change from baseline total hair count of 6.2 hairs/cm² and 12.3 hairs/cm² respectively.

**Minoxidil, Diclofenac and Tea Tree Oil Combination**

A pilot study by Sakr et al compared a multimodal oil/water micro emulsion comprising minoxidil 5%, diclofenac 0.5% and tea tree oil 5% (n=11), a formulation containing minoxidil 5% alone (n=11), and placebo (n=10) applied twice daily for 32 weeks (72). Mean changes from baseline total hair count were 84 hairs/cm² (63.2%), 48 hairs/cm² (39.3%) and -57 hairs/cm² (-41%) respectively. Improvement in hair count with the multimodal minoxidil microemulsion was significantly greater than with minoxidil alone or placebo throughout the treatment period (P < 0.01 and P < 0.001, respectively). The study obtained an evidence grade B. However, due to the small number of subjects per group, the results should be confirmed in larger cohorts.

**Minoxidil, Betamethasone Valerate and Azelaic Acid Combination**

Pazoki-Toroudi et al. compared in a study in male and female patients minoxidil 5% topical solution, combination of minoxidil 12.5% with azelaic acid 5.0% and betamethasone valerate 0.025%1x/d and placebo topical solution 2x/d (75). At 24 weeks, improvement was found according to investigator’s assessment in 40%, 61.91% and 37.5% of male patients in the minoxidil, combination and placebo group respectively. Improvement was reportedly statistically significant in the combination group compared to placebo (p<0.001) and topical minoxidil 5% (p<0.05). This study obtained a grade of evidence B.

**Minoxidil and Tretinoin Combination**

Bazzano et al. compared in a study in male and female patients minoxidil 0.5% solution, 2x/d, tretinoin 0.025% solution, 2x/d, placebo and the combination of minoxidil 0.5% with tretinoin 0.025% (74). At 12 months, 58% of the patients of the tretinoin group and 66% of the patients with the combined treatment had at least 20% or more increase from baseline total hair count. Shin et al. failed to prove significance between minoxidil 5% solution, twice daily and a combination of minoxidil 5% and tretinoin 0.01%, once daily in men with androgenetic alopecia (69). The mean change from baseline total hair count at 18 weeks was 15.9 hairs/cm² (12.8%) vs. 18.2 hairs/cm² (14.7%) (p not significant).

**Minoxidil and Microneedling Combination**

In a 12-week study by Dhurat et al. (71), combination therapy consisting of weekly microneedling treatment and twice daily 5% minoxidil topical lotion showed a mean change in total hair count from baseline of 91.4 hairs/cm², while 5% minoxidil topical lotion monotherapy showed a mean change in total hair count from baseline of 22.2 hairs/cm² (p=0.039).

### 3.1.7 Combination therapies – females

5 studies investigating the effect of minoxidil topical solution alone vs combination therapy in females could be included in the evidence based evaluation (74, 75, 86,
2 studies treated male and female patients. 3 studies obtained grade B evidence and 2 studies grade C evidence resulting in an EVIDENCE LEVEL 3.

**MINOXIDIL AND ORAL SUPPLEMENT COMBINATION**
Trüeb et al compared in a study in female patients minoxidil 2% monotherapy with combination therapy with minoxidil 2% and an oral supplement (medicinal yeast 100 mg, thiamine mononitrate 60 mg, calcium pantothenate 60 mg, paraaminobenzoic acid 20 mg and keratin 20 mg), showing comparable change from baseline percentage of telogen hair count after 9 months of treatment (93).

**MINOXIDIL AND KOREAN RED GINSENG COMBINATION**
A study by Ryu et al. failed to show that combination of minoxidil 3% topical solution and Korean red ginseng is superior to minoxidil monotherapy in women (92).

**MINOXIDIL, BETAMETHASONE VALERATE AND AZELAIC ACID COMBINATION**
Pazoki-Toroudi et al. compared in a study in male and female patients minoxidil 5% topical solution, combination of minoxidil 12.5% with azelaic acid 5.0% and betamethasone valerate 0.025% 1x/d and placebo topical solution 2x/d. At 24 weeks, improvement was found according to investigator’s assessment in 37.5% of the female patients in the minoxidil group and in 14.9% of the female patients in the placebo group. Improvement was only significant compared to placebo (p<0.01) but not compared to minoxidil 5% topical solution (75).

**MINOXIDIL AND HORMONAL CONTRACEPTIVE COMBINATION**
Topical minoxidil 2% solution, 2x/d in combination with an oral hormonal contraceptive led to a mean change from baseline total hair count of 16.1 hairs/cm² (8.6%) at 6 months, 16.9 hairs/cm² (9.1%) at 12 months, whereas cyproterone acetate 50 mg in combination with oral hormonal contraceptive led to decreased values (-2.8 hairs/cm² (-1.4%) at 6 months, -7.8 hairs/cm² (-3.9%) at 12 months (p < 0.001) (86).

3.1.8 Summary
Minoxidil 2% solution twice daily is effective to prevent progression and improve androgenetic alopecia in male and female patients (LEVEL OF EVIDENCE 1). Minoxidil 5% solution or foam twice daily is more effective than the 2% solution in male patients (LEVEL OF EVIDENCE 2). In female patients, the efficacy of minoxidil 5% solution or foam applied once daily is comparable to minoxidil 2% solution applied twice daily (LEVEL OF EVIDENCE 2). Patients should be informed on telogen shedding within the first 8 weeks of therapy. Further studies are required to compare efficacy of minoxidil solution and foam formulation.

3.1.9 Therapeutic recommendation – Male

↑↑ Topical Minoxidil 2 to 5% solution 1 ml or half a cap of 5% foam twice daily is recommended to improve or to prevent progression of AGA in male patients above 18 years with mild to moderate AGA (Hamilton-Norwood II-V).

↑ We suggest using 5% solution or half a cap of 5% foam for greater efficacy.

Ο We cannot make a recommendation for the 5% minoxidil foam instead of the 5% solution at the present time.
↑ The response to treatment should be assessed at 6 months. If successful, treatment needs to be continued to maintain efficacy.

→ For greater efficacy the combination of oral finasteride 1 mg, 1x/d and topical Minoxidil 2% to 5% solution, 2x/d can be considered.

Ο We cannot make a recommendation for combination therapy of topical minoxidil with topical 5α-reductase or azelaic acid and betamethasone valerate at the present time.

Further studies are needed to confirm superiority of combination therapies consisting of topical minoxidil, diclofenac and tea tree oil, topical minoxidil, azelaic acid and betamethasone or topical minoxidil and microneedling.

3.1.11 Therapeutic recommendation – Female

↑↑ Topical Minoxidil 2% solution 1 ml twice daily or half a cap of 5% minoxidil topical foam once daily is recommended to improve or to prevent progression of AGA in female patients above 18 years with AGA.

Ο We cannot make a recommendation for the 5% minoxidil foam once daily instead of the 2% solution twice daily at the present time.

↑ The response to treatment should be assessed at 6 months. If successful, treatment needs to be continued to maintain efficacy.

Ο We cannot make a recommendation for combination therapy of topical minoxidil with red ginseng, azelaic acid and betamethasone or oral nutritional supplements at the present time

3.2 5-ALPHA-REDUCTASE-INHIBITORS

3.2.1 Introduction

Androgenetic alopecia (AGA) occurs after puberty in men with an inherent sensitivity to the effects of androgens on androgenetic sensitive scalp hair follicles. AGA does not develop in men who lack nor in men with a genetic deficiency of the enzyme 5α-reductase type 2 which converts testosterone to dihydrotestosterone (DHT). There are three 5α-reductase isoenzymes. Type 1 predominates in liver, skin and scalp. Type 2 is found mainly in prostate and genitourinary tract and also in the human hair follicle. Type 3 5α-reductase is widely distributed including in skin, prostate and brain.

Pharmaceutical 5α-reductase inhibitors were initially developed for the treatment of benign prostatic hyperplasia. Two drugs inhibiting 5α-reductase are available on the market: finasteride registered in Europe in 1992, and dutasteride registered in 2003. Finasteride is a type 2 5α-reductase inhibitor which decreases DHT by about 65% in serum, prostate and scalp. Finasteride also inhibits type 3 5α-reductase. Dutasteride inhibits both type 1 and type 2 5α-reductase decreasing serum DHT level by about 90%.
Two years after the registration of finasteride for the treatment of benign prostatic hyperplasia, the first publications appeared concerning the efficacy of finasteride in androgenetic alopecia in male patients. At the same time the drug was registered in the US (1993) and Europe (1994) for treatment of mild to moderate androgenetic alopecia in men.

The first report on the use of dutasteride as a treatment for androgenetic alopecia was published in 2006, but it has not been registered for this indication in Europe, only for treatment of benign prostatic hyperplasia.

3.2.2 Mechanism of action

A single oral dose of finasteride 1 mg decreases serum and scalp DHT up to 70% compared to baseline. Tachyphylaxis is not observed with long-term administration. Finasteride is quickly absorbed after oral intake with peak plasma level occurring 1 to 2 hours after drug intake. The serum half-life of the drug is about 6 hours. 90% of the drug is bound to plasma proteins. Finasteride is metabolised in the liver by hydroxylation and oxidation using P 450 3A4 pathway. There is no interaction with other drugs known to be metabolized by this cytochrome such as warfarin, theophylline, digoxin, propranolol and others.

3.2.3 Efficacy – males

Finasteride

25 studies investigating the efficacy of finasteride in male patients with androgenetic alopecia met the inclusion criteria of the guideline (63, 64, 67, 70, 73, 96-117). 24 out of these 25 studies assessed the efficacy of finasteride monotherapy in male patients with androgenetic alopecia. One included both male and female patients. Thirteen studies obtained grade A2 evidence, 9 grade B and 3 grade C. 14 studies were placebo controlled. Summarizing these results an EVIDENCE LEVEL 1 can be attributed for finasteride.

Outcomes

In all of the included trials, the intake of finasteride 1 mg daily led to a significant increase in total hair counts compared to placebo. The mean change from baseline total hair count was 7.0 hairs/cm² (3.3%) in the frontal/centroparietal region (p < 0.0001 vs. placebo) (107) and 13.5 hairs/cm² (7.3%) in the vertex (p < 0.0001 vs. placebo) (103) at 6 months.

The mean increase from baseline total hair counts at 12 months was between 7.2 hairs/cm² (3.6%) and 36.1 hairs/cm² (29.1%) for the vertex (p between < 0.05 and 0.001 vs. placebo) (98, 103, 104, 106-108) and 9.3 hairs/cm² (4.9%) and 9.6 hairs/cm² (4.6%) in the frontal/centroparietal region (p between < 0.01 and 0.001 vs. placebo) (97, 101). The placebo group showed mean changes from baseline total hair count between 2.4 hairs/cm² (1.4%) and -10.1 hairs/cm² (-5.2%).

At global expert panel assessment between 37 % and 54 % of the patients were rated as improved at 12 months (p < 0.001 vs. placebo) (98, 99, 103, 104, 107, 109, 111). In addition subjective assessments by investigator and patients yielded significant improvements in the finasteride group (98, 99, 103, 104, 107, 109).

Long-term results were available for 24, 36, 48, 60 and 120 months (96, 97, 102, 107, 109, 111-113, 118). The mean changes from baseline total hair counts were
13.0 hairs/cm² (6.2%) at 24 months (107), 8.5% at 36 months (102), 7.2% at 48 months (102) and 7.5 hairs/cm² (4.3%) at 60 months (111) respectively. In comparison to placebo they were statistically significant different.

Price et al. reported increase in hair weight at 12 to 48 months (20.4% at 12 months, 21.5% at 24 months, 19.5% at 36 months and 21.6% at 48 months versus -5.2%, -14.2%, -14.8% or -24.5% in the placebo group, p< 0.001) (101, 102).

In a 3.5-year study by Sato et al. in Japanese man with androgenetic alopecia receiving 1 mg finasteride once daily hair growth improved in 87.1% (greatly in 11.1%, moderately in 36.5% and slightly in 39.5%) according to investigator assessment (112). The response rate improved with increasing duration of treatment. Adverse reactions occurred in 0.7% of men, while no specific safety issues associated with long-term use were observed. In a 5-year open-label study by Yoshitaki et al. in Japanese men with androgenetic alopecia receiving 1 mg finasteride once daily hair growth improved in 99.4% and progression of hair loss was halted in 100% as assessed by global photography. The degree of improvement was highest after 1 year of treatment (96).

In a 10-year study by Rossi et al., at global expert panel assessment, 40.5% of patients between 26-30 years of age showed a remarkable improvement after 1 year of therapy with finasteride 1 mg/day, 16.7% showed a remarkable improvement after 2 years of therapy and 42.8% remained unchanged after 10 years (113). Patients between 31-40 years of age showed 53.6% remarkable improvement after 1 year of therapy, 14.3% after 2 years, 10.7% after 5 years, while 21.4% remained unchanged after 10 years of treatment. Patients older than 40 years showed 47.4% remarkable improvement after 1 year of therapy, 15.8% after 2 years, 5.2% after 5 years, and 31.6% remained unchanged after 10 years of treatment.

Dosage

Concentration. Two studies examining different finasteride dosages could be included in the evidence based evaluation (99, 103). Roberts et al. examined finasteride 0.01 mg, 0.2 mg, 1 mg and 5 mg versus placebo (103). The mean change from baseline total hair counts under finasteride therapy (0.2 mg, 1 mg and 5 mg) was significantly different to placebo at 6 and 12 months (p < 0.001), whereas dosage of 0.01 mg showed progressing hair loss (difference to placebo not statistically significant). The differences in mean change from baseline total hair count between the finasteride groups (0.2 – 5mg) did not reach significance. Kawashima et al. reported 58% and 54% improvement in global expert panel assessment for finasteride 1 mg and 0.2 mg respectively (99). The efficacy in both groups was comparable and significantly different to placebo (p< 0.001).

Finasteride vs. Minoxidil

Only few data comparing finasteride 1 mg daily and minoxidil solution are available. Two of the included studies examined finasteride 1 mg against twice daily topical application of minoxidil 2% solution (64, 67). Both studies showed superiority for finasteride. At 12 months the mean change from baseline total hair count was 36.1 hairs/cm² (29.1%) for finasteride 1 mg and 19.6 hairs/cm² (14.8%) for minoxidil 2%, twice daily application (p = 0.003) (64). 87% of the patients taking finasteride versus 42% of the minoxidil 2% patients were rated as improved (p < 0.001) (67).

Arca et al. reported a better outcome for minoxidil 5% solution applied twice daily against finasteride 1 mg daily at global photographic assessment of the frontal/parietal region at 12 months (80% vs. 52% improvement) (63). In the study by
Hu et al. improvement was found in 80.5%, 59%, and 94.1% of men treated with finasteride 1 mg once daily, 5% minoxidil topical solution twice daily and combination therapy with finasteride 1 mg and 5% minoxidil topical solution respectively (73).

**FINASTERIDE PER OS VS. TOPICAL FINASTERIDE**

Hajheydari et al. found a similar small but significant increase in total hair count from baseline in male patients with androgenetic alopecia receiving a topical gel of 1% finasteride twice daily and placebo tablets once daily and male patients receiving finasteride 1 mg tablets once daily and placebo topical gel twice daily for 6 months (114). No data on serum DHT levels were given and more studies are required to confirm this result.

Other botanically derived 5α-reductase inhibitors, such as serenoa repens and Curcuma aeruginosa were assessed in 2 studies and compared to finasteride per os and topical minoxidil respectively:

**FINASTERIDE VS. SERENOA REPENS**

Serenoa repens is a plant of the Arecaceae’s family, acting as a competitive, non-selective inhibitor of 5α-reductase of types 1 and 2. Rossi et al. compared finasteride 1 mg per os once daily to serenoa repens 320 mg per os once daily for 24 months in male patients with androgenetic alopecia (118). According to global expert panel assessment, 38% of patients treated with Serenoa repens and 68% of patients treated with finasteride showed an increase in hair growth.

**CURCUMA AERUGINOSA TOPICAL EXTRACT VS. MINOXIDIL**

In a study by Pumthong et al. males with androgenetic alopecia were randomized to receive a hair tonic including 5% hexane extract of Curcuma aeruginosa, a botanically derived 5α-reductase inhibitor, minoxidil 5% topical hair tonic, combination formulation (5% hexane extract of Curcuma aeruginosa + 5% minoxidil) or placebo hair tonic twice daily for 6 months (79). Mean changes from baseline non-vellus hair counts were 30.62 hairs/cm² (20.0%) for the Curcuma aeruginosa 5% extract, 31.32 hairs/cm² (18.1%) for minoxidil 5% topical hair tonic, 32.59 hairs/cm² (20.7%) for the combination topical treatment and 20.41 hairs/cm² (11.4%) in the placebo hair tonic group (p<0.001). No significant differences were found between the groups (p>0.05).

**Dutasteride**

5 studies investigating dutasteride in androgenetic alopecia were included in the evidence based evaluation, 4 of which with grade A2 evidence and 1 of which with grade C evidence, resulting in a **LEVEL OF EVIDENCE 1** (100, 117, 119-121).

**OUTCOMES**

Stough et al. reported a significant mean increase from baseline total hair count of 6.8 hairs/cm² at 6 months and 16.5 hairs/cm² at 12 months for dutasteride 0.5 mg daily (119).

Eun et al. reported a significant mean increase from baseline total hair count of 12.2 hairs/cm² (8.2%) for dutasteride 0.5 mg daily vs 4.7 hairs/cm² (3.3%) for placebo at 6 months (P = 0.03) (121). The improvement ratio of investigator photographic assessment at 6 months was 61.6% in the dutasteride group and 20.0% in the placebo group.
In a study in 35 Korean men with androgenetic alopecia Jung et al. showed a mean change from baseline total hair count of 14 hairs/cm$^2$ for dutasteride 0.5 mg daily (120).

**DUTASTERIDE VS. FINASTERIDE**

In a 24-week study of 416 patients Olsen et al. showed a significant increase from baseline total hair count of 15.4 hairs/cm$^2$ (8.7%), 18.6 hairs/cm$^2$ (10.2%) and 21.5 hairs/cm$^2$ (11.3%) in men treated with dutasteride 0.1mg daily, 0.5mg daily and 2.5mg daily (p=0.009) respectively (100). All dutasteride arms and finasteride 5 mg showed a significant difference of $p < 0.001$ vs. placebo.

It should be pointed out that the most effective dosage of dutasteride (2.5mg daily) is 5 times higher than the standard dose used in the treatment of benign prostatic hyperplasia (dutasteride 0.5 mg corresponds to finasteride 5 mg).

In a study by Gubelin Harcha et al. 917 male patients with androgenetic alopecia were randomized to receive different dutasteride doses (0.02 mg/d, 0.1 mg/d, 0.5 mg/d), finasteride 1 mg/d, or placebo for 24 weeks (117). A significant increase from baseline in hair counts and hair diameters and improved hair growth at global panel photographic assessment was reported in patients receiving dutasteride 0.1mg and 0.5 mg daily and finasteride 1mg daily. Dutasteride 0.5mg daily was significantly superior to finasteride 1 mg/d ($p=0.16$). Some aspects of sexual dysfunction were more common in men receiving dutasteride and finasteride (e.g. altered libido: finasteride 6.7%, dutasteride 0.5mg 4.9%, placebo 1.7%) whereas there was no difference between treatment and placebo groups in the frequency of ejaculation disorders.

### 3.2.4 Efficacy – females

One study assessing the efficacy of finasteride 1mg daily (122) and two studies assessing the efficacy of finasteride 5 mg daily in female patients were included in the evidence based evaluation (115, 116). The grades of evidence were A2, C, C resulting in an **EVIDENCE LEVEL 3**.

**Outcomes**

A 12-month randomised controlled trial of finasteride 1mg daily in postmenopausal women with AGA showed a further progression of hair loss and no significant difference from the placebo-control group. After one year there was a mean change from baseline hair count at -8.7 hairs/cm$^2$ in women taking finasteride and -6.6 hairs/cm$^2$ in the control group.

On the contrary, both studies assessing the efficacy of finasteride 5 mg daily reported improvement in hair growth. In the study by Yeon et al. in normoandrogenic Asian women with female pattern hair loss, there was a mean increase in hair count from baseline of 18.9 hairs/cm$^2$ (21%) and a mean increase from baseline in hair diameter of 9.4 µm (14.7%) after 12 months of treatment (115). Reported adverse events included headache, menstrual irregularity, dizziness and increased body hair growth. Oliveira-Soares et al. found ‘major’ improvement in 55%, as assessed by global photography, and ‘moderate’ improvement in 37.5% of normo-androgenic postmenopausal women treated with finasteride 5 mg daily for 18 months (116). However, both studies using finasteride daily 5mg were uncontrolled.
3.2.5 Instructions for use / Practicability

Finasteride can be taken with or without food and there is no known interaction with other drugs.

Finasteride is not licenced in women and is contraindicated in pregnant women and women of childbearing potential, because of the risk of feminisation of a male foetus. Finasteride treated men must therefore avoid donating their blood.

The level of finasteride in the semen of treated man is very low even with regular intake of finasteride 5 mg/day, and there is no risk in case of sexual relation with pregnant women. The use of a condom is not necessary for this reason.

The recommended dosage of finasteride in men is 1 mg a day, but in a dose finding study with a lower dosage of 0.2 mg/day also led to significant improvement compared to placebo. For this reason, if a patient forgets a pill, we do not recommend taking two the next day.

The minimal period of use to assess the efficacy for reducing hair loss is 6 months and 12 months for regrowth of hair. If a patient intends to switch from minoxidil to finasteride we recommend a combination therapy for at least 3, better 6 months before stopping minoxidil in order to avoid significant hair loss before finasteride action can take over.

Finasteride reduces PSA levels and may decrease prostate size. If treatment is started after 45 years of age, a baseline PSA level should be obtained and regular prostate screening by a urologist should be recommended. The PSA levels should be doubled to compensate the reduction due to finasteride for an accurate interpretation of the test.

Additional research is required in different subgroups of female patients with pattern hair loss including younger female patients and female patients with or without clinical hyperandrogenism. However, the use of finasteride in females can be considered only in combination with safe contraceptive methods due to the risk of malformation of genitals in male foetus (feminization).

Adverse effects of finasteride

Sexual dysfunction

Impaired sexual function is the most commonly reported adverse effect of finasteride, including erectile dysfunction, ejaculation dysfunction, reduced ejaculate volume and loss of libido. In controlled clinical trials of finasteride in AGA the frequency of adverse effects on sexual function has been around 2-6% although not all studies have shown this when compared to rates in placebo groups. In a study where sexual function was specifically assessed using the International Index of Erectile Function questionnaire there was no significant difference in sexual or erectile function between 236 men taking finasteride for AGA and 236 controls (123). A review of 12 controlled trials of finasteride in the treatment of AGA concluded there was moderate evidence for an increase in erectile dysfunction in men taking finasteride (RR 2.2, 95% CI 1.03-4.78) and a possible increased risk of any sexual disturbance (124). However, the quality of safety reporting in clinical trials of finasteride has been criticized. In a meta-analysis of 34 trials the authors concluded that none had adequate safety reporting and 19 were only partially adequate (125). They stated that published trials provided insufficient information to establish the safety profile for finasteride in the treatment of AGA.
Depression

Depression as an adverse effect of finasteride has also received much media attention though the evidence is limited. Altomare et al reported 19 cases (14 men, 5 women) of depression that appeared temporally related to finasteride 1mg daily for treatment of AGA(126). Symptoms resolved promptly when the drug was discontinued. In a prospective study in 128 men prescribed finasteride 1mg for AGA there was a significant increase in Beck’s Depression Inventory (BDI) and Hospital Anxiety and Depression Scale (HADS) scores after 2 months of treatment (127). It has been proposed that an adverse effect of 5α-reductase inhibitors on mood is caused by inhibition of GABAergic neuroactive steroids (e.g. allopregnanolone, 3α-androstanediol), which are derived from 5α-reduced steroid metabolites. A study in 12 men found a significant and progressive reduction of plasma neuroactive steroids during one year of treatment with finasteride 1mg daily (128). Low levels of neuroactive steroids have been associated with depression (in the absence of finasteride therapy), post-natal depression and post-traumatic stress disorder (129), providing some support for this idea.

The frequency of depression and alteration of mood in men taking finasteride is unknown. It was not reported in the pivotal clinical trials and is probably uncommon. However, it is possible that finasteride does have a negative impact on those who have a constitutive predisposition to psychological disorders.

Others

Less common or rare adverse effects of finasteride include gynaecomastia, testicular pain and hypersensitivity reactions.

Prostate cancer

In a study published in 2003 of 9060 men aged over 55 years randomised to finasteride 5mg daily or placebo and followed for 7 years the frequency of prostate cancer in the finasteride cohort was 18.4% compared to 24.4% in men receiving placebo but there was a significantly greater frequency of high-grade prostate cancer (Gleason grade 7-10) in the finasteride group (6.4% vs 5.1%) (130). However, a later study of 18,880 men in the same trial followed for up to 18 years found no difference in survival between the finasteride and placebo groups (131). Two other studies, using datasets from the UK and Scandinavia, also found no effect of finasteride on overall or prostate cancer-specific survival (132, 133). Current data suggest that finasteride reduces the overall risk of prostate cancer by about a third and may increase the detection of high-risk prostate cancer (detection bias) but does not affect the outcome in terms of survival.

Breast cancer

In 2009 the UK Medicines and Healthcare Regulatory Agency (MHRA) reported there had been 50 cases of breast cancer worldwide in men taking finasteride 5mg daily and 3 cases taking 1mg daily. Breast cancer is a rare tumour in men raising the possibility of a causal relationship. However, two controlled studies using datasets from the UK and the USA found no increase in the incidence of breast cancer in men taking finasteride (134, 135). In the large long-term Prostate Cancer Prevention Trial there were two cases of breast cancer in the finasteride arm and two cases in the placebo arm (136). The Propecia Summary of Product Characteristics (SPC) mentions breast cancer as a possible risk but current data suggest the occurrence of breast cancer in men taking finasteride is coincidental.
Spermatogenesis

In a prospective placebo controlled study finasteride 5mg daily reduced sperm counts by an average of 34% at 24 weeks. Counts recovered to near-baseline levels after 52 weeks treatment and had recovered further at 24 weeks post-treatment follow up (137). A randomised controlled study of finasteride 1mg daily vs placebo in 79 men found no effect on sperm parameters despite a reduction in circulating DHT similar to that in the Amory study (138).

However, there are a small number of case reports of infertility and oligospermia in men taking finasteride 1mg daily (139-142). In a case series of 14 men presenting with infertility who were taking finasteride 1mg daily 9 had oligospermia (143). There was an average 11.6-fold increase in sperm counts after finasteride was discontinued, which was more pronounced in those with initially severe oligospermia. Sperm counts recovered in 4 of the 7 men with severe oligospermia. The authors suggested that finasteride may negatively impact spermatogenesis in those men with pre-existing conditions relating to infertility.

Post-finasteride syndrome

Over the last 5 years several published case series have reported various symptoms persisting for months or years after discontinuation of finasteride (144-149). The most frequent symptoms are sexual dysfunction, loss of libido and depression. Other symptoms include suicidal ideation, impaired cognition, fatigue and decreased penile sensitivity. This complaint has been termed post-finasteride syndrome (PFS) although a clear causal relationship with finasteride use has not yet been established. Studies reporting PFS have all been retrospective and many cases have been recruited through internet websites targeted at those with persistent symptoms, making selection bias a significant limitation. Assessment of any relationship with finasteride is complicated by the fact that these symptoms also occur in the general population and may be exacerbated psychologically through a nocebo effect (150).

A possible explanation for symptoms occurring for the first time shortly after discontinuation of the drug is a withdrawal effect comparable to a steroid withdrawal. It has been hypothesized that alterations of androgen receptors, androgen resistance or changes of androgen production levels during the time the drug was taken have lead to irreversible androgen-deprivation changes, for example in erectile tissue physiology and function. Another explanation is a sustained change of neuroactive steroids and androgen receptors in the brain tissue (151). One study found significantly lower levels of 5α-reduced neuroactive steroids (allopregnanolone, 3α-androstanediol) in plasma and CSF of men with neuropsychiatric symptoms post-finasteride compared to otherwise healthy control subjects undergoing spinal surgery(152). However, levels were not measured prior to finasteride treatment.

In a small controlled study, an increased number of androgen receptors (AR) was found in the foreskin stromal and epithelial cells of patients with PFS but not in vessel smooth muscle cells, while the nerve density was not different (153). The ratio of AR to testosterone (T) or free-testosterone (fT) levels was 2-fold higher than in controls. Those patients with more severe sexual side effects had relatively more AR. The reason for these changes and the actual activity of these AR is still unknown. Possible reasons are a regulatory feedback-effect, a direct effect of low androgens or inhibition of the AR by finasteride. However, no pre-treatment data are available and some of the patients were already treated with testosterone or tadalafil. Most affected patients reported low testosterone levels which were detected after symptoms
occurred, but no pre-finasteride levels are known. In the study, the levels of T and fT were not significantly different than in control patients.

The frequency of PFS in men who have taken finasteride is unknown. Many clinicians who frequently prescribe finasteride doubt its existence suggesting that it is uncommon. Nevertheless, despite the uncertainties over the causal relationship it is clear that some men who have taken finasteride for AGA do experience long-term disability and patients should be informed about the matter. It is not clear whether there are risk factors for the development of PFS that can be identified pre-treatment. In a study of 95 men complaining of persistent post-finasteride symptoms 55% gave a history of a psychiatric diagnosis prior to taking finasteride suggesting a pre-morbid component to the development of PFS (154). From a practical standpoint it may be wise to advise caution in men with a history of sexual dysfunction or a personal or family history of psychiatric illness. In patients with active depression or current sexual dysfunction, finasteride is contra-indicated.

Whether PFS is a true consequence of finasteride treatment is controversial. Although there is a body of opinion that strongly believes its existence the case is unproven and further research is needed, ideally prospective in nature. We also need to establish its frequency, how to identify those at particular risk and how best to treat those men who develop persistent symptoms.

Regulatory authorities have changed the package labelling for finasteride to include persistent side effects, which may or may not have a causal relationship to the drug. The UK Patient Information Leaflet lists the following information on side effects:

Frequency unknown:
- Persistent difficulty having an erection after discontinuation of treatment
- Persistent decrease in sex drive after discontinuation of treatment
- Persistent problems with ejaculation after discontinuation of treatment

3.2.6 Combination therapies

Leavitt et al. showed in 79 male patients undergoing hair transplantation, that the combination with finasteride 1 mg daily led to increased hair counts after 12 months, whereas hair transplantation alone resulted in decreased hair count in the frontal area (mean change from total baseline hair count 18.5 hairs/cm² (12.6%) vs. -13.5 hairs/cm² (-8.9%), p = 0.019) (110).

Khandpur et al. compared the combination of finasteride 1 mg daily with minoxidil 2% solution twice daily respectively ketoconazole 2% shampoo, 3x weekly to finasteride 1mg daily and minoxidil 2% solution twice daily as monotherapies (67). At 12 months, 100% of the patients of each combined therapy, 87% for finasteride and 42% for minoxidil 2% solution were rated as improved by investigator. The combination of minoxidil 2% and finasteride 1 mg was statistically significant superior to finasteride or minoxidil monotherapies. Furthermore, Diani et al. showed an additive effect of finasteride and minoxidil in stumptail macaque (155).

Hu et al., showed better efficacy of combination therapy with finasteride 1 mg per os once daily and topical minoxidil 5% twice daily for 12 months (94.1% improvement) compared to finasteride 1 mg per os once daily (80.5% improvement) or topical minoxidil 5% twice daily (59% improvement) as rated by global photographic evaluation (73).
A study by Tanglertsampan failed to show an advantage of therapy with combined minoxidil 3% and finasteride 0.1% topical lotion vs with minoxidil 3% topical lotion after 24 weeks (p=0.503) (70).

The mechanisms of action of minoxidil and finasteride treatments are different. Thus association of topical minoxidil and oral finasteride is possible and can be considered in motivated patients.

3.2.7 Summary

Finasteride 1 mg daily is effective in prevention of progression and induction of hair regrowth in androgenetic alopecia in male patients (evidence level 1).

Evaluation of the efficacy should be assessed 6 months after treatment initiation.

Patients should be aware of reduction of prostate specific antigen, which is important in prostate cancer screening in men < 45 years of age.

Further studies comparing the efficacy of finasteride 1 mg versus minoxidil 5% are needed. If the therapeutic approach is insufficient the combination of finasteride 1 mg and minoxidil 2% or 5% can be considered.

In patients with insufficient efficacy of finasteride 1 mg, the off-label use of Dutasteride 0.5 mg can be considered.

In female postmenopausal patients finasteride 1 mg failed to show efficacy (LEVEL OF EVIDENCE 2). Finasteride 5 mg may be effective in female normoandrogenic pre- and postmenopausal patients (LEVEL OF EVIDENCE 3). However, there is insufficient data to recommend it, as no placebo-controlled trials are available. Studies in different subgroups of female patients with androgenetic alopecia are required. In women of childbearing age, a safe contraceptive method is essential as finasteride may lead to feminisation of a male foetus.

3.2.8 Therapeutic recommendation – Male

**Finasteride**

↑↑ Oral Finasteride 1 mg a day is recommended to improve or to prevent progression of AGA in male patients above 18 years with mild to moderate AGA (Hamilton-Norwood IIv-V).

↑ The response to treatment should be assessed at 6 months, although in some men it may not become evident before 12 months. If successful, treatment needs to be continued to maintain efficacy.

Ο We cannot make a recommendation for or against treatment with topical finasteride at the present time

→ For greater efficacy the combination of oral finasteride 1 mg, 1x/d and topical Minoxidil 2% to 5% solution or 5% foam 2x/d can be considered.

**Dutasteride**

→ Oral Dutasteride 0.5 mg a day can be considered in case of ineffective previous treatment with 1 mg finasteride over 12 months as a second line
treatment to improve or to prevent progression of AGA in male patients above 18 years with mild to moderate AGA (Hamilton-Norwood IIIv-V).

Serenoa repens
O We cannot make a recommendation for or against treatment with Serenoa repens per os at the present time

Curcuma Aeruginosa
O We cannot make a recommendation for or against treatment with topical Curcuma aeruginosa at the present time

3.2.9 Therapeutic recommendation – Female
↓ Oral Finasteride 1mg daily is not suggested in the treatment of postmenopausal women with female pattern hair loss.
O We cannot make a recommendation for or against treatment with oral finasteride 5 mg a day at the present time.

3.3 HORMONES

3.3.1 Introduction
The role of androgens in the aetiology of androgenetic alopecia has led to the widespread use of hormonal agents in its treatment. They fall into two broad groups – antiandrogens and oestrogenic (or anti-oestrogenic) drugs, although evidence of efficacy for any of these treatments is limited or absent.

3.3.2 Mechanism of action
Antiandrogens act primarily through blockade of the androgen receptor. Different agents may have other relevant effects on endocrine biology including inhibition of steroid synthesis and progestational activity. Antiandrogens have mainly been delivered systemically and used in women (they are contraindicated in men due to their feminizing action).

Topical oestrogens and anti-oestrogens have been used in both men and women. The rationale for their use is less clear than for antiandrogens as the effect, if any, of oestrogens on human hair growth is unknown. Oestrogens inhibit hair growth in several other mammals lending some support for the potential of antioestrogens to promote hair growth in humans.

3.3.3 Efficacy – males
Oral hormonal treatment
There is no evidence to support the use of oral estrogens or antiandrogens to improve or prevent progression of androgenetic alopecia in male patients (EVIDENCE LEVEL 4).

Topical hormonal treatment
There are only two controlled trials of topical hormonal treatment that have employed modern methods of assessment.

**OUTCOMES**

Sovak et al. studied the change of anagen hair count following daily topical application of the antiandrogen FLURIDIL versus placebo. At 12 months, the response to fluridil was not significantly different from placebo. Therefore there is limited evidence that topical fluridil is ineffective in men (156).

Gassmueller et al. (62) compared topical application of FULVESTRANT (70mg/ml twice daily), an estrogen receptor antagonist, to minoxidil 2% and placebo. At 16 weeks the mean change from baseline hair counts was not significantly different from placebo in the fulvestrant group whereas there was a significant increase in hair counts in subjects treated with minoxidil. Therefore there is evidence that topical fulvestrant is ineffective in men.

There are three earlier studies on the efficacy of the topical estrogen ALFATRADIOL (=17 alpha-oestradiol) in men. Unfortunately they either had no control group (157, 158) and/or the results were not reported separately for each sex (158, 159). In one study, topical corticosteroid was included (158).

3.3.4 Efficacy – females

**Oral hormonal treatment**

5 studies met the inclusion criteria, 1 of which was placebo-controlled. 4 of the studies obtained a grade of evidence B and 1 of them obtained a grade of evidence C, resulting in LEVEL OF EVIDENCE 3).

**OUTCOMES**

Peereboom-Wynia et al. compared a group of women treated for one year with 50 µg estradiol +2 mg cyproterone acetate + 20 mg cyproterone acetate (CPA) days 1-14 with an untreated control group (160). Trichogram data showed a mean change in anagen percent from 49.7 at baseline to 74.4 after one year in the treated group compared to a fall from 60.4 to 48.8 in the controls. Subjects appeared not to be randomized to treatment or control groups and hair counts were not performed.

In a 6-month open-label study by Kapadia et al. 26 normoandrogenic women were treated with 35 µg estradiol +2 mg CPA + 50 mg CPA for the first 10 days in combination with 5% topical minoxidil twice daily. According to investigator’s assessment, improvement was found in 72.7% of the patients in the frontotemporal region and in 50% of the patients in the vertex region. However, this study was not placebo-controlled (95).

Vexiau et al. reported a mean change baseline total hair count of -2.8 hairs/cm² (-1.4) at 6 months and -7.8% hairs/cm² (-3.9%) at 12 months in subjects receiving oral contraceptive + 50 mg cyproterone acetate (86) whereas subjects treated with a combination of minoxidil 2% solution twice daily and oral contraceptive showed a mean increase in hair count of 16.1 hair/cm² (8.6%) at 6 months and 16.9 hair/cm² (9.1%) at 12 months. The differences in total hair count at 12 months were statistically significant between groups (p<0.0001).

In subgroup analysis, patients under treatment with cyproterone acetate with clinical signs of hyperandrogenism tended to show increased hair counts at month 12.
compared to those without hyperandrogenism, although the results were not statistically significant. Consequently, there is insufficient evidence that oral hormonal treatment prevents progression or improves androgenetic alopecia in female patients. Nevertheless, subgroup analysis suggests that oral cyproterone acetate may improve androgenetic alopecia in female patients with hyperandrogenism.

In a study by Paradisi et al., 101 female patients with androgenetic alopecia received flutamide in a dosage of 250 mg/day during the first year as a loading dose, 125 mg/day during the second year as a continuing dose, and 62.5 mg/day during the third and fourth years as a maintenance dose with or without a monophasic oral contraceptive, comprising of ethinyl estradiol (0.030 mg/day) plus gestodene (0.075 mg/day) for 21 days/month (161). According to the global expert panel assessment, no significant differences were found between the groups: in total, alopecia improved significantly in Ludwig scores after 6 months of treatment (p < 0.001) and continued to improve until 2 years of treatment, remaining stable afterwards. The mean improvement of Ludwig score was 15%, 20%, 26%, and 28% at 0.5, 1, 1.5 and 2 years.

**Topical hormonal treatment**

**OUTCOMES**

Blume-Peytavi et al. (80) reported a decreased total hair count after 6 months therapy with ALFATRADIOL 0.025% solution once daily (mean change from baseline -7.8 hairs/cm², -4.3%, p<0.0005). Subjects treated with minoxidil 2% solution twice daily showed increased total hair counts at 6 months (15.3 hairs/cm²; 8.7%). Non-vellus hair counts and cumulative hair thickness also showed a decrease in the alfatradiol group and an increase in the minoxidil group at 6 months (-6.0 hairs/cm² versus 14.0 hairs/cm², p<0.001; -0.5mm/cm² versus 1.8mm/cm², p<0.0001).

There are three earlier studies (157, 159, 160) on the efficacy of the TOPICAL ESTROGEN alfatradiol in women and one of topical estrogen combined with corticosteroid (158). All assessed responses were obtained using a trichogram. Two studies did not report separately male and female subjects and are not considered further (158, 159). Orfanos and Vogels reported a mean decrease in telogen rate of 24.4% for patients treated with alfatradiol 0.025% solution once daily at 30 weeks (157).

In a study by Georgala et al. the mean change from baseline anagen/telogen ratios at 12 and 24 weeks of treatment with alfatradiol solution once daily was 38.7% and 44.6% respectively (162). The change in anagen/telogen ratio differed significantly from placebo treatment (-3.9% at 24 weeks; p<0.01).

In a current one-arm study, Kim et al. reported an increased hair count after 8 months therapy with 17alpha-estradiol in Korean women with androgenetic alopecia (mean change from baseline 31.5 hairs/cm², 9.8%, p<0.0001). Furthermore an increased cumulative hair thickness was found (mean change from baseline 10.39 µm, p<0.0001) (163).

As there are contrary results on the efficacy of topical alfatradiol the evidence is insufficient to support his use in female patients with androgenetic alopecia. Further studies are needed to clarify the efficacy of alfatradiol.

Gassmueller et al. (62) compared FULVESTRANT (70mg/ml twice daily) to minoxidil 2% and placebo. The mean change in total hair count did not differ from placebo.
(14.7 hair/cm², 6.9%, versus 15.3 hair/cm², 7.9%). Therefore we suggest that topical fulvestrant is not effective in women with androgenetic alopecia.

There is no evidence to support the use of topical natural estrogens, progestogens or antiandrogens in female androgenetic alopecia.

3.3.5 Instructions for use / Practicability
Oral antiandrogen therapy in women:
*Cyproterone acetate* (25 - 50mg per day, days 1-10) is generally prescribed together with an oral contraceptive e.g. Dianette.
Side effects of cyproterone acetate include depressive mood changes and liver toxicity. There is an increased risk of venous thromboembolism in patients taking estrogen-containing oral contraceptives, which may be greater in those taking cyproterone acetate than other oral contraceptives.
*Spironolactone* 100-200mg per day is taken continuously. Concurrent contraception is required in fertile women. Side effects include menstrual disturbance and hyperkalaemia.

3.3.6 Combination therapies
There are no instructive studies of combination therapy (e.g. minoxidil + antiandrogen).

3.3.7 Summary
There is little evidence to support the use of oral or topical hormonal treatment in men and women in androgenetic alopecia (LEVEL OF EVIDENCE 4). There is limited proof that oral cyproterone acetate may be helpful in women with AGA and hyperandrogenism.

3.3.8 Therapeutic recommendation – Male
↓↓ We do not recommend the use of oral estrogens or androgen-receptor-antagonists to improve or prevent progression of AGA in male patients.

Ο We cannot make a recommendation for topical alfatradiol in male patients at the present time

↓ We suggest, that topical fluridil should not be used in male patients with AGA.

↓ We suggest, that topical fulvestrant should not be used in male patients with AGA.

3.3.9 Therapeutic recommendation – Female
Ο We cannot make a recommendation for the use of oral antiandrogens (clomadinone acetate, cyproterone acetate (CPA), drospirenone, spironolactone, flutamide) to improve or prevent progression of AGA in normoandrogenic female patients at the present time.

⇒ Oral CPA can be considered to prevent progression of AGA in women with clinical or biochemical evidence of hyperandrogenism.
We cannot make a recommendation for the use of topical alfatradiol to improve or prevent progression of AGA in female patients at the present time.

We cannot make a recommendation for the use of topical natural estrogens or progesterones to improve or prevent progression of AGA in female patients at the present time.

We cannot make a recommendation for the use of topical fluridil to improve or prevent progression of AGA in female patients at the present time.

We suggest that topical fulvestrant should not be used in female patients with AGA.

3.4 SURGERY

3.4.1 Introduction
Hair restoration surgery involves hair transplantation, scalp reduction surgery or a combination of both. Compared to scalp reduction surgery, hair transplantation is less invasive. In androgenetic alopecia, hairless areas can be permanently covered again cosmetically, albeit with a decreased density. In thinning areas the hair density can be at least temporarily improved, and even in case of progression the coverage will be relatively higher than it would be without the surgery. Over the last decades, hair transplantation has evolved into a microsurgical procedure. Follicular units of 1 to 4 hairs are transplanted in large numbers and high densities.

3.4.2 Mechanism of action
The efficacy of hair transplantation is based on donor dominance, i.e. non-androgen-sensitive hair follicle keep their properties even when transplanted into scalp areas affected by androgenetic alopecia. Follicles that are not affected by miniaturization are re-distributed over the scalp under local anaesthesia.

The outcome of hair transplantation-objectively depends on the number of transplanted hairs in relation to the area to be covered or densified, on the quality of hairs such as curl, color and caliber, and on the characteristics of the recipient area.

The technical success of this multi-step procedure is determined by the ability of the surgical team to successfully harvest, prepare and insert the grafts without impairing their viability. Another aspect is a minimal trauma to the recipient and donor areas. The cosmetic effect greatly depends on the aesthetic skills of the surgeon, as well as patient selection, planning of the procedure considering an optimum life-long result, the creation of an authentic hairline design, the distribution of grafts with different numbers of hair and the natural creation of recipient sites with appropriate size, density and direction.

3.4.3 Efficacy – males
Although there are a lot of publications dealing with hair surgery, there were no randomised controlled studies (RCT) comparing hair transplantation versus no hair transplantation. This is most probably due to high variation in techniques, multiple
steps in the surgical process, problems in measuring hair growth, lack of financial support and difficult patient recruitment for a RCT in hair transplantation. Only 4 studies comparing hair transplantation with or without added combination treatment fulfilled the inclusion criteria of this guideline. 2 of the studies obtained a grade of evidence B, 1 study obtained a grade of evidence A2 and 1 study obtained a grade of evidence C, resulting in a LEVEL OF EVIDENCE 2 (110, 164-166).

OUTCOMES
Bernstein et al. compared different preparation techniques for follicular unit transplantation (165). The resulting mean harvested hairs were 17% higher for preparation by dissecting microscope compared to preparation by magnifying loupe with transillumination (9.6% more follicular units and 2.28 vs. 2.14 mean hairs per follicular unit).

Uebel et al. (164) showed, that treatment of follicular units (FU) with platelet plasma growth factor before implantation could reduce the number of non-surviving FU grafts after follicular unit transplantation compared to follicular unit transplantation alone (mean change from baseline FU graft number: -25 (-17.6%) vs. -40 (-28.2%), p < 0.001).

In a study by Leavitt et al. (110), the combination of FU transplantation and finasteride 1 mg daily in patients with partially still existing hair in the recipient area resulted in an increase of hair density 12 months after transplantation, whereas the patients treated with FU transplantation alone had decreased hair counts. The mean change from baseline total hair count at 12 months was 18.5 hairs/cm² (12.6%) and -13.5 hairs/cm² (-8.9%) respectively (p = 0.019). On frontal-superior global photography, 67% of patients improved and 30% did not improve after hair transplantation alone, versus 94% and 6% after combination therapy, respectively. This is a considerably higher efficacy than previously reported in other studies with finasteride alone.

The differing results of hair counts and frontal-superior global photography in hair transplantation alone may partly be due to replacement and compensation of miniaturizing hairs by thicker permanent hair from the occipital area. Magnification should be used when making recipient sites in-between pre-existing hairs.

A study by Rinaldi et al. reported that treatment with psittacofulvin topical solution once daily 15 days before to 90 days after FUE transplantation could reduce the number of apoptotic fragments compared to treatment with placebo solution (number of apoptotic fragments 3 months after FUE transplantation 0.07 vs 2.05) (166).

A non-controlled trial by Sethi et al., which did not fulfil the inclusion criteria of the guideline, studied a modified follicular extraction technique called direct hair transplantation (DHT) (167). In this technology the graft was implanted as soon as it was harvested, in order to reduce the risk of desiccation, infection, mechanical trauma and grafts getting heated up and with the intention to improve graft survival. The authors report a good survival of the graft. Practical questions regarding patient comfort and position changes with possible graft dislocation remain, as well as a comparison to a stepwise approach.

3.4.4 Efficacy – females
Only few publications concerning hair surgery studied efficacy in female patients. None of them fulfilled the inclusion criteria.

### 3.4.5 Instructions for use / Practicability

While scalp reduction and flap surgery in combination with extenders is only successfully performed by a few skilled surgeons, hair transplantation is extensively conducted worldwide with further refined micro-techniques and larger graft numbers.

Hair transplantation in suitable candidates with a good donor hair supply, performed by a skilled team of a surgeon and several assistants, can permanently improve androgenetic alopecia by up to 3 stages on the Norwood-Hamilton scale. In women, hair transplantation can be considered in the male pattern and the frontal accentuation subtypes and Ludwig stage II of stabilized androgenetic alopecia. This only applies if sufficient permanent donor hair is available and no overlying diffuse telogen effluvium is present.

In many cases, more than one surgical session is required and often only critical areas can be improved. Magnification should be used to cautiously insert the grafts in-between pre-existing hair follicles.

The best long-term results can be achieved in medically controlled or spontaneously stabilized androgenetic alopecia. If hair transplantation is performed in early progressive AGA, a sufficient reserve of donor hair should be available for additional surgery, grafts should also be transplanted in-between miniaturizing hairs and the vertex area should not be transplanted initially. Patients should be extensively counselled regarding the possible outcome and the progressive nature of androgenetic alopecia which may require subsequent surgery and/or medical therapy or even shaving the transplanted hairs.

Body dysmorphic disorder or unrealistic expectations are contraindications for this aesthetic surgery.

Follicular unit transplantation (FUT) has become the standard technique in hair transplantation. Physiologic follicular units are smaller with less interfollicular tissue and can thus be placed denser with less traumatisation into finer recipient sites. Larger grafts with multiple FU’s should only be used in combination with FUT and in patients with a very good donor hair supply. The harvesting of FU grafts from the donor area is usually performed by careful excision of a hair-bearing strip. Several techniques are used to minimize follicle transection and scar formation during this step. The use of stereo-microscopes then allows for exact and fast dissection of large numbers of FU's with minimal trauma. The dissected grafts contain follicles with surrounding tissue which maybe be beneficial for short- and long-term graft survival.

FUT is indicated for patients who do not mind covering the linear scar with longer adjacent hairs, for patients with fine or light hair, for patients who do not want to shave their head, as needed while taking FU grafts, and for maximum donor yield without visible thinning of the donor area. In many patients, FUT provides an option of repeated surgery from the safe permanent mid-occipital donor area.

Individual extraction of FU's from the donor area (FUE) with a manual or motorized punch is also possible but associated with a potentially higher risk of follicle injury and impairment of graft viability. The extracted FU have less surrounding tissue. It
remains unclear if the short- and long-term outcome is equivalent to FUT where more perifollicular tissue is transplanted. The donor and recipient areas have to be trimmed. FUE may be indicated for smaller graft numbers, in patients with thick hair, in cases of tight occipital scalp elasticity, and in patients who do not want a linear scar or who want to wear a short occipital hair cut. Over-harvesting and extraction outside of the safe donor area should be avoided, but this limits the graft yield. In some patients, a combination of FUT and FUE harvesting is possible for maximum yield.

Recipient sites are prepared with different instruments. The creation of slits using micro-blades or needles adapted to graft size enables to achieve high densities. In the frontal area, a transition zone of 1-hair-FU’s is created with micro- and macro-irregularities for a more natural appearance.

Patients should be informed, that temporary post-operative telogen effluvium may appear if pre-existing hair is present. This may be minimized by making smaller incisions using magnification.

The final result can be evaluated at 9-12 months.

3.4.6 Combination therapies

As hair surgery has no efficacy to prevent further progression of androgenetic alopecia, a combination of medical and surgical therapy seems to be superior to surgery alone.

In male patients Leavitt et al. (110) reported a better clinical outcome at 12 month after follicular unit transplantation for patients treated with combination of finasteride 1 mg daily and hair surgery versus patients treated with hair surgery alone (see section efficacy males).

Rinaldi et al. reported that treatment with psittacofulvin topical solution reduced the number of apoptotic fragments after FUE transplantation compared to treatment with placebo solution (166).

In female patients there is lack of evidence concerning combination therapies. We suggest that combination therapy may reduce further post-operative progression of androgenetic alopecia.

3.4.7 Summary

4 studies concerning hair surgery fulfilled inclusion criteria of the S3 guideline. Hair transplantation can be considered to improve androgenetic alopecia in suitable patients with sufficient donor hair supply and medically controlled or spontaneously stabilized androgenetic alopecia, especially for the fronto-parietal area. As hair surgery does not influence progression of androgenetic alopecia, long-term results in early stages depend on spontaneous respectively medical stabilization. The result greatly depends on the skills of the surgical team and the adjustment of the surgical plan to individual patient characteristics. Preparation of follicular units using dissecting microscopes and pre-treatment of FU’s with platelet growth factor lead to higher graft survival rates.

While follicular unit transplantation (FUT) can be considered a standard, especially when stereo-microscopic dissection is used by a skilled team, other components of the surgical technique require further evaluation. As there are no randomised controlled studies comparing hair surgery versus no hair transplantation, only a LEVEL
OF EVIDENCE 2 can be attributed to the included studies comparing hair transplantation versus hair transplantation with supportive therapies (LEVEL OF EVIDENCE 2). Combination of finasteride 1 mg and follicular unit transplantation may reduce post-operative progression of androgenetic alopecia.

3.4.8 Therapeutic recommendation – Male
→ Surgery, especially follicular unit transplantation (FUT) can be considered in male patients with sufficient donor hair.
↑ We suggest, follicular unit transplantation (FUT) to be combined with finasteride 1 mg daily to achieve a better clinical outcome.

3.4.9 Therapeutic recommendation – Female
→ Surgery especially follicular unit transplantation (FUT) can be considered in female patients with sufficient donor hair.

3.5 PLATELET-RICH PLASMA (PRP)
3.5.1 Introduction
Platelet-rich plasma (PRP) is defined as an autologous preparation of plasma containing a supraphysiological concentration of platelets. PRP has been studied in several medical fields, mainly because of its known properties to promote wound healing, and is now largely utilized in orthopedics, sport medicine, plastic and aesthetic surgery, and in the treatment of diabetic ulcers. Its possible effects on hair growth were first studied in vitro and in vivo in mice in 2012 (168). Since that time, the clinical usage of PRP has become widespread with the aim to promote hair growth in several hair disorders, alone or in association with hair transplantation.

3.5.2 Mechanism of action
PRP is obtained collecting whole venous blood from the patient and then processing it in order to isolate a solution rich in platelets that is then injected intradermally. Platelet activation induces release of different growth factors, such as platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), transforming growth factor (TGF), insulin-like growth factor (IGF), epidermal growth factor (EGF) and interleukin (IL)-1. The local environment becomes enriched of a natural concentration of autologous growth factors and cytokines that induce tissue regeneration. The presence of leukocytes in PRP is responsible for anti-infectious and immune regulation functions.

The precise mechanisms by which PRP acts on hair follicles are still unclear. In vitro, PRP induces the proliferation of dermal papilla cells and increases their expression of Akt and Bcl-2, which promote cell survival by preventing apoptosis. It also increases the phosphorylation of extracellular signal-regulated kinases known to induce cell growth, increases beta-catenin activity, which plays an important role in hair growth cycle regulation and promotes differentiation of stem cells into hair follicle cells, and upregulates fibroblast growth factor (FGF)-7, which delays hair follicle progression from anagen to catagen phase (168). The backs of rabbits treated with PRP have a higher expression of WNT10a mRNA, which via beta-catenin activity induces follicular stem cell activation that initiates anagen phase, activating anagen reentry of telogen hair follicles (169).

The released VEGF and PDGF have an angiogenic potential and may induce increased follicle vascularization.

Up to now, there is not a standard procedure for treatment with PRP, in regard of:
a) technical procedures to obtain the platelet preparation, resulting in a variable platelet concentration and growth factors and cytokines in the final substance (including speed of centrifugation)
b) different modalities to activate platelets, which may cause different concentrations of growth factors;
b) volume of PRP injected per scalp area (which corresponds to different concentration of platelet-derived factors);
c) time interval between each injection;
d) quantity of injections performed in time;
e) maintenance of results after interruption of treatment.

3.5.3 Efficacy – males
2 studies assessing the efficacy of PRP in male and female patients with androgenetic alopecia met the inclusion criteria for the guideline, both with grade C evidence, resulting in LEVEL OF EVIDENCE 3 (170, 171).

OUTCOMES
Schiavone et al. (170) used macrophotographic evaluation to assess, in a non-controlled double-blind study, the effectiveness of 2 injections at 3-month interval, of autologous platelet and leukocyte concentrate at high concentration levels (L-PRP) plus autologous concentrated plasmatic protein solution. Sixty four patients (42 men and 22 women) were enrolled and evaluated by 2 evaluators using a clinical rating. Platelet activation was based on scalp inflammation induced by gentle pressure of a 1.0- mm deep Scalproller before the injections. The platelet concentration injected on the scalp was six fold to sevenfold greater than that of the patient’s blood in the first injection and 4 times greater in the second injection. Macrophotographs were taken at baseline and after 3 and 6 months. After 6 months of follow-up, the overall proportion of patients reaching a clinically important difference was 40.6% and 54.7%, according to the 2 evaluators respectively. A “Minimal Clinical Important Difference” in the clinical change score which was defined as a score of at least +4, “moderately better” on a 15-point scale (Jaeschke Rating), was reached by 41.9 to 58.1% of patients, according to the assessment of the 2 evaluators. However, this study was not placebo-controlled, no long-term follow-up was performed and the reported results were pooled for men and women. To evaluate the effectiveness of PRP in AGA, randomized controlled clinical trials over longer follow-up periods are necessary.

Gkini et al. (171) performed 3 treatment sessions of PRP at 3-week interval, with an additional treatment after 6 months (the data include results of 18 men and 2 women). Platelet concentration in PRP was approximately 5.8 times greater than in whole blood. Activation of PRP included adding of calcium gluconate in a 1:9 ratio. At the 1-year follow up the mean hair density (hair/cm²) increased by 7.41% compared to baseline (P<0.001). The highest hair density recorded was at 3 months, after the 3rd treatment session (9.19%), followed by a gradual downward trend. In this study statistical significant results were obtained within a short time of evaluation, however a control group and a long-term follow up are lacking.

3.5.4 Efficacy – females
3 studies assessing the efficacy of PRP in female patients were included in the evidence based evaluation (169-171). Two out of them included male and female patients, the study by Gkini only 2 females (170, 171). The grades of evidence were B, C and C, resulting in a LEVEL OF EVIDENCE 3.

OUTCOMES
Schiavone et al. (170) investigated the effect of two L-PRP injections at 3-month interval in 22 women. Pooled results for men and women at 6 months showed an at least moderate response in 41.9 to 58.1% of patients, according to the macro-photographic assessment of 2 evaluators. The results of Gkini et al (171), with 3 treatment sessions of PRP at 3-week interval with an additional treatment after 6 months refer to 2 female patients with androgenetic alopecia of grade I-III severity, according to the Ludwig scale. Pooled results for men and women showed an increase of the mean hair density (hair/cm²) of 7.41% compared to baseline (P<0.001) at the 1 year follow-up, with the highest hair density recorded after the 3rd treatment session. Due to the small sample size and the non-controlled study setting, this study provides insufficient evidence that PRP therapy is able to induce significant improvement of AGA in females within one year.

Lee at al (169) performed a double blind study in 40 Korean females affected by androgenetic alopecia, treating 1 arm with a single injection of CD34+ cell (Stem cells) -containing PRP preparation, without prior activation, followed by 12 sessions of polydeoxyribonucleotide (PDRN) intra-perifollicular injection performed at weekly intervals. The 2nd arm was treated with 12 sessions of intra-perifollicular PDRN injection alone at weekly intervals. Phototrichogram showed statistically significant improvements of both the mean hair count and the mean hair thickness after 3 months in both groups compared to baseline (p<0.001), with PRP + PDRN treatment being more effective than PDRN alone in improving hair thickness not hair count. Compared to the baseline value the patients treated with both PRP+PDRN and PRDN alone for 12 weeks exhibited statistically significant clinical improvement in mean hair counts and mean hair thickness. However, this study was not placebo controlled and no long-term follow-up was performed.

3.5.5 Instructions for use / Practicability
There is not a standard procedure for treatment of androgenetic alopecia with PRP. There are no standardized techniques for platelet isolation and activation, for dosage and frequency of injections, also more information about the need to combine PRP with other chemical/cells is needed. No standardized procedures for the implementation of PRP in the treatment of AGA have been evaluated. Moreover, as AGA is a genetic trait, the clinical advantage of intermittent PRP treatment needs to be further investigated. Main side effect of PRP include immediate effects of the procedure, including pain and transient post-treatment edema and tenderness, which are reported by almost all patients, and post treatment sequelae, reported in a smaller number of cases. These include persistent trichodynia, psoriasiform scalp reactions, telogen effluvium, and more rarely, secondary infections and scarring. The impact of PRP treatment on quality of life of the patients should be further questioned.

3.5.6 Summary
3 studies concerning PRP fulfilled inclusion criteria of the S3 guideline. The grades of evidence were C for all studies, resulting in a LEVEL OF EVIDENCE 3. Based on these
studies, there is little evidence to support the use of PRP in men and women with androgenetic alopecia.

3.5.7 Therapeutic recommendation for men and women
There is no standardized technique for performing PRP to permit objective evaluation of its effects on AGA.

O We cannot make a recommendation for or against treatment of AGA with platelet-rich plasma at the present time

3.6 LOW LEVEL LASER (LIGHT) THERAPY (LLLT, LASER HAIR COMB)
3.6.1 Introduction
Low Level Laser therapy (LLLT), or Laser phototherapy, consists in the exposure of tissues to low levels of visible or near infrared light. LLLT has shown beneficial effects for a variety of medical conditions such as wound healing, nerve regeneration, joint pain relief, stroke recovery, and the prevention and treatment of mucositis. The idea to apply LLLT to hair disorders came from the observation that some patients treated with for hair removal exhibited paradoxical hair growth at the periphery or at the treated areas. Currently, several LLLT devices are marketed for the treatment of alopecia.

3.6.2 Mechanism of action
The basis of the biostimulatory effect of laser phototherapy during wound healing is not fully understood. LLLT seems to stimulate cell proliferation both directly, through increase of endogenous growth factors, and secondarily, through increased cutaneous microcirculation. Other hypothesized effects include decrease of 5-alpha reductase expression and modulatory effects on inflammation.

3.6.3 Efficacy – males
Two studies assessing the efficacy of LLLT in male patients with androgenetic alopecia with grade of evidence A2 and C were included in the evaluation, resulting in a LEVEL OF EVIDENCE 2 (172, 173).

OUTCOMES
Leavitt et al. performed a 26-week randomized, double-blind, sham device-controlled, multicentre trial to investigate the effect of LLLT (665 nm) in 123 male patients with AGA Grade 2a to V according to the Norwood Hamilton Classification (172). The study results showed a significant increase in the hair count in the patients treated compared to controls (+19.8 versus -7.6 hairs/cm², p < 0.0001). According to the subjects’ assessment, patients in the LLLT group perceived significantly greater improvement in hair regrowth than those in the sham device group at the end of the study. The investigator’s global assessment, on the other hand, did not detect substantial differences between treatment groups. Satino et al. examined the effects of LLLT in men and women with androgenetic alopecia (173). They reported a mean change from baseline total hair count of 14.1 hairs/cm². A control group for comparison was missing.

3.6.4 Efficacy – females
Two studies assessing the efficacy of LLLT in female patients with androgenetic alopecia met the inclusion criteria of the guideline, with grade of evidence A2 and C, resulting in a LEVEL OF EVIDENCE 2 (173, 174).
OUTCOMES
Lanzafame et al. performed a double-blind, sham device-controlled multicenter study on 47 women with AGA Ludwig grade I-II (174). A 48.7±17.61% increase in hair count was reported after 16 weeks of LLLT (60 treatments) vs an increase of 11.05 ± 48.30% in the sham device group (p<0.001).
Satino et al. examined the effects of a low level laser comb in men and women with androgenetic alopecia (173). Pooled results showed a mean change from baseline total hair count of 14.1 hairs/cm². A control group for comparison was missing.

3.6.5 Instructions for use / Practicability
Treatment with LLLT is performed at home, using a LaserComb or wearing for a certain amount of time a helmet whose power cord is plugged into a standard outlet. Duration of therapy and frequency varies for the different devices. LLLT is generally well tolerated and reported adverse events are usually mild, including scalp dryness, itching, tenderness and a warm sensation.

3.6.6 Summary
3 studies concerning LLLT fulfilled the inclusion criteria of the S3 guideline. When used for 16 and 26 weeks under different protocols and with 2 different devices, LLLT showed an increased hair count (LEVEL OF EVIDENCE 2). However, no long-term follow-up was performed. Further controlled randomized clinical studies are required to establish the efficacy of these devices for hair growth in comparison to established therapies and to evaluate long-term use.

3.6.7 Therapeutic recommendation for men and women

→ We suggest using LLLT as ancillary therapy for AGA with devices that use energy levels shown to be effective in randomized controlled clinical trials

Ο We cannot make a recommendation for or against treatment for more than 6 months with LLLT for AGA at the present time

3.7 MISCELLANEOUS

3.7.1 Introduction
Besides the pharmacologic therapeutic options, which were already assessed in the previous chapters, the patient afflicted with androgenetic alopecia is faced to a confusing panel of molecules, products and interventions claiming to be efficient in androgenetic alopecia. The range of products is wide and reaches from cosmetic to pharmaceutical agents, natural products, functional food and even electrostatic/magnetic treatment. The mode of application comprises topical application, oral intake and scalp injections. The majority of these products claim hair promoting properties, even though controlled clinical studies are scarce. The aim of this chapter is to gather available evidence for these miscellaneous products.

3.7.2 Mechanism of action
The herein described miscellaneous products are grouped based on their reported assumed main mechanism of action (Table 2):
   a) DHT inhibitory activity* (hormonal effects, mainly inhibition of 5-alpha-reductase and reduced DHT activity)
b) Anti-inflammatory activity

c) Improved perifollicular vascularisation

d) Improved hair follicle nutrition (anti-apoptotic activity, anti-fibrotic activity)

e) Not precisely reported or unknown mechanism

*Botanically derived 5α-reductase inhibitors, which were compared to established therapies for androgenetic alopecia (finasteride per os and topical minoxidil) are cross-referenced in the corresponding chapters and tables.

### 3.7.3 Efficacy – males and females

Due to the limited number of studies, the efficacy of the miscellaneous therapies is in contrast to all other chapters summarized based on the application mode (oral, topical, interventions) grouped for males and females.

For many miscellaneous products, no clinical studies fulfilling the inclusion criteria of the guideline were found. Evaluation of individual ingredients is limited, as most of the tested products contain multiple different substances, e.g. food supplements with aminoacids and trace elements or different herbal preparations. Furthermore, even though the degree of evidence of the included studies was generally good, a single or max. 2 studies were available on each individual miscellaneous agent or product.

Hereafter, we provide a short overview on the different miscellaneous products.

21 of the included trials examined a single product (66, 68, 78, 175-192), while 5 trials investigated combinations of different products (65, 69, 74, 176, 193).

**Oral Supplements**

*Serenoa repens, β-sitosterol, niacin, biotin:* A combination of serenoa repens, β-sitosterol, niacin and biotin in an oral softgel taken twice daily led to improvement significantly different to placebo treatment (investigator assessment 60% improved vs. 11%) (175).

In a study by Rossi et al. 38% of male patients with androgenetic alopecia treated with *serenoa repens* 320 mg per os once daily for 24 months showed an increase in hair growth according to global expert panel assessment. However this increase was less than in the group treated with finasteride 1 mg once daily (increase in hair growth in 68% of patients) (118).

**Aminoacids:** Morganti et al. report a significant mean change from total hair count in male and female patients after a 50-week-treatment with an oral supplement containing cysteine, histidine, copper and zinc taken 4 times daily (29% vs. 11% placebo, p< 0.005) (193). A combination of cysteine, calcium pantothenate and millet seed twice a day for 6 months in 40 female patients showed increased anagen rate that was significantly different to placebo (p = 0.0225) (187).
Millet seed is a natural product that contains silicic acid, aminoacids, vitamins and minerals. An oral supplement composed of millet seed extract, cysteine and calcium pantothenate taken twice the day for 6 months led to increased anagen rates female patients (p = 0.0225 vs. placebo) (187). Another oral supplement composed of marine extracts and a silicea component was studied by Lassus et al. in comparison to fish extract and in combination of topical and oral use (176, 194). However, these studies were not placebo controlled.

Vitamines: Prager et al. reported 60% improvement rated by investigator in 26 male patients after 18-24 weeks treatment with an oral combination containing biotin and niacin, but also β-sitosterol and serenoa repens (175).

Moers-Campi et al. investigated the effect of an oral supplement containing fenugreek and micronutrients (vitamins C, E, nicotinamide, panthotenacid, zinc, vitamins B1, B6, B12, copper, biotin, folic acid, iod, selen) compared to placebo (2 capsules once per day) in 56 male and female patients with androgenetic alopecia (177). After 6 months of treatment, the supplement group showed a mean change of anagen hair count from baseline of 5.9% (p<0.0001). In the placebo group, no significant changes were found in mean anagen hair count after 6 months (0.62%).

Omega 3&6: In a study be Le Floc'h et al. 120 female patients were randomized to receive a nutritional supplement containing omega 3&6 and antioxidants or no treatment for 6 months (190). In the investigator’s assessment, increased hair density was reported in 62% of subjects in the supplement group versus 28.2% in the no treatment group after 6 months (p=0.001). There is no report of hair count in this study.

Different opinions exist concerning the supplementation of iron in absence of iron deficiency in patients with androgenetic alopecia. Various observational studies discussed relation between hair loss and decreased serum ferritin levels with controversial results (195). There is insufficient evidence for iron supplementation in absence of iron deficiency in patients with androgenetic alopecia.

Trace elements like copper and zinc: As zinc and copper were only studied in combination with other agents, evidence on their efficacy is inadequate.

Topically applied products
Ketoconazole or zinc pyrithione are effective agents in the treatment of seborrheic dermatitis. As concomitant seborrheic dermatitis is common in androgenetic alopecia and may aggravate hair loss, impact on androgenetic alopecia is difficult to evaluate. Berger et al. showed significant improvement for 1% pyrithione zinc shampoo, minoxidil 5% solution or the combination of both compared to placebo treatment at 26 weeks (65). The mean change from baseline hair count for the 1% pyrithione zinc shampoo group was significantly below the standard therapy with minoxidil. Combination of minoxidil and pyrithione zinc was inferior to minoxidil monotherapy. Baek et al. investigated the application of a commercially available shampoo containing 0.6% zinc pyrithione, 0.5% dexamphenol, 0.1% nicotinamide, 0.5% triminodil and 0.17% Thujae occidentalis semen (TOS) extract in male and female subjects in comparison to placebo (189). After 16 weeks, a mean change from baseline total hair count of 3.4 hairs/cm² (3.9%) was found in the 20 patients of the shampoo group, whereas a mean change from baseline hair count of -0.8
hairs/cm² (-0.9%) was found in the 20 patients of the placebo group (p>0.05 between the two groups).

**Niacin derivates:** Draelos et al. studied the effect of topical applied niacin derivates once daily in 60 female patients. After 6 months 69% were rated as improved in global photographic assessment (p = 0.04 vs. placebo) (186).

**Melatonin:** A trial by Fischer et al. in 35 males with androgenetic alopecia (stage I to II of Hamilton/Norwood Scale) reported an increased hair count in 54.8% and 58.1% of participants after respectively 3 and 6 months of topical use of melatonin solution once daily for 6 months, and with no control group (185). In a further open-label, 3-month, multicenter study, which did not fulfil the inclusion criteria of the guideline due to lack of a standardized objective quantification technique, 901 men and 990 women with androgenetic alopecia included in 200 dermatological centers applied a topical melatonin solution once daily for 3 months. Evaluation via hair pull test showed a decrease from 61.6% to 7.8% of the percentage of patients with a 2- to 3-fold positive hair-pull test and an increase from 12.2% to 61.5% in the percentage of patients with a negative hair-pull test (p<0.001) (196): Study outcomes were obtained by hair pull tests, a semi-quantitative method with high investigator dependent variations, performed by doctors from 200 different centers on more than 1800 patients.

**Roxithromycin** is an antimicrobial macrolide, with anti-inflammatory and antioxidant effects and anti-apoptotic activity on keratinocytes. Ito et al. performed a double blind trial with topical 0.5% roxithromycin or placebo applied once a day on the scalp for 6 months, on 24 Japanese males with AGA (13 in the RXM group and 11 in the placebo group) (184). 58% of the patients applying 0.5% RXM solution were improved, compared to 0% with placebo, after 6 months of treatment, according to the global expert panel assessment. The hair shaft thickness measured on 5 cutting hairs was significantly increased compared to baseline only in the treated group (+30.09 µm) but there is no hair count in this study.

**Proanthocyanidines** like procyanidine B belong to the group of flavonoids, which are antioxidants. Kamimura et al. showed, that the topical application of procyanidine B 1% twice the day leads to significant mean changes from total hair count in male patients after 6 months (p < 0.0005 vs. placebo) (178).

**Adenosine** is an endogenous nucleoside. Oura et al. performed a double-blind, randomized, placebo-controlled study with topical 0.75% adenosine or placebo applied on the scalp twice a day on 30 Japanese women affected by androgenetic alopecia (188). After 12 months, 62% (8/13) of the treated patients were rated as improved in global photographic assessment, compared to the 36% (5/14) improved with placebo (p=0.0337). Phototrichogram did not show significant changes in hair density, anagen hair ratio and thin hair ratio in both groups, while it showed a significantly increased anagen growth rate in the adenosine group.

2 trials examining the efficacy of topically applied **herbal preparations** fulfilled the inclusion criteria of the guideline (179, 180). As the ingredients of the particular herbal preparations significantly differ, they have to be evaluated separately. Kessels et al. reported a mean change from baseline nonvellus hair count of 26.6 hairs/cm² vs. 21.8 hairs/cm², p = 0.02 vs. placebo in 396 male patients, who applied twice daily
a Chinese herbal preparation for 6 months (179). Greenberg et al. reported a mean change from baseline total hair count of 77.4% in 24 men after 40 weeks usage of herbal extract containing fennel, polygonum, menthe, chamomile, thuja, hibiscus) (p = 0.003) (180).

A lotion containing Biochanin A and acetyl tetrapeptide-3 applied once a day by males with androgenetic alopecia induced an 13% increase in the number of anagen hair in 14 patients (p < 0.1; NS)) compared to the −2% decreased induced by placebo in 15 patients, after 4 months of treatment (191).

**Serenoa repens:** The application of a lotion containing serenoa repens extract twice a day showed statistically significant improvement in mean change from baseline total hair count at 50 weeks (p < 0.005 vs. placebo) (193).

A trial by Groveman et al. failed to prove efficacy of the non-ionic detergent polysorbate 60 applied twice daily topical in 174 male patients (182). After 16 weeks global photographic assessment for the polysorbate group was below the placebo group.

**Red ginseng:** A study by Ryu et al. failed to show that combination of minoxidil 3% topical solution and red ginseng is superior to minoxidil monotherapy in women (92).

**Retinoids** modulate proliferation, differentiation of keratinocytes and the T-cellular immune response. Their usage as pharmaceutical excipients to improve minoxidil resorption is discussed. Two trials fulfilled the inclusion criteria of the guideline (69, 74). Bazzano et al. reported in 58% of the male and female patients, who treated their scalp twice daily with tretinoin 0.025% solution, at least 20% increase from baseline hair count at 12 months (74). It is conspicuous that the placebo and the minoxidil 0.5% group reached no improvement at all. The trial was not blinded and not randomized. Shin et al. failed to show superiority of minoxidil 5% solution combined with tretinoin 0.01% once daily versus minoxidil 5% solution applied twice daily in 31 male patients (69). The mean changes from baseline total hair count did not differ significantly at 18 weeks, though the combination of minoxidil and tretinoin led to slightly elevated values (15.9 hairs/cm² vs. 18.2 hairs/cm²).

**Ciclosporin:** The induction of hypertrichosis is known as adverse event in systemic treatment with ciclosporin. Experimental models could also demonstrate this effect for topical application of ciclosporin. In a small study by Gilhar et al., which did not fulfil the inclusion criteria for the guideline, 2 patients out of 8 had response to topical application of ciclosporin after 12 months (197).

Another group of substances were the prostaglandine analogues like viprostol or latanoprost. The topical application of viprostol for 24 weeks in male patients did not show significant difference compared to placebo or vehicle treatment (181).

**Minerals and niacin derivates:** Reygagne et al. assessed the efficacy of a topical combination of glycerol oxyesters and silicium (Maxilene®) (66). In comparison to standard minoxidil treatment Maxilene® led to statistically significant hair loss.

**Aminexil** is a molecule chemically similar to minoxidil. Studies, that provide evidence for its efficacy, are missing. Stemoxydine is a molecule which mimics effect of
hypoxia with stabilisation of Hypoxia Inducible Factor HIF 1 alpha. Published studies providing efficacy in androgenetic alopecia are missing.

**Cimicifuga racemosa** is a natural product with positive influence on the estrogenic level, mainly used for perimenopausal complaints. No evidence was found for its efficacy in androgenetic alopecia.

No trials were found concerning the **natural products gingko biloba, aloe vera, bergamot or sorphora**. Animal models and resp. or in vitro studies suggest hair growth promoting properties. The agents are used in cosmetical hair care products.

There are different hair care products containing **caffeine** claiming to be an effective in treating androgenetic alopecia in men and women. Caffeine showed in in vitro studies higher transfollicular penetration rates than in vivo (198); in microdissected male and female human scalp hair follicles caffeine led to an enhanced hair shaft elongation (199). Currently only clinical studies on the efficacy of caffeine shampoo or topical caffeine solution in AGA not meeting the inclusion criteria for the current guideline are available, which reported increased patient satisfaction after caffeine use as well as a positive effect of the combination of caffeine and minoxidil (in one study additionally with azelaic acid) compared to topical minoxidil solution or placebo (200-204). However, these studies present methodological limitations (lack of a standardized evaluation, high publication bias risk, in most cases uncontrolled study design) (205).

**Interventions**

Besides cosmetic and pharmaceutic agents, **pulsed electromagnetic/-static field** is also claiming efficacy in androgenetic alopecia. 4 trials for pulsed electrostatic field could be included into the evidence-based evaluation of the guideline (206-209). Though the trials showed modest increase in total, anagen or nonvellus hair counts, the implementation in clinical routine is doubtful due to unfavourable cost-benefit ratio.

Another therapeutic regimen that claims to improve androgenetic alopecia is **mesotherapy**. Different agents, e.g. vitamins are intracutaneously injected. Few available studies on the efficacy of these procedures did not meet the inclusion criteria of this guideline.

The injection of **botulinum toxin** has been suggested to improve androgenetic alopecia. Freund and Schwartz (183) reported 18% increase in hair count between baseline and week 48 in 40 male subjects with androgenetic alopecia, who underwent 2 cycles of botulinum toxin scalp injections, at baseline and after 24 weeks. Each treatment cycle consisted in injections of 150 units of Botox (5 units per 0,1ml saline) in 30 sites, in the muscles surrounding the scalp. Therefore, there is insufficient evidence for therapy with Botulin toxin injection in patients with androgenetic alopecia.

### 3.7.4 Instructions for use / Practicability

For instructions for use for the miscellaneous products the reader is asked to consult the information of the particular product information. In case of an intervention, such as botulinum toxin injections or mesotherapy, the treating physician is responsible to provide detailed patient information on the procedure and possible side effects.
3.7.5 Combination therapies
Patients often ask for one of the particular miscellaneous therapies in combination with another treatment. As evidence is insufficient to missing for the therapies mentioned above, the combination of different miscellaneous products cannot be recommended. Additional use depends on the individual case and decision of the patient and the physician.

3.7.6 Summary
Plenty of marketed oral and topical miscellaneous therapies and interventions claim to be effective in the treatment of androgenetic alopecia in men and women. Based on currently available literature data no evidence-based recommendation can be given for these miscellaneous products. Their use as a supportive strategy within an individually tailored management approach remains to the discretion of the treating dermatologist and the decision of the patient. Further controlled studies to prove the relevance of these and other new approaches in the treatment of AGA are needed.

3.7.7 Therapeutic recommendation – Male and Female
O We cannot make a recommendation for or against a treatment with the mentioned molecules, substances and interventions at the present time.
References


93. Trüeb R, Gadzhigoroeva AG, Kubanov AA, Tsimbalenko TV, Chistiakova T, Kondrakhina IN, et al. Superiority of combination treatment over monotherapy for female alopecia. 8th World Congress for Hair Research; Jeju Island, South Korea 2014.


Jo SJ, Shin HS, Park YW, Paik SH, Park WS, Jeong YS, et al. Topical valproic acid increases the hair count in male patients with androgenetic alopecia: A
Figure 1. Flow Diagram of the search and selection process

- Records identified through database searching Medline (n = 171)
- Records identified through database searching Medline in Process (n = 151)
- Records identified through database searching EMBASE (n = 417)
- Records identified through database searching Cochrane Library (n = 65)
- Additional records identified through other sources (n = 7)

Records after duplicates removed (n = 811 records, of which n = 9 duplicates removed automatically and n = 122 duplicates removed manually)

- Records screened (n = 680)
- Records excluded (n = 578)

Full-text studies assessed for eligibility (n = 102)

- Full-text studies excluded (n = 55)
  - No confirmed diagnosis of AGA or less than 20 patients (n = 24)
  - No prospective study (n = 10)
  - Reviews (n = 12)
  - No outcome measures described (n = 6)
  - Other reasons (n = 3)

Studies included in synthesis (n = 47)
# Table 1: Summary Table

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Level of evidence</th>
<th>Efficacy to prevent progression</th>
<th>Efficacy to improve</th>
<th>Safety</th>
<th>Practicality (patient)</th>
<th>Practicality (physician)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Male patients</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finasteride 1 mg QD</td>
<td>1</td>
<td>+++</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
</tr>
<tr>
<td>Dutasteride 0.5 mg QD</td>
<td>1</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
<td>+++</td>
<td>++</td>
</tr>
<tr>
<td>Minoxidil 5% BID (solution, foam)</td>
<td>1</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>++/++</td>
<td>+++</td>
</tr>
<tr>
<td>Hair transplantation with/without combination treatment</td>
<td>2</td>
<td>-</td>
<td>+++</td>
<td>++</td>
<td>intervention +++</td>
<td>long-term +</td>
</tr>
<tr>
<td>LLLT</td>
<td>2</td>
<td>+/-</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>PRP</td>
<td>3</td>
<td>+/-</td>
<td>+</td>
<td>*</td>
<td>*</td>
<td>+</td>
</tr>
<tr>
<td><strong>Female patients</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minoxidil 2% BID solution</td>
<td>1</td>
<td>+++</td>
<td>++</td>
<td>+++</td>
<td>*</td>
<td>+++</td>
</tr>
<tr>
<td>Minoxidil 5% QD foam</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hormones oral in hyperandrogenism</td>
<td>3</td>
<td>+</td>
<td>+</td>
<td>+++</td>
<td>++</td>
<td></td>
</tr>
<tr>
<td>Hormones oral in normal hormones</td>
<td>3</td>
<td>+/-</td>
<td>+</td>
<td>+++</td>
<td>++</td>
<td></td>
</tr>
<tr>
<td>Hair transplantation</td>
<td>4</td>
<td>-</td>
<td>++</td>
<td>++</td>
<td>intervention +++</td>
<td>long-term +</td>
</tr>
<tr>
<td>LLLT</td>
<td>2</td>
<td>+/-</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>PRP</td>
<td>3</td>
<td>+/-</td>
<td>+</td>
<td>*</td>
<td>*</td>
<td>+</td>
</tr>
</tbody>
</table>

**Global consideration:**

- poor
  - +/-
  - +
  - ++
  - +++
  - ++++

**LLLT:** Low Level Laser therapy  
**PRP:** Platelet-rich plasma
<table>
<thead>
<tr>
<th>Claimed mechanism of action</th>
<th>Active</th>
<th>Level of evidence</th>
<th>Studies included (n)</th>
<th>Grade of evidence</th>
<th>Mode of application</th>
<th>Part of combination product</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 DHT-inhibitory activity</td>
<td>β-sitosterol</td>
<td>3</td>
<td>1</td>
<td>B</td>
<td>oral</td>
<td>yes</td>
</tr>
<tr>
<td></td>
<td>biochanin A</td>
<td>3</td>
<td>1</td>
<td>B</td>
<td>topical</td>
<td>no</td>
</tr>
<tr>
<td></td>
<td>polysorbate 60</td>
<td>2</td>
<td>1</td>
<td>A2</td>
<td>topical</td>
<td>no</td>
</tr>
<tr>
<td></td>
<td>serenoa repens</td>
<td>3</td>
<td>1</td>
<td>B, B</td>
<td>oral</td>
<td>yes, no</td>
</tr>
<tr>
<td></td>
<td>curcuma aeruginosa</td>
<td>2</td>
<td>1</td>
<td>A2</td>
<td>topical</td>
<td>yes, no</td>
</tr>
<tr>
<td></td>
<td>biochanin A</td>
<td>3</td>
<td>1</td>
<td>B</td>
<td>topical</td>
<td>no</td>
</tr>
<tr>
<td>2 Anti-inflammatory activity</td>
<td>ketoconazol</td>
<td>3</td>
<td>1</td>
<td>B</td>
<td>topical</td>
<td>yes</td>
</tr>
<tr>
<td></td>
<td>roxithromycin</td>
<td>3</td>
<td>1</td>
<td>B</td>
<td>topical</td>
<td>no</td>
</tr>
<tr>
<td></td>
<td>zinc pyrithione</td>
<td>2</td>
<td>2</td>
<td>B, A2</td>
<td>topical</td>
<td>yes, no</td>
</tr>
<tr>
<td>3 Improved perifollicular vascularisation</td>
<td>glycerolxyesters and silicium</td>
<td>3</td>
<td>1</td>
<td>B</td>
<td>topical</td>
<td>yes</td>
</tr>
<tr>
<td></td>
<td>niacin derivates</td>
<td>2</td>
<td>2</td>
<td>A2</td>
<td>topical</td>
<td>yes</td>
</tr>
<tr>
<td></td>
<td>prostaglandines (viprostol, latanoprost)</td>
<td>2</td>
<td>1</td>
<td>A2</td>
<td>topical</td>
<td>no</td>
</tr>
<tr>
<td>4 Improved hair folliclenutrition</td>
<td>aminoacids (cysteine, histidine)</td>
<td>3</td>
<td>1</td>
<td>B</td>
<td>topical</td>
<td>yes</td>
</tr>
<tr>
<td></td>
<td>vitamins (biotin, niacin)</td>
<td>3</td>
<td>2</td>
<td>B</td>
<td>oral</td>
<td>yes</td>
</tr>
<tr>
<td></td>
<td>trace elements (zinc, copper)</td>
<td>3</td>
<td>1</td>
<td>B</td>
<td>oral</td>
<td>yes</td>
</tr>
<tr>
<td>5 Not precisely reported or unknown mechanism of action</td>
<td>adenosine</td>
<td>3</td>
<td>1</td>
<td>B</td>
<td>topical</td>
<td>no</td>
</tr>
<tr>
<td></td>
<td>biotin</td>
<td>3</td>
<td>1</td>
<td>B</td>
<td>oral</td>
<td>yes</td>
</tr>
<tr>
<td></td>
<td>hibiscus</td>
<td>2</td>
<td>1</td>
<td>A2</td>
<td>topical</td>
<td>yes</td>
</tr>
<tr>
<td></td>
<td>marine extract and silica component</td>
<td>2</td>
<td>1</td>
<td>A2</td>
<td>oral</td>
<td>no</td>
</tr>
<tr>
<td></td>
<td>melatonin</td>
<td>4</td>
<td>1</td>
<td>C</td>
<td>topical</td>
<td>no</td>
</tr>
<tr>
<td></td>
<td>millet seed</td>
<td>3</td>
<td>1</td>
<td>B</td>
<td>oral</td>
<td>yes</td>
</tr>
<tr>
<td></td>
<td>niacin derivates</td>
<td>2</td>
<td>2</td>
<td>A2</td>
<td>topical</td>
<td>yes</td>
</tr>
<tr>
<td></td>
<td>proanthocyanidines</td>
<td>3</td>
<td>1</td>
<td>B</td>
<td>topical</td>
<td>no</td>
</tr>
<tr>
<td></td>
<td>red ginseng</td>
<td>4</td>
<td>1</td>
<td>C</td>
<td>topical</td>
<td>yes</td>
</tr>
<tr>
<td></td>
<td>tretinoin</td>
<td>2</td>
<td>2</td>
<td>B, A2</td>
<td>topical</td>
<td>yes, no</td>
</tr>
<tr>
<td></td>
<td>red ginseng</td>
<td>4</td>
<td>1</td>
<td>C</td>
<td>topical</td>
<td>yes</td>
</tr>
<tr>
<td></td>
<td>valproic acid</td>
<td>2</td>
<td>1</td>
<td>A2</td>
<td>topical</td>
<td>no</td>
</tr>
</tbody>
</table>

Interventions

| Not precisely reported or unknown mechanism of action | botulinum toxin | 4 | 1 | C | scalp injections | no |
| | electromagnetic/- static field | 1 | 4 | A2, A2, B, B | device | yes, no |

Additional reported actives without clinical studies included in the guideline comprise: aloe, aminexil, bergamot, caffeine, ciclosporin, cimicifuga racemosa, ginkgo, mesotherapy, sophora.
<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Number of patients</th>
<th>Gender</th>
<th>Time of evaluation</th>
<th>Dosage</th>
<th>Method</th>
<th>Outcome</th>
<th>Degree of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>32</td>
<td>1987</td>
<td>777</td>
<td>male</td>
<td>6m</td>
<td>minoxidil 2.8%, 2x/d, topical</td>
<td>ArtNumber</td>
<td>66.6%</td>
<td>unclear</td>
</tr>
<tr>
<td>33</td>
<td>1987</td>
<td>127</td>
<td>male</td>
<td>123w</td>
<td>minoxidil 3%, solution, 2x/d, topical</td>
<td>ArtNumber</td>
<td>65.7</td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>1990</td>
<td>33</td>
<td>male</td>
<td>24w</td>
<td>minoxidil 2% solution, 2x/d, topical</td>
<td>ArtNumber</td>
<td>46.1</td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>1990</td>
<td>31</td>
<td>male</td>
<td>3y</td>
<td>minoxidil 3%, solution, 2x/d, topical</td>
<td>ArtNumber</td>
<td>4.4</td>
<td>p &lt; 0.05 vs Arm1</td>
</tr>
<tr>
<td>36</td>
<td>1990</td>
<td>105</td>
<td>male</td>
<td>48w</td>
<td>minoxidil 2% solution, 2x/d, topical</td>
<td>ArtNumber</td>
<td>64.7 (52.1%)</td>
<td>p = 0.000 vs Baseline</td>
</tr>
<tr>
<td>37</td>
<td>2009</td>
<td>300</td>
<td>male</td>
<td>24w</td>
<td>minoxidil 1% solution, 2x/d, topical</td>
<td>ArtNumber</td>
<td>47.0 (17.7%)</td>
<td>p = 0.000 vs Baseline</td>
</tr>
<tr>
<td>38</td>
<td>2009</td>
<td>300</td>
<td>male</td>
<td>3y</td>
<td>minoxidil 2% solution, 2x/d, topical</td>
<td>ArtNumber</td>
<td>27.4 (25.4%)</td>
<td>p = 0.001 vs Baseline</td>
</tr>
<tr>
<td>39</td>
<td>2015</td>
<td>45</td>
<td>male</td>
<td>104w</td>
<td>minoxidil 5% foam, 2x/d, topical</td>
<td>ArtNumber</td>
<td>22.5 (3.6%)</td>
<td>p = 0.001 vs Baseline</td>
</tr>
<tr>
<td>40</td>
<td>2016</td>
<td>764</td>
<td>female</td>
<td>76w</td>
<td>minoxidil 2% solution, 2x/d, topical</td>
<td>ArtNumber</td>
<td>2.8%</td>
<td></td>
</tr>
</tbody>
</table>

**Outcome Measures**

- **Mean change from baseline hair count (total)**: 66.6% (minoxidil 2.8%, 2x/d, topical) vs 65.7% (minoxidil 3%, solution, 2x/d, topical)
- **Mean change from baseline hair count (nonvellus)**: 46.1% (minoxidil 2% solution, 2x/d, topical)
- **Mean change from baseline hair weight / thickness**: 4.4 (minoxidil 3%, solution, 2x/d, topical)
- **Global expert panel assessment**: 2.8% (minoxidil 2% solution, 2x/d, topical)
- **Investigator assessment**: 77.4% (minoxidil 5% foam, 2x/d, topical)
- **Patient assessment**: 81.1% (minoxidil 5% foam, 2x/d, topical)
- **Investigational area**: 46.6% (minoxidil 2.8%, 2x/d, topical)
- **Degree of evidence**: C

**Other Measurements**

- **Manual hair count**: 82.1% (minoxidil 2% solution, 2x/d, topical)
- **Phototrichogram**: 13.4 (minoxidil 3%, solution, 2x/d, topical)
- **W104: Frontal and vertex**: 35% (minoxidil 5% foam, 2x/d, topical)
- **W104: Frontal and vertex**: 67% (minoxidil 5% foam, 2x/d, topical)
<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Treatment</th>
<th>Gender</th>
<th>Time</th>
<th>Patient Count</th>
<th>Improved</th>
<th>Unchanged</th>
<th>p Value vs. Placebo</th>
<th>Degree of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Califano</td>
<td>2001</td>
<td>Minoxidil 2% solution, 2x/d, topical</td>
<td>Male</td>
<td>24w</td>
<td>154</td>
<td>25.4 (10.3%)</td>
<td>25.4 (10.9%)</td>
<td>p &lt; 0.01 vs. Placebo</td>
<td>A2</td>
</tr>
<tr>
<td>Califano</td>
<td>2001</td>
<td>Placebo, 2x/d, topical</td>
<td>Male</td>
<td>24w</td>
<td>151</td>
<td>10.3 (15.5%)</td>
<td>12.1 (31.0%)</td>
<td>p = 0.002 vs. Placebo</td>
<td>A2</td>
</tr>
<tr>
<td>Califano</td>
<td>2001</td>
<td>Minoxidil 2% solution, 2x/d, topical</td>
<td>Male</td>
<td>16w</td>
<td>201</td>
<td>16.1 (14.9%)</td>
<td>2.5 (7.3%)</td>
<td>p = 0.0001 vs. Placebo</td>
<td>A2</td>
</tr>
<tr>
<td>Califano</td>
<td>2001</td>
<td>Placebo, 2x/d, topical</td>
<td>Male</td>
<td>16w</td>
<td>68</td>
<td>6.1 (14.9%)</td>
<td>2.5 (7.3%)</td>
<td>p = 0.0001 vs. Placebo</td>
<td>A2</td>
</tr>
<tr>
<td>Olsen</td>
<td>2001</td>
<td>Minoxidil 2% solution, 2x/d, topical</td>
<td>Male</td>
<td>24w</td>
<td>154</td>
<td>16.1 (39.2%)</td>
<td>10.8 (33.1%)</td>
<td>p = 0.0076 vs. Placebo</td>
<td>A2</td>
</tr>
<tr>
<td>Olsen</td>
<td>2001</td>
<td>Placebo, 2x/d, topical</td>
<td>Male</td>
<td>16w</td>
<td>201</td>
<td>6.1 (14.9%)</td>
<td>2.5 (7.3%)</td>
<td>p = 0.0104 vs. Placebo</td>
<td>A2</td>
</tr>
<tr>
<td>Califano</td>
<td>2001</td>
<td>Minoxidil 2% solution, 2x/d, topical</td>
<td>Male</td>
<td>16w</td>
<td>120</td>
<td>16.1 (39.2%)</td>
<td>10.8 (33.1%)</td>
<td>p = 0.0076 vs. Placebo</td>
<td>A2</td>
</tr>
<tr>
<td>Califano</td>
<td>2001</td>
<td>Placebo, 2x/d, topical</td>
<td>Male</td>
<td>16w</td>
<td>68</td>
<td>6.1 (14.9%)</td>
<td>2.5 (7.3%)</td>
<td>p = 0.0104 vs. Placebo</td>
<td>A2</td>
</tr>
<tr>
<td>Arm</td>
<td>Drug</td>
<td>Gender</td>
<td>Time</td>
<td>Effect</td>
<td>Significance</td>
<td>Number of Patients</td>
<td>Donor Site</td>
<td>Improved</td>
<td>Unchanged</td>
</tr>
<tr>
<td>-------</td>
<td>------------------------</td>
<td>--------</td>
<td>------</td>
<td>--------</td>
<td>--------------</td>
<td>--------------------</td>
<td>-------------</td>
<td>----------</td>
<td>-----------</td>
</tr>
<tr>
<td>Arm 1</td>
<td>minoxidil 0.01%</td>
<td>6m</td>
<td>24w</td>
<td>16.5</td>
<td>(15.3%)</td>
<td>5.4</td>
<td>(14.2%)</td>
<td>vertex</td>
<td>A2</td>
</tr>
<tr>
<td>Arm 2</td>
<td>minoxidil 0.1%</td>
<td>6m</td>
<td>24w</td>
<td>18.0</td>
<td>(18.9%)</td>
<td>15.9</td>
<td>(27.1%)</td>
<td>vertex</td>
<td>B</td>
</tr>
<tr>
<td>Arm 3</td>
<td>minoxidil 1%</td>
<td>6m</td>
<td>24w</td>
<td>29.2</td>
<td>(27.9%)</td>
<td>35.3</td>
<td>(53.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 4</td>
<td>minoxidil 2%</td>
<td>6m</td>
<td>24w</td>
<td>34.3</td>
<td>(33.1%)</td>
<td>37.3</td>
<td>(52.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 5</td>
<td>placebo</td>
<td>6m</td>
<td>24w</td>
<td>17.6</td>
<td>(17.1%)</td>
<td>15.9</td>
<td>(23.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 1</td>
<td>placebo</td>
<td>6m</td>
<td>48w</td>
<td>16.5</td>
<td>(15.3%)</td>
<td>5.4</td>
<td>(14.2%)</td>
<td>vertex</td>
<td>A2</td>
</tr>
<tr>
<td>Arm 2</td>
<td>minoxidil 0.01%</td>
<td>6m</td>
<td>48w</td>
<td>18.0</td>
<td>(18.9%)</td>
<td>15.9</td>
<td>(27.1%)</td>
<td>vertex</td>
<td>B</td>
</tr>
<tr>
<td>Arm 3</td>
<td>minoxidil 0.1%</td>
<td>6m</td>
<td>48w</td>
<td>29.2</td>
<td>(27.9%)</td>
<td>35.3</td>
<td>(53.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 4</td>
<td>minoxidil 1%</td>
<td>6m</td>
<td>48w</td>
<td>34.3</td>
<td>(33.1%)</td>
<td>37.3</td>
<td>(52.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 5</td>
<td>placebo</td>
<td>6m</td>
<td>48w</td>
<td>17.6</td>
<td>(17.1%)</td>
<td>15.9</td>
<td>(23.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 1</td>
<td>placebo</td>
<td>24w</td>
<td></td>
<td>2.9</td>
<td>(14.4%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 2</td>
<td>minoxidil 0.01%</td>
<td>24w</td>
<td></td>
<td>0.3</td>
<td>(1.2%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 3</td>
<td>minoxidil 0.1%</td>
<td>24w</td>
<td></td>
<td>0.1</td>
<td>(0.5%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 4</td>
<td>minoxidil 1%</td>
<td>24w</td>
<td></td>
<td>7.3</td>
<td>(3.9%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 5</td>
<td>placebo</td>
<td>24w</td>
<td></td>
<td>10.6</td>
<td>(5.2%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 1</td>
<td>placebo</td>
<td>48w</td>
<td></td>
<td>18.6</td>
<td>(12.3%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 2</td>
<td>minoxidil 0.01%</td>
<td>48w</td>
<td></td>
<td>12.7</td>
<td>(8.9%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 3</td>
<td>minoxidil 0.1%</td>
<td>48w</td>
<td></td>
<td>3.9</td>
<td>(2.9%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 4</td>
<td>placebo</td>
<td>48w</td>
<td></td>
<td>5.4</td>
<td>(3.1%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 5</td>
<td>minoxidil 1%</td>
<td>48w</td>
<td></td>
<td>15.5</td>
<td>(8.4%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:
- Arm 1: Placebo, 2x/d, topical
- Arm 2: Minoxidil 0.01%, 2x/d, topical
- Arm 3: Minoxidil 0.1%, 2x/d, topical
- Arm 4: Minoxidil 1%, 2x/d, topical
- Arm 5: Placebo, 2x/d, topical
- Effect: Improved, Unchanged
<table>
<thead>
<tr>
<th>Art Number</th>
<th>Author</th>
<th>Year</th>
<th>Number of Patients</th>
<th>Gender</th>
<th>Time of Evaluation</th>
<th>Dosage</th>
<th>Method</th>
<th>Mean Change from Baseline Hair Count</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(Total) hairs/cm (%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(Nonvellus) hairs/cm (%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(Anagen, Telogen, Anagen/Telogen Ratio)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Mean Change from Baseline Hair Weight / Thickness</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Global Expert Panel Assessment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Investigator Assessment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Patient Assessment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Investigational Area</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Degree of Evidence</td>
</tr>
</tbody>
</table>

**Arm 2:**
- 24w placebo, 2x/d, topical
- 25-48w minoxidil 2% solution, 2x/d, topical

24w:
- 4.7 (10.4%)

48w:
- 12.2 (27.1%)

24w:
- 2.9 (10.8%)

48w:
- 10.5 (39.4%)
<table>
<thead>
<tr>
<th>Year</th>
<th>Study</th>
<th>No.</th>
<th>Gender</th>
<th>Time of evaluation</th>
<th>Investigational area</th>
<th>Investigational area 2</th>
<th>Degree of evidence</th>
<th>Investigational area 3</th>
<th>Dosage</th>
<th>Investigational area 4</th>
<th>Investigational area 5</th>
<th>Investigational area 6</th>
<th>Investigational area 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>1988</td>
<td>Olsen</td>
<td>426</td>
<td>male</td>
<td>24w, 48w</td>
<td>minoxidil 2% solution, 2x/d, topical</td>
<td>24w: 23.8 (54.8%)</td>
<td>p = 0.001 vs. Arm2</td>
<td>48w: 15.3 (48.0%)</td>
<td>p = 0.001 vs. Arm1</td>
<td>24w: 36.1 (93.7%)</td>
<td>p = 0.001</td>
<td>24w: 25.0 (91.3%)</td>
<td>p = 0.001 vs. Arm2</td>
</tr>
<tr>
<td>1989</td>
<td>Civatte</td>
<td>240</td>
<td>male</td>
<td>24w, 48w</td>
<td>minoxidil 2% solution, 2x/d, topical</td>
<td>24w: 13.7 (25.0%)</td>
<td>p = 0.001 vs. Arm1</td>
<td>48w: 25.5 (47.0%)</td>
<td>p = 0.001 vs. baseline</td>
<td>24w: 5.1 (9.3%)</td>
<td>p = 0.001 vs. baseline</td>
<td>48w: 16.0 (31.0%)</td>
<td>p = 0.001 vs. baseline</td>
</tr>
<tr>
<td>1988</td>
<td>Alanis</td>
<td>72</td>
<td>male</td>
<td>6m</td>
<td>minoxidil 2% solution, 2x/d, topical</td>
<td>24w: 24.7 (100.0%)</td>
<td>ns vs. Arm3</td>
<td>12m: 42.8 (173.0%)</td>
<td>ns vs. Arm1, Arm2</td>
<td>24w: 11.6 (44.7%)</td>
<td>ns vs. Arm2</td>
<td>12m: 42.9 (165.0%)</td>
<td>ns vs. Arm2</td>
</tr>
<tr>
<td>1988</td>
<td>Piepkorn</td>
<td>153</td>
<td>male</td>
<td>4m, 12m</td>
<td>minoxidil 2% solution, 2x/d, topical</td>
<td>4m: 29.6 (100.0%)</td>
<td>12m: 24.7 (100.0%)</td>
<td>12m: 42.8 (173.0%)</td>
<td>24m: 27.5 (95.2%)</td>
<td>12m: 53.5 (185.7%)</td>
<td>24m: 11.6 (44.7%)</td>
<td>12m: 42.9 (165.0%)</td>
<td>24m: 11.6 (44.7%)</td>
</tr>
<tr>
<td>Art Number</td>
<td>Number of patients</td>
<td>Year</td>
<td>Gender</td>
<td>Time of evaluation</td>
<td>Investigational area</td>
<td>Degree of evidence</td>
<td>Investigator assessment</td>
<td>Patient assessment</td>
<td>Global expert panel assessment</td>
<td>Mean change from baseline hair count (total) hairs/cm (%)</td>
<td>Mean change from baseline hair count (nonvellus) hairs/cm (%)</td>
<td>Mean change from baseline hair weight / thickness</td>
<td>Mean change from baseline hair count (anagen, telogen, anagen/telogen ratio)</td>
</tr>
<tr>
<td>-------------</td>
<td>--------------------</td>
<td>------</td>
<td>--------</td>
<td>-------------------</td>
<td>----------------------</td>
<td>-------------------</td>
<td>---------------------</td>
<td>----------------------</td>
<td>-------------------------</td>
<td>----------------------------------</td>
<td>----------------------------------</td>
<td>---------------------------------</td>
<td>-----------------------------------------------------</td>
</tr>
<tr>
<td>Arm1: minoxidil 2% solution, 2x/d, topical</td>
<td>96</td>
<td>1987</td>
<td>Male</td>
<td>4m, 12m</td>
<td>4m: 0.8</td>
<td>p = 0.005 vs. Baseline</td>
<td>12m: 0.4</td>
<td>p = 0.001 vs. Baseline</td>
<td>4m: 11.4</td>
<td>12m: 22.0</td>
<td>p = 0.005 vs. Arm1</td>
<td>12m: 15.4</td>
<td>p = 0.001 vs. Baseline</td>
</tr>
<tr>
<td>Arm2: minoxidil 3% solution, 2x/d, topical</td>
<td>152</td>
<td>1987</td>
<td>Male</td>
<td>4m, 12m</td>
<td>4m: 0.8</td>
<td>p = 0.005 vs. Baseline</td>
<td>12m: 0.4</td>
<td>p = 0.001 vs. Baseline</td>
<td>4m: 9.6</td>
<td>12m: 30.9</td>
<td>p = 0.005 vs. Arm1</td>
<td>12m: 15.4</td>
<td>p = 0.001 vs. Baseline</td>
</tr>
<tr>
<td>Arm3: 4m placebo, 2x/d, topical, 5-12m minoxidil 3% solution, 2x/d, topical</td>
<td>54</td>
<td>1987</td>
<td>Male</td>
<td>4m, 12m</td>
<td>4m: 0.8</td>
<td>p = 0.005 vs. Baseline</td>
<td>12m: 0.4</td>
<td>p = 0.001 vs. Baseline</td>
<td>4m: 9.6</td>
<td>12m: 30.9</td>
<td>p = 0.005 vs. Arm1</td>
<td>12m: 15.4</td>
<td>p = 0.001 vs. Baseline</td>
</tr>
<tr>
<td>Arm4: 4m placebo, 2x/d, topical, 5-24m minoxidil 3% solution, 2x/d, topical</td>
<td>64</td>
<td>1987</td>
<td>Male</td>
<td>4m, 12m</td>
<td>4m: 0.8</td>
<td>p = 0.005 vs. Baseline</td>
<td>12m: 0.4</td>
<td>p = 0.001 vs. Baseline</td>
<td>4m: 9.6</td>
<td>12m: 30.9</td>
<td>p = 0.005 vs. Arm1</td>
<td>12m: 15.4</td>
<td>p = 0.001 vs. Baseline</td>
</tr>
<tr>
<td>Arm5: 4m placebo, 2x/d, topical, 5-24m minoxidil 3% solution, 2x/d, topical</td>
<td>64</td>
<td>1987</td>
<td>Male</td>
<td>4m, 12m</td>
<td>4m: 0.8</td>
<td>p = 0.005 vs. Baseline</td>
<td>12m: 0.4</td>
<td>p = 0.001 vs. Baseline</td>
<td>4m: 9.6</td>
<td>12m: 30.9</td>
<td>p = 0.005 vs. Arm1</td>
<td>12m: 15.4</td>
<td>p = 0.001 vs. Baseline</td>
</tr>
<tr>
<td>Arm6: 4m placebo, 2x/d, topical, 5-24m minoxidil 3% solution, 2x/d, topical</td>
<td>64</td>
<td>1987</td>
<td>Male</td>
<td>4m, 12m</td>
<td>4m: 0.8</td>
<td>p = 0.005 vs. Baseline</td>
<td>12m: 0.4</td>
<td>p = 0.001 vs. Baseline</td>
<td>4m: 9.6</td>
<td>12m: 30.9</td>
<td>p = 0.005 vs. Arm1</td>
<td>12m: 15.4</td>
<td>p = 0.001 vs. Baseline</td>
</tr>
<tr>
<td>Investigational area</td>
<td>Arm1: Minoxidil 2% solution, 2x/d, topical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Degree of evidence</td>
<td>72 (Male) 12m, 30m</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>252 (Male) 12m, 30m</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p &lt; 0.001 (4m, 12m) vs. Baseline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n.s. vs. Arm2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Investigational area</th>
<th>Arm2: Minoxidil 2% solution, 2x/d, topical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Degree of evidence</td>
<td>72 (Male) 24w, 48w</td>
</tr>
<tr>
<td></td>
<td>252 (Male) 24w, 48w</td>
</tr>
<tr>
<td></td>
<td>p &lt; 0.001 (4m, 12m) vs. Baseline</td>
</tr>
<tr>
<td></td>
<td>n.s. vs. Arm2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Investigational area</th>
<th>Arm3: Minoxidil 3% solution, 2x/d, topical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Degree of evidence</td>
<td>72 (Male) 24w, 48w</td>
</tr>
<tr>
<td></td>
<td>252 (Male) 24w, 48w</td>
</tr>
<tr>
<td></td>
<td>p &lt; 0.001 (4m, 12m) vs. Baseline</td>
</tr>
<tr>
<td></td>
<td>p &lt; 0.01 (4m), p &lt; 0.001 (12m) vs. Baseline</td>
</tr>
<tr>
<td>Year</td>
<td>Study</td>
</tr>
<tr>
<td>------</td>
<td>-------</td>
</tr>
<tr>
<td>1987</td>
<td>A2</td>
</tr>
<tr>
<td>1990</td>
<td>A2</td>
</tr>
<tr>
<td>1999</td>
<td>A2</td>
</tr>
<tr>
<td>2014</td>
<td>A2</td>
</tr>
<tr>
<td>2014</td>
<td>A2</td>
</tr>
<tr>
<td>ArtNumber</td>
<td>Year</td>
</tr>
<tr>
<td>-----------</td>
<td>------</td>
</tr>
<tr>
<td>Arm1: minoxidil 1% solution, 2x/d, topical</td>
<td>2007</td>
</tr>
<tr>
<td>Arm2: placebo, 2x/d, topical</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm1: minoxidil 1% solution, 2x/d, topical</td>
<td>1998</td>
</tr>
<tr>
<td>Arm2: placebo, 2x/d, topical</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm1: minoxidil 2% solution, 2x/d, topical</td>
<td>1998</td>
</tr>
<tr>
<td>Arm2: placebo, 2x/d, topical</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm1: minoxidil 2% solution, 2x/d, topical</td>
<td>2002</td>
</tr>
<tr>
<td>Arm2: placebo, 2x/d, topical</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm1: minoxidil 2% solution, 2x/d, topical</td>
<td>2001</td>
</tr>
<tr>
<td>Arm2: placebo, 2x/d, topical</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm1: minoxidil 5% solution, 2x/d, topical</td>
<td>2004</td>
</tr>
<tr>
<td>Arm2: placebo, 2x/d, topical</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm1: minoxidil 5% foam, 1x/d, topical</td>
<td>2011</td>
</tr>
<tr>
<td>Arm2: placebo, 2x/d, topical</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm1: 5% minoxidil foam 1x/d, topical</td>
<td>2010</td>
</tr>
<tr>
<td>Arm2: placebo, 2x/d, topical</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm1: minoxidil 5% foam, 1x/d, topical</td>
<td></td>
</tr>
</tbody>
</table>

Minoxidil vs. placebo female patients
<table>
<thead>
<tr>
<th>Arm</th>
<th>Method</th>
<th>w0:</th>
<th>Increase from Baseline</th>
<th>Degree of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arm 1: 2% minoxidil solution</td>
<td>2x/d, topical</td>
<td>24w</td>
<td>30.9 (102.5%)</td>
<td>p &lt; 0.001 vs. Baseline, n.s. vs. Arm 2+3</td>
</tr>
<tr>
<td>Arm 2: placebo foam</td>
<td>1x/d, topical</td>
<td>4w</td>
<td>1.4 (13.6%)</td>
<td>p = 0.968 vs. Placebo, p &lt; 0.001 vs. Minoxidil</td>
</tr>
<tr>
<td>Arm 2:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 3: 3% minoxidil solution</td>
<td>2x/d, topical</td>
<td>4w</td>
<td>5.3 (19.6%)</td>
<td>p = 0.0001 vs. Baseline, n.s. vs. Arm 2</td>
</tr>
<tr>
<td>Arm 3:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 4: placebo, 2x/d, topical</td>
<td>15w</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 5: 3% minoxidil solution</td>
<td>2x/d, topical</td>
<td>4w</td>
<td>10.5 (41.8%)</td>
<td></td>
</tr>
<tr>
<td>Arm 5:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 6: 2% minoxidil solution</td>
<td>2x/d, topical</td>
<td>4w</td>
<td>2.4 (8.0%)</td>
<td>p = 0.0001 vs. Placebo, n.s. vs. Minoxidil</td>
</tr>
<tr>
<td>Arm 6:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 7: placebo, 1x/d, topical</td>
<td>5w</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 7:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 8: 3% minoxidil solution</td>
<td>1x/d, topical</td>
<td>4w</td>
<td>3.3 (12.5%)</td>
<td>p = 0.0001 vs. Baseline</td>
</tr>
<tr>
<td>Arm 8:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 9: placebo, 2x/d, topical</td>
<td>15w</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 9:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 10: 3% minoxidil solution</td>
<td>1x/d, topical</td>
<td>4w</td>
<td>6.9 (26.1%)</td>
<td></td>
</tr>
<tr>
<td>Arm 10:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 11: placebo, 2x/d, topical</td>
<td>5w</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 11:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 12: 3% minoxidil solution</td>
<td>1x/d, topical</td>
<td>4w</td>
<td>6.7 (26.1%)</td>
<td></td>
</tr>
<tr>
<td>Arm 12:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 13: placebo, 2x/d, topical</td>
<td>15w</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 13:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 14: 3% minoxidil solution</td>
<td>1x/d, topical</td>
<td>4w</td>
<td>7.7 (29.4%)</td>
<td></td>
</tr>
<tr>
<td>Arm 14:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ArtNumber</td>
<td>Author</td>
<td>Year</td>
<td>Number of patients</td>
<td>Gender</td>
</tr>
<tr>
<td>-----------</td>
<td>--------</td>
<td>------</td>
<td>--------------------</td>
<td>--------</td>
</tr>
<tr>
<td>A2</td>
<td>Gassmueller</td>
<td>2008</td>
<td>172</td>
<td>Male</td>
</tr>
</tbody>
</table>

**Arm 3:**
- Minoxidil 2% solution, 2x/d, topical, men
- **Mean change from baseline hair count**:
  - (total) hairs/cm: 25.4 (13.3%)
  - (nonvellus) hairs/cm: 2.9 (17.3%)

**Arm 4:**
- Fulvestrant 70 mg/ml, 2x/d, topical, women
- **Mean change from baseline hair count**:
  - (total) hairs/cm: 14.7 (6.9%)
  - (nonvellus) hairs/cm: 1.54 (7.2%)

*Statistical significance:
- p 0.340 vs. Placebo
- p = 0.227
<table>
<thead>
<tr>
<th>Arm</th>
<th>Treatment</th>
<th>Gender</th>
<th>Number</th>
<th>Year</th>
<th>Number</th>
<th>Degree of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>minoxidil 5% solution, 2x/d, topical</td>
<td>male</td>
<td>65</td>
<td>2004</td>
<td>43</td>
<td>B</td>
</tr>
<tr>
<td></td>
<td><strong>Mean change from baseline hair count</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>hairs/cm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Mean change from baseline</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 (2.2%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>%</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>52%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>finasteride 1 mg, 1x/d, oral</td>
<td>male</td>
<td>93</td>
<td>2003</td>
<td>54</td>
<td>B</td>
</tr>
<tr>
<td></td>
<td><strong>Mean change from baseline hair count</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>hairs/cm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Mean change from baseline</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>18.6 (14.4%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>minoxidil 5% solution, 2x/d, topical + pyrithione zinc 1% shampoo, 1x/d,</td>
<td>male</td>
<td>200</td>
<td>2003</td>
<td>28</td>
<td>A2</td>
</tr>
<tr>
<td></td>
<td>topical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Mean change from baseline hair count</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>hairs/cm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Mean change from baseline</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 (2.2%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>%</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>finasteride 5% solution, 2x/d, topical + pyrithione zinc 1% shampoo, 1x/d,</td>
<td>male</td>
<td>6m</td>
<td>2003</td>
<td>25</td>
<td>B</td>
</tr>
<tr>
<td></td>
<td>topical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Mean change from baseline hair count</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>hairs/cm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Mean change from baseline</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6.8 (11.6%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>%</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>87%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>finasteride 1 mg, 1x/d, oral</td>
<td>male</td>
<td>72</td>
<td>2003</td>
<td>65</td>
<td>B</td>
</tr>
<tr>
<td></td>
<td><strong>Mean change from baseline hair count</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>hairs/cm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Mean change from baseline</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-3.0 (-4.0%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>%</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-1.8 (-3.7%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>finasteride 1 mg, 1x/d, oral</td>
<td>male</td>
<td>100</td>
<td>2002</td>
<td>67</td>
<td>B</td>
</tr>
<tr>
<td></td>
<td><strong>Mean change from baseline hair count</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>hairs/cm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Mean change from baseline</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6.8 (11.6%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>%</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>87%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>finasteride 1 mg, 1x/d, oral</td>
<td>male</td>
<td>110</td>
<td>2013</td>
<td>72</td>
<td>C</td>
</tr>
<tr>
<td></td>
<td><strong>Mean change from baseline hair count</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>hairs/cm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Mean change from baseline</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3m: 2.4%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>%</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3m: 1.5%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Year</td>
<td>Gender</td>
<td>Treatment</td>
<td>Time</td>
<td>Mean Change from Baseline Hair Count (hairs/cm²)</td>
<td>Mean Change from Baseline Hair Count (nonvellus) hairs/cm²</td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
<td>--------</td>
<td>-----------</td>
<td>------</td>
<td>-----------------------------------------------</td>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td>Arm 1:</td>
<td>2015</td>
<td>male</td>
<td>2% Minoxidil topical solution, 2x/d, topical</td>
<td>6m</td>
<td>2.3 (1.66%)</td>
<td>6.8 (5.54%)</td>
</tr>
<tr>
<td>Arm 2:</td>
<td>2015</td>
<td>female</td>
<td>Rosemary oil 2x/d, topical</td>
<td>6m</td>
<td>6.8 (5.54%)</td>
<td>2.3 (1.66%)</td>
</tr>
<tr>
<td>Arm 3:</td>
<td>2007</td>
<td>male and female</td>
<td>Fulvestrant 70 mg/ml, 2x/d, topical, men</td>
<td>6m, 12m</td>
<td>8.2 (4.4%)</td>
<td>8.0 (4.4%)</td>
</tr>
<tr>
<td>Arm 4:</td>
<td>2008</td>
<td>male</td>
<td>Minoxidil 2% solution, 2x/d, topical</td>
<td>6m</td>
<td>25.4 (13.3%)</td>
<td>14.7 (7.2%)</td>
</tr>
<tr>
<td>Arm 5:</td>
<td>2002</td>
<td>male</td>
<td>Fulvestrant 1 mg, 1x/d, oral</td>
<td>12m</td>
<td>12m</td>
<td>12m</td>
</tr>
<tr>
<td>Arm 6:</td>
<td>2003</td>
<td>male</td>
<td>Minoxidil 1 mg, 1x/d, oral + minoxidil 2% solution, 2x/d, topical</td>
<td>6m, 12m</td>
<td>15.3 (7.2%)</td>
<td>15.3 (7.2%)</td>
</tr>
</tbody>
</table>

**Investigational Area:** Minoxidil combination therapies

**Degree of Evidence:** C - Poor, B - Moderate, A - Good
<table>
<thead>
<tr>
<th>ArtNumber</th>
<th>Year</th>
<th>Gender</th>
<th>Arm1</th>
<th>Method</th>
<th>Mandate</th>
<th>Transition zone to balding area</th>
</tr>
</thead>
<tbody>
<tr>
<td>165</td>
<td>2007</td>
<td>31</td>
<td>18w</td>
<td>5% minoxidil 5% solution, 2x/d, topical</td>
<td>Minoxidil</td>
<td>A2</td>
</tr>
<tr>
<td>120</td>
<td>2012</td>
<td>40</td>
<td>24w</td>
<td>5% minoxidil 5% solution, 2x/d, topical</td>
<td>Minoxidil</td>
<td>B</td>
</tr>
<tr>
<td>130</td>
<td>2012</td>
<td>83</td>
<td>6m</td>
<td>5% minoxidil 5% solution, 2x/d, topical</td>
<td>Minoxidil</td>
<td>A2</td>
</tr>
<tr>
<td>71</td>
<td>2013</td>
<td>100</td>
<td>12w</td>
<td>5% minoxidil 5% solution, 2x/d, topical</td>
<td>Minoxidil</td>
<td>B</td>
</tr>
<tr>
<td>72</td>
<td>2013</td>
<td>32</td>
<td>30w</td>
<td>5% minoxidil 5% solution, 2x/d, topical</td>
<td>Minoxidil</td>
<td>B</td>
</tr>
</tbody>
</table>

**Investigational area:**

- Arm1: Minoxidil 5% solution, 2x/d, topical
  - Mean change from baseline hair count (total): 15.9 (12.8%) p < 0.05 vs. Baseline
  - Mean change from baseline hair count (nonvellus): 2 (2%)%
  - Mean change from baseline hair count (anagen, telogen, anagen/telogen ratio): -0.014 (-2.5%) n.s. vs. Baseline
  - Hair diameter: 2.6 (7.7%) µm
  - Global expert panel assessment: Improved 43%, unchangsd 38%

- Arm2: Minoxidil 5% + tretinoin 0.01% solution, 1x/d, topical, morning; placebo solution, 1x/d, topical
  - Mean change from baseline hair count (total): 18.2 (14.7%) p < 0.05 vs. Baseline, n.s. vs. Arm1
  - Mean change from baseline hair count (nonvellus): 6.1 (4.3%) p < 0.05 vs. Baseline, n.s. vs. Arm1
  - Mean change from baseline hair weight / thickness: 1.9 (5.3%) n.s. vs. Baseline
  - Anagen ratio: -0.033 (-5.0%) n.s. vs. Baseline
  - Hair diameter: 1.9 (5.3%) µm
  - Global expert panel assessment: Improved 61%, unchanged 39%

- Arm3: Minoxidil 3% lotion, 2x/d, topical
  - 24w: 2.9 (4.7%) n.s. vs. Baseline, n.s. vs. Arm 2

- Arm4: Placebo, hair tonic, 2x/d, topical
  - 6m: 20.4 (11.4%) p < 0.001 vs. Baseline
  - 6m: Improved 14%, unchanged 54%
  - 12m: 73 (40.3%) p < 0.05 vs. Baseline
  - 12m: Improved 50%, unchanged 32%

**Methodology:**

- Clinical scoring: vertex, anterior/mid scalp regions, frontotemporal hairline
- Phototrichogram: vertex
- Hair count: transitional zone to balding area

**Investigator Assessment:**

- Arm1: Minoxidil 5% solution, 2x/d, topical
  - 12m: 59%
- Arm2: Minoxidil 5% + tretinoin 0.01% solution, 1x/d, topical
  - 12m: 65%
- Arm3: Minoxidil 3% lotion, 2x/d, topical
  - 24w: 2.9 (4.7%) n.s. vs. Baseline
- Arm4: Placebo, hair tonic, 2x/d, topical
  - 6m: Improved 14%, unchanged 54%
  - 12m: 73 (40.3%) p < 0.05 vs. Baseline
  - 12m: Improved 50%, unchanged 32%

**Patient Assessment:**

- Arm1: Minoxidil 5% solution, 2x/d, topical
  - 12m: 59%
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Year</th>
<th>Gender</th>
<th>Duration</th>
<th>Investigational Area</th>
<th>Degree of Evidence</th>
<th>Method</th>
<th>Feature</th>
<th>Arm 1</th>
<th>Arm 2</th>
<th>Arm 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>92</td>
<td>2015</td>
<td>male</td>
<td>12m</td>
<td>Minoxidil combination therapies female patients</td>
<td>unclear</td>
<td></td>
<td></td>
<td>Arm 2: finasteride 1 mg, 1x/d, oral</td>
<td>12m: 80.5%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Arm 3: minoxidil 5% solution, 2x/d and finasteride 1 mg, 1x/d oral</td>
<td>12m: 94.1%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Arm 1: placebo, topical</td>
<td>6m: 0%</td>
<td>6m: 0%</td>
<td>6m: 0%</td>
</tr>
<tr>
<td>95</td>
<td>2009</td>
<td>female</td>
<td>6m</td>
<td>Arm 1: minoxidil 2%, solution, 2x/d, topical + oral contraceptive (ethinyl estradiol 35 µg and cyproterone acetate 2 mg), 1x/d, oral</td>
<td>100%</td>
<td></td>
<td></td>
<td>Arm 1: placebo, 2x/d, topical</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>93</td>
<td>2014</td>
<td>female</td>
<td>9m</td>
<td>Arm 1: minoxidil 2%, solution, topical and Pantoprazole 3x/d, oral</td>
<td>unclear</td>
<td></td>
<td></td>
<td>Arm 1: placebo, 2x/d, topical</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>99</td>
<td>2016</td>
<td>female</td>
<td>24w</td>
<td>Arm 1: minoxidil 2%, solution, 3x/d, topical</td>
<td>50%</td>
<td></td>
<td></td>
<td>Arm 1: placebo, 2x/d, topical</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>77</td>
<td>1986</td>
<td>female</td>
<td>12m</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Arm 1: placebo, 2x/d, topical</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Number of patients</td>
<td>Gender</td>
<td>Time of evaluation</td>
<td>Dosage</td>
<td>Method</td>
<td>Investigational area</td>
<td>Degree of evidence</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>--------</td>
<td>--------------------</td>
<td>--------</td>
<td>--------</td>
<td>----------------------</td>
<td>-------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>male</td>
<td>24w</td>
<td>minoxidil 0.5%, 2x/d, topical</td>
<td>adverse open study design</td>
<td>16/16</td>
<td>cr</td>
<td>S3 AGA Guideline Update_Results.xlsx</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Article number</td>
<td>Author</td>
<td>Year</td>
<td>Number of patients</td>
<td>Gender</td>
<td>Time of evaluation</td>
<td>Dosage</td>
<td>Method</td>
<td>Global expert panel assessment</td>
<td>Investigator assessment</td>
<td>Patient assessment</td>
</tr>
<tr>
<td>----------------</td>
<td>--------</td>
<td>------</td>
<td>-------------------</td>
<td>--------</td>
<td>-------------------</td>
<td>--------</td>
<td>--------</td>
<td>-------------------------------</td>
<td>------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>105</td>
<td>Trüeb</td>
<td>2001</td>
<td>265</td>
<td>male</td>
<td>6m</td>
<td>n.a.</td>
<td></td>
<td></td>
<td>38.0%</td>
<td></td>
</tr>
<tr>
<td>112</td>
<td>Sato</td>
<td>2012</td>
<td>3177</td>
<td>male</td>
<td>3.5y</td>
<td>Arm1:</td>
<td>finasteride 1 mg, 1x/d, oral</td>
<td>time point unclear</td>
<td>improved 87.1%</td>
<td>unchanged 12.5%</td>
</tr>
<tr>
<td>113</td>
<td>Yoshitake</td>
<td>2015</td>
<td>801</td>
<td>male</td>
<td>5y</td>
<td>Arm1:</td>
<td>finasteride 1 mg, 1x/d, oral</td>
<td>5y: 99,4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>115</td>
<td>Oliviera</td>
<td>2013</td>
<td>40</td>
<td>female</td>
<td>18m</td>
<td>Arm1:</td>
<td>finasteride 5mg, 1x/d, oral</td>
<td>major: 55% moderate: 37,5%</td>
<td>major: 57,5% moderate: 30,0%</td>
<td>not reported</td>
</tr>
<tr>
<td>106</td>
<td>Rossini</td>
<td>2011</td>
<td>118</td>
<td>male</td>
<td>10y</td>
<td>Arm1:</td>
<td>finasteride 1 mg, daily, oral</td>
<td>p &lt; 0.05 vs. placebo</td>
<td>44%</td>
<td></td>
</tr>
<tr>
<td>107</td>
<td>Hajheydari</td>
<td>2009</td>
<td>45</td>
<td>male</td>
<td>6m</td>
<td>Arm1:</td>
<td>finasteride 5mg, daily, oral</td>
<td>p &lt; 0.01 vs. placebo</td>
<td>-4 (-2.5%)</td>
<td></td>
</tr>
<tr>
<td>108</td>
<td>van Neste</td>
<td>2000</td>
<td>212</td>
<td>male</td>
<td>48w</td>
<td>Arm1:</td>
<td>finasteride 1 mg, daily, oral</td>
<td>18 (14.5%)</td>
<td>p &lt; 0.001</td>
<td></td>
</tr>
</tbody>
</table>

**Finasteride male patients**

**Finasteride vs. Placebo male patients**

**Finasteride female patients**
| Arm        | Dosage                        | Gender | Time of Evaluation | Number of Patients | Method                                      | Investigational Area | Degree of Evidence | Improved:          |unchanged:       |
|------------|-------------------------------|--------|-------------------|-------------------|---------------------------------------------|----------------------|-------------------|-------------------|------------------|------------------|
| Arm 1:     | finasteride 1 mg, 1x/d, oral  | male   | 6m, 12m           | 414               | mean change from baseline hair count (total) | vertex A2            | 41%               | 58%               | 40%              |
| Arm 2:     | finasteride 0.2 mg, 1x/d, oral| male   | 6m, 12m           | 1553              | mean change from baseline hair count (nonvellus) | vertex A2            | 49%               | 54%               | 41%              |
| Arm 3:     | placebo, 1x/d, oral           | male   | 24m               | 424               | mean change from baseline hair count (anagen, telogen, anagen/telogen ratio) | vertex A2            | 1%                | 6%                | 72%              |
| Arm 4:     | placebo, 1x/d, oral           | male   | 2y                | 693               | mean change from baseline hair weight / thickness | vertex A2            | 7%                | 12%               | 82%              |
| Arm 5:     | placebo, 1x/d, oral           | male   | 2y                | 424               | global expert panel assessment                | vertex A2            | 10%               | 10%               | 83%              |
| Arm 6:     | finasteride 1 mg, 1x/d, oral  | male   | 24m               | 1553              | investigator assessment                     | vertex A2            | 1%                | 2%                | 99%              |
| Arm 7:     | placebo, 1x/d, oral           | male   | 24m               | 424               | patient assessment                          | vertex A2            | 1%                | 1%                | 99%              |

**5-alpha-reductase-inhibitors**

2/7
<table>
<thead>
<tr>
<th>Arm</th>
<th>Treatment</th>
<th>48w</th>
<th>96w</th>
<th>p-value</th>
<th>48w</th>
<th>96w</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arm1</td>
<td>Finasteride 1 mg, 1x/d, oral</td>
<td>12.4</td>
<td>9.1</td>
<td>&lt;0.001</td>
<td>20.4</td>
<td>21.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Arm2</td>
<td>Placebo, 1x/d, oral</td>
<td>3.2</td>
<td>-6.3</td>
<td>0.11</td>
<td>-5.2</td>
<td>-14.2</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>

The Finasteride Male Pattern Hair Loss Study Group 2002

Investigational area: 3/7 5-alpha-reductase-inhibitors

Degree of evidence: S3 AGA Guideline Update

Method:
- mean change from baseline hair count (total) hairs/cm
- mean change from baseline hair count (nonvellus) hairs/cm
- mean change from baseline hair weight/thickness
- global expert panel assessment
- investigator assessment
- patient assessment

Investigator:
- Vertex

Phototrichogram:
- Manual hair count
- Vertex

Location:
- Frontoparietal

Patient characteristics:
- 1553 male
- 24m, 60m

Price:
- 2002 66

111
<table>
<thead>
<tr>
<th>Article number</th>
<th>Year</th>
<th>Number of patients</th>
<th>Gender</th>
<th>Time of evaluation</th>
<th>Dosage</th>
<th>Method</th>
<th>Investigational area</th>
<th>Degree of evidence</th>
<th>Investigational area</th>
<th>Degree of evidence</th>
<th>Investigational area</th>
<th>Degree of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>107</td>
<td>1999</td>
<td>326 male</td>
<td>6m, 12m, 24m</td>
<td></td>
<td>Finasteride 1 mg, 1x/d, oral</td>
<td>6m: 7.0 (3.3%) 12m: 9.6 (4.6%) 24m: 13.0 (6.2%)</td>
<td>mean change from baseline hair count</td>
<td>Arm1</td>
<td></td>
<td>vs. placebo</td>
<td>vs. placebo</td>
<td></td>
</tr>
<tr>
<td>57</td>
<td>1999</td>
<td>28 male</td>
<td>6m, 12m, 24m</td>
<td></td>
<td>Placebo</td>
<td>6m: 0.6 12m: 3.6 24m: -0.8</td>
<td>mean change from baseline hair count</td>
<td>Arm2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>102</td>
<td>2006</td>
<td>28 male (14/14) 48f (16f)</td>
<td></td>
<td></td>
<td></td>
<td>6m: -1.2 12m: -0.6 24m: 8.0</td>
<td>mean change from baseline hair count</td>
<td>Arm1</td>
<td></td>
<td>vs. placebo</td>
<td>vs. placebo</td>
<td></td>
</tr>
<tr>
<td>101</td>
<td>2000</td>
<td>102 female</td>
<td></td>
<td></td>
<td></td>
<td>6m: 0.9 12m: 1.9 24m: -0.1</td>
<td>weight (% baseline)</td>
<td>Arm2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>108</td>
<td>2004</td>
<td>162 male</td>
<td>12m</td>
<td></td>
<td></td>
<td>17.7 (5.6%) 41.6 (34.6%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>63</td>
<td>2004</td>
<td>65 male</td>
<td>12m (52w)</td>
<td></td>
<td></td>
<td>36 (28.1%) 82 (% 121)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>64</td>
<td>2003</td>
<td>99 male</td>
<td>12m</td>
<td></td>
<td></td>
<td>19.6 (16.0%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigational area</td>
<td>Degree of evidence</td>
<td>Arm1</td>
<td>Arm2</td>
<td>Arm3</td>
<td>Arm4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hair transplant + finasteride 1 mg, 1x/d, oral</td>
<td>2</td>
<td>hair transplant + placebo, 1x/d, oral</td>
<td>18.5 (12.6%)</td>
<td>-13.5 (-8.9%)</td>
<td>59%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>minoxidil 2% solution, 2x/d, topical</td>
<td>4</td>
<td>minoxidil 3% lotion, 2x/d, topical</td>
<td>2.9 (4.7%)</td>
<td>4.8 (8.3%)</td>
<td>94.1%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>minoxidil 3% + finasteride 0.1% lotion, 2x/d, topical</td>
<td>4</td>
<td>minoxidil 3% + finasteride 1 mg, 1x/d, oral</td>
<td>6.8</td>
<td>16.5</td>
<td>94%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dutasteride 0.5 mg, 1x/d, oral</td>
<td>1</td>
<td>dutasteride 0.5 mg, 1x/d, oral</td>
<td>12.2 (8.2%)</td>
<td>4.7 (3.3%)</td>
<td>94%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Global Expert Panel Assessment**

- Arm1: minoxidil 2% solution, 2x/d, topical
- Arm2: minoxidil 3% lotion, 2x/d, topical
- Arm3: minoxidil 5% solution, 2x/d and finasteride 1 mg, 1x/d, oral
- Arm4: finasteride 1 mg, 1x/d, oral

**Patient Assessment**

- Arm1: minoxidil 5% solution, 2x/d and finasteride 1 mg, 1x/d, oral

**Study Details**

- **Jung** 2014
- **Khandpur** 2002
- **Leavitt** 2005
- **Hu** 2015
- **Tanglertsampan** 2012
- **Stough** 2007
- **Eun** 2010

**5-alpha-reductase-inhibitors**

- S3 AGA Guideline Update: Results.xlsx
<table>
<thead>
<tr>
<th>Arm</th>
<th>Study</th>
<th>Duration</th>
<th>Gender</th>
<th>Time of evaluation</th>
<th>Dosage</th>
<th>Outcome Measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arm 1: Placebo 1x/d, oral</td>
<td>Dutasteride 0.1 mg, 1x/d, oral</td>
<td>15.4 (8.7%)</td>
<td><em>p</em> &lt; 0.001 vs. placebo</td>
<td>Arm 2: Dutasteride 0.5 mg, 1x/d, oral</td>
<td>18.6 (10.2%)</td>
<td><em>p</em> &lt; 0.001 vs. placebo</td>
</tr>
<tr>
<td>Arm 3: Dutasteride 2.5 mg, 1x/d, oral</td>
<td>21.5 (11.3%)</td>
<td><em>p</em> &lt; 0.001 vs. placebo</td>
<td>Arm 4: Finasteride 5 mg, 1x/d, oral</td>
<td>14.8 (8.4%)</td>
<td><em>p</em> &lt; 0.001 vs. placebo</td>
<td></td>
</tr>
<tr>
<td>Arm 5: Placebo, 1x/d, oral</td>
<td>-6.3 (-3.5%)</td>
<td>2%</td>
<td>Arm 1: Placebo 1x/d, oral</td>
<td>mean change from baseline: 12w: -4.0 (2.54 cm), -0.4 (1.13 cm) 24w: -4.9 (2.54 cm), -0.3 (1.13 cm)</td>
<td>hair width w24: -0.9</td>
<td></td>
</tr>
<tr>
<td>Arm 2: Dutasteride 0.02 mg, 1x/d, oral</td>
<td>mean change from baseline: 12w: 22.9 (2.54 cm), 5.1 (1.13 cm) 24w: 17.1 (2.54 cm), 4.2 (1.13 cm)</td>
<td>hair width w24: 0.0</td>
<td>Arm 3: Dutasteride 0.1 mg, 1x/d, oral</td>
<td>mean change from baseline: 12w: 59.6 (2.54 cm), 12.8 (1.13 cm) 24w: 63.0 (2.54 cm), 12.4 (1.13 cm)</td>
<td>hair width w24: 3.9</td>
<td></td>
</tr>
<tr>
<td>Arm 4: Placebo, 1x/d, oral</td>
<td>mean change from baseline: 12w: 30.62 (20.0%)</td>
<td><em>p</em> &lt; 0.001 vs. Baseline</td>
<td>Arm 5: Placebo, 1x/d, oral</td>
<td>mean change from baseline: 12w: 50.9 (2.54 cm), 10.8 (1.13 cm) 24w: 56.5 (2.54 cm), 12.1 (1.13 cm)</td>
<td>hair width w24: 4.0</td>
<td></td>
</tr>
<tr>
<td>Arm</td>
<td>Treatment</td>
<td>24m:</td>
<td>6m:</td>
<td>12m:</td>
<td>24m:</td>
<td>6m:</td>
</tr>
<tr>
<td>-----</td>
<td>-----------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>Arm1</td>
<td>Finasteride 1mg, 1x/d, oral</td>
<td>Improved 68%</td>
<td>Unchanged 22%</td>
<td>Worsened 10%</td>
<td>Improved 52%</td>
<td>Unchanged 40%</td>
</tr>
<tr>
<td>Arm2</td>
<td>Seronoa repens 320mg, 1x/d, oral</td>
<td>Improved 38%</td>
<td>Unchanged 52%</td>
<td>Worsened 10%</td>
<td>Improved 40%</td>
<td>Unchanged 45%</td>
</tr>
</tbody>
</table>

* _blinding till 12m, afterwards open study design
** _mean of 3 reviewers
*** _investigator = outcome assessor

118
Rossi
2012

Gender: Male
Number of patients: 100

**Method**

| Mean change from baseline hair count (total) hairs/cm | 2 |
| Mean change from baseline hair count (nonvellus) hairs/cm | 2 |
| Mean change from baseline hair weight/ thickness | 2 |
| Global expert panel assessment | 2 |
| Investigator assessment | 2 |
| Patient assessment | 2 |

*Investigational area*

5-alpha-reductase-inhibitors

**Degree of evidence**

| 5/7 | S3 AGA Guideline Update_Results.xlsx | 2 |

**Cross-reference**

cr = cross reference, see also cited in the section of the comparator.
<p>| Year | Author | Number of patients | Gender | Time of evaluation | Dosage | Method | mean change from baseline hair count (total) hairs/cm² | mean change from baseline hair count (nonvellus) hairs/cm² | mean change from baseline hair weight / thickness | global expert panel assessment | investigator assessment | patient assessment | Investigational area | Degree of evidence |
|------|--------|--------------------|--------|-------------------|--------|--------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------|------------------|------------------|-------------------|-----------------|
| 2009 | Kapadia | 26 | female | 6m | Arm1: ethinyl oestradiol 50 µm + CPA 2 mg 1x/d, oral, day 5-27 of menstrual cycle, CPA 20 mg, 1x/d, oral day 5-20 of menstrual cycle | anagen / telogen ratio | 2.8 (164.7%) | Arm2: no treatment | -1.2 (-50%) | Arm1: | minoxidil 2% solution, 2x/d, topical + oral contraceptive (ethinyl oestradiol 30 µg and gestodene 75 µg), 1x/d, 21 of 28 days, oral | Arm2: | cyproterone acetate 50 mg, 1x/d, 20 of 28 days, oral + oral contraceptive (ethinyl estradiol 35 µg and cyproterone acetate 2 mg), 1x/d, 21 of 28 days, oral | 6m: 16.1 (8.6%) | 12m: 16.9 (9.1%) | p &lt; 0.001 (12m) vs. Baseline and Arm2 | Arm1: | Arm2: | C |
| 1989 | Peereboom-Wynia | 30 | female | 12m | | | | | | | | | | |
| 2011 | Paradisi | 101 | female | | | | | | | | | | | |
| 2002 | Vexiau | 66 | female | 6m, 12m | | | | | | | | | | |
| 1998 | | | | | | | | | | | | | | |
| 2002 | Sovak | 43 | male | 3m, 9m | | | | | | | | | | |
| 1998 | | | | | | | | | | | | | | |</p>
<table>
<thead>
<tr>
<th>Arm</th>
<th>Treatment</th>
<th>Study Duration</th>
<th>Gender</th>
<th>Study Duration</th>
<th>Changes from Baseline in Hair Count (mean change from baseline hair count)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arm 1</td>
<td>Alfatradiol 0.025% solution, 1x/d, topical</td>
<td>6m</td>
<td>female</td>
<td></td>
<td>5.3 (8.7%) (n.s. vs. Baseline)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12m</td>
<td>female</td>
<td></td>
<td>14.0 (p &lt; 0.001 vs. Baseline)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>female</td>
<td></td>
<td>14.9 (p &lt; 0.001 vs. Baseline)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>female</td>
<td></td>
<td>21h (0.05) (n.s. vs. Baseline)</td>
</tr>
<tr>
<td>Arm 2</td>
<td>Alfatradiol 0.025% solution, 1x/d, topical + Minoxidil 2% solution, 2x/d,</td>
<td>6m</td>
<td>female</td>
<td></td>
<td>-7.8 (-4.3%) (n.s. vs. Baseline)</td>
</tr>
<tr>
<td></td>
<td>topical</td>
<td>12m</td>
<td>female</td>
<td></td>
<td>7.8 (7.8%) (p &lt; 0.001 vs. Baseline)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>female</td>
<td></td>
<td>8.8 (p &lt; 0.001 vs. Baseline)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>female</td>
<td></td>
<td>13h (0.05) (n.s. vs. Baseline)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>female</td>
<td></td>
<td>14 (p &lt; 0.001 vs. Baseline)</td>
</tr>
</tbody>
</table>

**Statistical Significance:**
- n.s.: Not significant
- p < 0.05
- p < 0.01
- p < 0.001

**Investigational Area:**
- Arm 1: 17alpha-estradiol (Ell-Cranell)
- Arm 2: Alfatradiol lotion 0.03%, 1x/d, topical, 12w
- Arm 3: Placebo lotion, 1x/d, topical, 24w

**Degree of Evidence:**
- A: Strong
- B: Moderate
- C: Poor

**Method:**
- Mean change from baseline hair count
- Global expert panel assessment
- Investigator assessment
- Patient assessment
<table>
<thead>
<tr>
<th>Arm</th>
<th>Placebo, 2x/d, topical</th>
<th>15.3 (7.9%)</th>
<th>1.58 (8.1%)</th>
</tr>
</thead>
</table>

**Investigational area**
- Hormones

**Degree of evidence**
- **_** blinding till 12m, afterwards open study design
- **_** mean of 3 reviewers
- **_** investigator = outcome assessor
- **_** improvement > 10% decrease
- cr = cross reference, see also cited in the section of the comparator
<table>
<thead>
<tr>
<th>Patient</th>
<th>Year</th>
<th>Age</th>
<th>Gender</th>
<th>Time of Evaluation</th>
<th>Investigational Area</th>
<th>Degree of Evidence</th>
<th>% Improved</th>
<th>% Unchanged</th>
<th>Mean Hairs/Follicular Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uebel</td>
<td>2006</td>
<td>20</td>
<td>Male</td>
<td>7m</td>
<td>Arm1: follicular unit transplantation</td>
<td></td>
<td></td>
<td></td>
<td>2.28</td>
</tr>
<tr>
<td>Uebel</td>
<td>2005</td>
<td>70</td>
<td>Male</td>
<td>12m</td>
<td>Arm1: hair transplantation + transparent (mg. 1x1v, 3%) + psittacofulvin solution, topical 15 days before till 90 days after FUT + placebo solution, topical 15 days before till 90 days after FUT</td>
<td></td>
<td></td>
<td></td>
<td>2.14</td>
</tr>
<tr>
<td>Leavitt</td>
<td>2005</td>
<td>41</td>
<td>Male</td>
<td>7m</td>
<td>Arm1: follicular unit transplantation, preparation by dissecting microscope</td>
<td></td>
<td></td>
<td></td>
<td>18.5 (12.6%) p &lt; 0.001 (Arm1 vs. Arm2)</td>
</tr>
<tr>
<td>ArtNumber</td>
<td>Author</td>
<td>Year</td>
<td>Number of patients</td>
<td>Gender</td>
<td>Time of evaluation</td>
<td>Dosage</td>
<td>Method</td>
<td>Evaluation</td>
<td>Degree of evidence</td>
</tr>
<tr>
<td>-----------</td>
<td>------------</td>
<td>------</td>
<td>--------------------</td>
<td>--------</td>
<td>--------------------</td>
<td>--------</td>
<td>--------</td>
<td>------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>169</td>
<td>Lee</td>
<td>2015</td>
<td>60</td>
<td>female</td>
<td>3m</td>
<td>23.2%</td>
<td>PRP</td>
<td>1 Arm: platelet rich plasma and polydeoxiribonucleotid injections on the scalp</td>
<td>B</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PRP</td>
<td>2 Arm: polydeoxiribonucleotid injections on the scalp</td>
<td></td>
</tr>
<tr>
<td>170</td>
<td>Gkini</td>
<td>2014</td>
<td>64</td>
<td>female and male</td>
<td>6m</td>
<td>1 Arm: platelet rich plasma injections on the scalp</td>
<td>17.9%</td>
<td>PRP</td>
<td>40 - 54% clinical improvement</td>
</tr>
<tr>
<td>171</td>
<td>Gkini</td>
<td>2014</td>
<td>22</td>
<td>female and male</td>
<td>52w</td>
<td>2 Arm: platelet rich plasma injections on the scalp</td>
<td>10.6%</td>
<td>PRP</td>
<td>vertex</td>
</tr>
<tr>
<td>172</td>
<td>Lanzafame</td>
<td>2009</td>
<td>125</td>
<td>male</td>
<td>6m</td>
<td>Arm1: HairMax LaserComb, 3x/week 15 minutes</td>
<td>17.3%</td>
<td>LLLT</td>
<td>6m: improved 36.1%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>LLLT</td>
<td>6m: improved 63.2%</td>
<td></td>
</tr>
<tr>
<td>173</td>
<td>Lanzafame</td>
<td>2013</td>
<td>42</td>
<td>female</td>
<td>16w</td>
<td>Arm1: Low level light therapy (650nm)/60x/16w</td>
<td>100.3%</td>
<td>LLLT</td>
<td>vertex</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>LLLT</td>
<td>midline</td>
<td></td>
</tr>
<tr>
<td>174</td>
<td>Lanzafame</td>
<td>2003</td>
<td>35</td>
<td>female and male</td>
<td>6m</td>
<td>Arm1: HairMax LaserComb (low level laser therapy), comb hair 1x/d 5-10 minutes</td>
<td>14.1%</td>
<td>LLLT</td>
<td>vertex/temporal</td>
</tr>
</tbody>
</table>

* prp = platelet rich plasma

**_ blinding till 12m, afterwards open study design

---

*investigator = outcome assessor

---

PRP_LLLT 1/1 S3 AGA Guideline Update_Results.xlsx
<table>
<thead>
<tr>
<th>Arm</th>
<th>Investigational area</th>
<th>Degree of evidence</th>
<th>Number of patients</th>
<th>Gender</th>
<th>Time of evaluation</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arm 1</td>
<td>active oral softgel supplement (β-sitosterol 50 mg + serenoa repens extract 200 mg, lecithin 50 mg, inositol 100 mg, phosphatidyl choline 25 mg, niacin 15 mg, biotin 100 µg), 2x/d, oral</td>
<td>60%</td>
<td>26</td>
<td>male</td>
<td>18-24w</td>
<td></td>
</tr>
<tr>
<td>Arm 2</td>
<td>softgel placebo, 2x/d, oral</td>
<td>11%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 1</td>
<td>finasteride 1mg, 1x/d, oral</td>
<td>24m: improved</td>
<td>68%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 2</td>
<td>serenoa repens 320 mg, 1x/d, oral</td>
<td>24m: improved</td>
<td>38%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm 1</td>
<td>viviscal (marine extracts and silicea component), 2x/d, oral</td>
<td>4.8 (38.1 %) p &lt; 0.001 vs. Arm 2</td>
<td>194</td>
<td>male</td>
<td>6m</td>
<td></td>
</tr>
<tr>
<td>Arm 2</td>
<td>fish extract, 2x/d, oral</td>
<td>0.3 (2.1%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ArtNumber</td>
<td>Author</td>
<td>Year</td>
<td>Gender</td>
<td>Number of patients</td>
<td>Total hairs/cm (average change from baseline)</td>
<td>Hair thinning (%) Mean percentage</td>
</tr>
<tr>
<td>-----------</td>
<td>---------------</td>
<td>------</td>
<td>--------</td>
<td>-------------------</td>
<td>-----------------------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>190</td>
<td>Le Floch</td>
<td>2015</td>
<td>female</td>
<td>120</td>
<td>6m: 11%</td>
<td>6m: 78,01%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6m: 88,6%</td>
</tr>
<tr>
<td>177</td>
<td>Moers-Carpi</td>
<td>2011</td>
<td>female and male</td>
<td>62</td>
<td>6m: 18%</td>
<td>6m: 75,68%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>28,5%</td>
</tr>
<tr>
<td>177</td>
<td>Moers-Carpi</td>
<td>2011</td>
<td>female and male</td>
<td>62</td>
<td>24w: 6.5</td>
<td>anagen: 6.5% n.s. vs. Arm2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>anagen: 8% vs. Arm2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>p&lt;0.001 vs. Arm2</td>
</tr>
</tbody>
</table>

**Arm 1:** Nutritional supplement with omega 3 & 6 and antioxidants: 460 mg fish oil, 460 mg blackcurrant seed oil, 5 mg Vitamin E, 30 mg Vitamin C, and 1 mg Lycopene. 1x/d, oral.

**Arm 2:** No treatment.

**Arm 1:** 2 capsules containing Fenugreek and micronutrients (vitamins C, E, nicotinamide, pantethenol, zinc, vitamins B1, B6, B12, copper, biotin, folic acid, iod, selenium). 1x/d, oral.

**Arm 2:** 2 placebo capsules, 1x/d, oral.

**Fotographs:** Whole scalp, parted and combed away.

**Phototrichogram:** Frontal and vertex.
<table>
<thead>
<tr>
<th>Art.</th>
<th>Year</th>
<th>Author</th>
<th>Gender</th>
<th>Number of Patients</th>
<th>Age</th>
<th>Treatment 1</th>
<th>Treatment 2</th>
<th>Treatment 3</th>
<th>p-value 1 vs. placebo</th>
<th>p-value 2 vs. placebo</th>
<th>p-value 3 vs. placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>178</td>
<td>2000</td>
<td>Kamimura</td>
<td>male</td>
<td>30</td>
<td>6 m</td>
<td>Arm1: procyanidin 1% solution, 2x/d, topical</td>
<td>Arm2: placebo, 2x/d, topical</td>
<td>-3.3</td>
<td>0.3</td>
<td>p &lt; 0.005</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Arm1: placebo, 2x/d, topical</td>
<td>Arm2: placebo, 2x/d, topical</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>179</td>
<td>1991</td>
<td>Kessels</td>
<td>male</td>
<td>295</td>
<td>6 m</td>
<td>Arm1: herbal preparation, 2x/d, topical</td>
<td>Arm2: placebo, 2x/d, topical</td>
<td>21.6</td>
<td>0.3</td>
<td>p = 0.02</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Arm1: placebo, 2x/d, topical</td>
<td>Arm2: placebo, 2x/d, topical</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>180</td>
<td>1998</td>
<td>Greenberg</td>
<td>male</td>
<td>24</td>
<td>40 w</td>
<td>Arm1: herbal extract cream (7.5% extract of fennel, polygonum, mentha, chamomile, roja, hibiscus, 1x, topical)</td>
<td>Arm2: placebo cream 1x/d, topical</td>
<td>33.9%</td>
<td>3%</td>
<td>p = 0.02</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Arm1: placebo cream 1x/d, topical</td>
<td>Arm2: placebo cream 1x/d, topical</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>181</td>
<td>1993</td>
<td>Olsen</td>
<td>male</td>
<td>72</td>
<td>6 m</td>
<td>Arm1: viprostol solution 120 µg, 2x/d, topical</td>
<td>Arm2: vehicle, 2x/d, topical</td>
<td>-3.1 (-3.3%)</td>
<td>-3.1 (-3.3%)</td>
<td>n.s. vs. Arm2/3</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Arm1: vehicle, 2x/d, topical</td>
<td>Arm2: vehicle, 2x/d, topical</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ArtNumber</td>
<td>Author</td>
<td>Year</td>
<td>Number of patients</td>
<td>Gender</td>
<td>Time of evaluation</td>
<td>Dosage</td>
<td>Method</td>
<td>Investigational area</td>
<td>Degree of evidence</td>
<td>Investigator assessment</td>
<td>Patient assessment</td>
</tr>
<tr>
<td>-----------</td>
<td>--------</td>
<td>------</td>
<td>-------------------</td>
<td>--------</td>
<td>-------------------</td>
<td>--------</td>
<td>--------</td>
<td>---------------------</td>
<td>-------------------</td>
<td>-----------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>183</td>
<td>Fischer</td>
<td>2010</td>
<td>50</td>
<td>male</td>
<td>48w</td>
<td>minoxidil 2% solution, 2x/d, topical</td>
<td>6.8 (11.0%)</td>
<td>p &lt; 0.001 vs. Arm2</td>
<td>hair thickness (µm):</td>
<td>2,6%**</td>
<td>2,4%</td>
</tr>
<tr>
<td>185</td>
<td>Fischer</td>
<td>2012</td>
<td>35</td>
<td>male</td>
<td>6m</td>
<td>maxilene lotion (glycerol oxyesters and organic silicium), 1x/d, topical</td>
<td>-3.0 (-4.8%)</td>
<td>-1.8 (-3.7%)</td>
<td>hair thickness (µm):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>186</td>
<td>Fagihi</td>
<td>2013</td>
<td>110</td>
<td>male</td>
<td>6m</td>
<td>5% lotion containing clover extract (15 ppm Biochanin A) + acetyl tetrapeptide-3 300 ppm, 1x/d, topical</td>
<td>4m: anagen 13% telogen -29% A/T ratio 46%</td>
<td>4m: improved 58%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>184</td>
<td>Ito</td>
<td>2009</td>
<td>24</td>
<td>male</td>
<td>6m</td>
<td>5% minoxidil solution, 1x/d, topical</td>
<td>3m: 2,4%</td>
<td>3m: 1,9%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>182</td>
<td>Groveman</td>
<td>1985</td>
<td>174</td>
<td>male</td>
<td>16w</td>
<td>Melatonin topical solution 1x/d</td>
<td>6m: 36,6 (42,6%)</td>
<td>6m: 50,41 (40,93%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>181</td>
<td>Loing</td>
<td>2013</td>
<td>30</td>
<td>male</td>
<td>4m</td>
<td>Roxithromycin 0.5% solution, 1x/d, topical</td>
<td>4m: anagen -2% telogen 23% A/T ratio -33%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>180</td>
<td>Reygagne</td>
<td>1997</td>
<td>72</td>
<td>male</td>
<td>6m</td>
<td>5% lotion containing clover extract (15 ppm Biochanin A) + acetyl tetrapeptide-3 300 ppm, 1x/d, topical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>179</td>
<td>Reygagne</td>
<td>1997</td>
<td>72</td>
<td>male</td>
<td>6m</td>
<td>placebo lotion, 1x/d, topical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>178</td>
<td>Loing</td>
<td>2013</td>
<td>30</td>
<td>male</td>
<td>4m</td>
<td>placebo solution, 1x/d, topical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>177</td>
<td>Groveman</td>
<td>1985</td>
<td>174</td>
<td>male</td>
<td>16w</td>
<td>5% minoxidil solution, 1x/d, topical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For more information, please see the attached Excel file: "AGA Guideline Update, Results.xlsx".
<table>
<thead>
<tr>
<th>Arm</th>
<th>Treatment</th>
<th>Phototrichogram</th>
<th>Phototrichogram</th>
<th>Anagen Rate</th>
<th>Hair Thickness (mm)</th>
<th>Investigation Area</th>
<th>Diagnosis of Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1</td>
<td>8.3% valproic acid topical solution</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A2</td>
<td>Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B1</td>
<td>2% Minoxidil topical solution, 2x/d, topical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B2</td>
<td>Rosemary oil 2x/d, topical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C1</td>
<td>Niacin derivate (cotylic nicotinate 0.5% and myristyl nicotinate 0.5%), 1x/d topical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C2</td>
<td>Placebo, 6 drops, 1x/d, topical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D1</td>
<td>Millet seed extract, L-cysteine and calcium pantothenate, 2x/d, oral</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D2</td>
<td>Placebo, 2x/d, oral</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E1</td>
<td>Adenosine 0.75% lotion, 2x/d, topical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E2</td>
<td>Placebo lotion, 2x/d, topical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F1</td>
<td>Shampoo containing zinc pyrithione 0.6%, dipropylene glycol 0.6%, nicotinamide 0.1%, terbinafine 0.5%, TOS extract 0.17%, 2x/d, topical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F2</td>
<td>Placebo, 2x/d, topical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Investigator**
- **Jo** 2014 40 male 24w
- **Peters** 2015 100 male 6m
- **Draelos** 2005 60 female 6m
- **Gehring** 2000 40 female 6m
- **Oura** 2008 30 female 12m
- **Baek** 2011 44 female and male 16w

**Results**
- **Mean change from baseline hair count (total)**: 2% (6.08%)
- **Mean change from baseline hair count (vellus)**: 2% (5.54%)
- **Mean change from baseline hair count (anagen, telogen, anagen/telogen ratio)**: 69% p = 0.04 vs. Placebo
- **Hair thickness (mm)**: 16w: -0.004 (-4.9%)
<table>
<thead>
<tr>
<th>Investigational area</th>
<th>Number of patients</th>
<th>Gender</th>
<th>Time of evaluation</th>
<th>Dosage</th>
<th>Method</th>
<th>Investigator assessment</th>
<th>Patient assessment</th>
<th>Comb.</th>
<th>Degree of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>65 cr</td>
<td>Berger</td>
<td>2003</td>
<td>200 male</td>
<td>28w</td>
<td>Arm1: minoxidil 5% solution, 2x/d, topical + pyrithione zinc 1% shampoo, 1x/d, topical</td>
<td>hair count (total): hairs/cm (2), hairs/cm (nonvellus): hairs/cm (anagen, telogen, anagen/telogen ratio): hairs/cm</td>
<td>6.2</td>
<td>5.7</td>
<td>-0.6</td>
</tr>
<tr>
<td>69 cr</td>
<td>Shin</td>
<td>2007</td>
<td>31 male</td>
<td>18w</td>
<td>Arm1: minoxidil 5% solution, 2x/d, topical</td>
<td>hair count (global expert panel assessment, investigator assessment, patient assessment): hairs/cm</td>
<td>15.9 (12.8%) p &lt; 0.05 vs. Baseline</td>
<td>6.1 (14.2%) p &lt; 0.05 vs. Baseline</td>
<td>-0.033 (-6.0%) n.s. vs. Baseline</td>
</tr>
<tr>
<td>92 cr</td>
<td>Ryu</td>
<td>2014</td>
<td>41 female</td>
<td>24w</td>
<td>Arm1: minoxidil 3% solution, 1x/d, topical and Korean Red Ginseng extract, 1x/d, oral</td>
<td>hair count (phototrichogram): hairs/cm</td>
<td>11.3 (12.4%)</td>
<td>13.4 (13.2%)</td>
<td>0.01 (16.7%)</td>
</tr>
<tr>
<td>Art Number</td>
<td>Author</td>
<td>Year</td>
<td>Number of Patients</td>
<td>Gender</td>
<td>Time of Evaluation</td>
<td>Dosage</td>
<td>Method</td>
<td>Investigational Area</td>
<td>Degree of Evidence</td>
</tr>
<tr>
<td>-----------</td>
<td>--------</td>
<td>------</td>
<td>-------------------</td>
<td>--------</td>
<td>-------------------</td>
<td>--------</td>
<td>--------</td>
<td>---------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bazzano</td>
<td>1986</td>
<td>56</td>
<td>female and male</td>
<td>12m</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Arm 1:** Placebo, 2x/d, topical

- % > 20% increase from baseline:
  - 0%

**Arm 2:** Minoxidil 0.5%, 2x/d, topical
<table>
<thead>
<tr>
<th>Arm</th>
<th>Treatment Details</th>
<th>Male</th>
<th>Female</th>
<th>Overall</th>
<th>p-value vs. Baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Lotion containing serenoa repens extract, 2x/d, topical</td>
<td>27%</td>
<td></td>
<td>27%</td>
<td>0.001</td>
</tr>
<tr>
<td>2</td>
<td>Placebo lotion, 2x/d, topical</td>
<td>13%</td>
<td></td>
<td>7%</td>
<td>0.001</td>
</tr>
<tr>
<td>3</td>
<td>Tretinoin 0.025% solution, 2x/d, topical</td>
<td>58%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Minoxidil 0.5% + Tretinoin 0.025% solution, 2x/d, topical</td>
<td>66%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Lotion containing serenoa repens extract, 2x/d, topical + Diet supplement</td>
<td>38%</td>
<td></td>
<td>60%</td>
<td></td>
</tr>
</tbody>
</table>

Manual hair count:
- Bald area: 79 cr
- Vertex: 89 cr

Method:
- Mean change from baseline hair count (total) hairs/cm^2 (%)
- Mean change from baseline hair count (nonvellus) hairs/cm^2 (%)
- Mean change from baseline hair weight/thickness
- Global expert panel assessment
- Investigator assessment
- Patient assessment

Degree of evidence:
- Investigational area
- Arm
- p < 0.005

8/10 S3 AGA Guideline Update, Results.xlsx
<table>
<thead>
<tr>
<th>Arm</th>
<th>Treatment Details</th>
<th>Week 1</th>
<th>Week 36</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arm1</td>
<td>Pulsed electrostatic field, 1x/w, week 1, 17, 33 2x/w</td>
<td>16w: 5.9 (25.0%)</td>
<td>34w: 20.6 (60.0%)</td>
<td>0.0298</td>
</tr>
<tr>
<td></td>
<td>Pulsed electrostatic field, 1x/w, pretreatment 30w</td>
<td>16w: -0.8 (-2.5%)</td>
<td>30w: 17.5 (55.6%)</td>
<td></td>
</tr>
<tr>
<td>Arm2</td>
<td>Sham treatment, 1x/w, week 1, 17, 33 2x/w</td>
<td>16w: 0.9%</td>
<td>36w: 1.0%</td>
<td></td>
</tr>
</tbody>
</table>

### Investigational Area

#### Degree of Evidence

- Arm1: Pulsed electromagnetic field
- Arm2: Sham treatment

### Manual Hair Count

**Vertex A2**
- Baseline: 73 hairs/cm²
- Week 36: 6.2% change

**Vertex B**
- Baseline: 5.6 hairs/cm²
- Week 36: 24.7% change

### Phototrichogram

- Baseline: 18w: 4.5%
- Week 36: 6.2%

### Bald Area B

- Baseline: 18w: 0.9%
- Week 36: 1.0%
<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Number of Patients</th>
<th>Gender</th>
<th>Time of Evaluation</th>
<th>Treatment</th>
<th>Method</th>
<th>Investigational Area</th>
<th>Degree of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bureau</td>
<td>2003</td>
<td>90</td>
<td>Female and Male</td>
<td>6m</td>
<td>Arm1: herbal solution (Pimenta racemosa, Myrtus communis, Cedrus atlantica, Laurus nobilis, Pogostemon patchouli, Nymphaea odorata, Salvia sclarea, Thymus vulgaris, Cananga odorata), 3x/w, topical + pulsed electromagnetic field 3x/w, topical</td>
<td>Phototrichogram</td>
<td>Bald area</td>
<td>A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Arm2: placebo, 3x/w, topical + pulsed electromagnetic field 3x/w, topical</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

34 (22.4%) p < 0.003 vs. Baseline, p = 0.01 vs. Arm2

9 (5.5%) n.s. vs. Baseline

* Blinding till 12m, afterwards open study design
** Mean of 3 reviewers
*** Investigator = outcome assessor

Miscellaneous

10/10

S3 AGA Guideline Update_Results.xlsx